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ABSTRACT 
 
J. Elliott Robinson: Translational Investigations of Rewarding Substances Using the 
Curve-Shift Method of Intracranial Self-Stimulation in Mice 
(Under the direction of C. J. Malanga) 
 
Drug and alcohol abuse represents a major public health burden in the United 
States and is responsible for a significant loss of productivity among U.S. citizens.  
As such, effective strategies will need to be developed that address the social and 
biomedical consequences of drug abuse in the United States, including the 
discovery of pharmacotherapies and cognitive behavioral interventions that 
decrease drug or alcohol intake, help maintain sobriety, and prevent or address the 
neurobiological sequelae associated with repeated drug exposure.  These pre-
clinical studies employed the curve-shift method of intracranial self-stimulation in 
mice to probe the behavioral effects of rewarding substances on mesocorticolimbic 
circuitry involved in positive reinforcement in order to 1) describe the reward-
potentiating effects of previously uncharacterized drugs of abuse (e.g. the synthetic 
stimulant mephedrone); 2) test the utility of candidate pharmacotherapies (e.g. 
neurokinin-1 receptor antagonists or the atypical antiepileptic levetiracetam) to blunt 
the positive subjective effects of drugs or alcohol; or 3) determine pharmacogenetic 
differences in acute drug responses using humanized mice modeling known genetic 
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variants associated with substance abuse or treatment efficacy (e.g. the mu opioid 
receptor gene (OPRM1) A118G polymorphism).  Taken together, these 
investigations reflect the neuropharmacological utility of ICSS as a translational tool 
to help address unmet needs in the treatment of substance use disorders.   
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Everett, someday – probably several years from now – you may find this doctoral 
dissertation dusty and forgotten, restlessly waiting for you amid the clutter of a quiet 
room.  I hope you read these words aloud and hear me calling out to you from the 
past:  Find your calling.  Have goals you want to achieve so badly that they keep you 
up at night.  Aim high, be charitable and kind, and always try to work harder than 
your peers.  Ask for help when you need it and never let anyone tell you that an 
ambition is unachievable.  If you will it, it is no dream.   
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CHAPTER 1: INTRODUCTION 
 
Drug and alcohol abuse represents a major public health burden in the United 
States and is responsible for a significant loss of productivity among U.S. citizens.  
Recent analysis by the National Center on Addiction and Substance Abuse at 
Columbia University suggests that 40 million Americans are addicted to nicotine, 
alcohol, or other drugs, while another 80 million people engage in substance use in 
ways that threaten their health and safety or the health and safety of others (CASA, 
2012).  The economic impact of tobacco, alcohol, and other drug abuse in this 
country is substantial and has been estimated to cost society over $500 billion in the 
form of health care spending, productivity loss, crime, incarceration, and drug 
enforcement (NIDA, 2008).  Additionally, the negative effects of the abuse of 
psychoactive substances extend beyond the abuser and include their immediate 
family, dependents – through teratogenic drug effects, neglect, or loss of social or 
financial support – and communities (Lester & Lagasse, 2010; Sartor, 1991).  These 
findings emphasize the importance of developing effective strategies to address the 
social and biomedical consequences of drug abuse in the United States, including 
the discovery of pharmacotherapies and cognitive behavioral interventions that 
decrease drug or alcohol intake, help maintain sobriety, and prevent or address the 
neurobiological sequelae associated with repeated drug exposure.  
2 
 
Substance use disorder (SUD) is characterized by a pathological pattern of 
behavior related to use of the substance, including impaired control and risky use; 
social impairment; prolonged drug intake; a persistent desire to cut down or regulate 
substance use, which may be accompanied by multiple unsuccessful efforts to 
decrease or discontinue use; and a significant dedication to obtaining the substance, 
using the substance, or recovering from its effects (American Psychiatric 
Association, 2013).  Very few pharmacotherapies have received approval by the 
Food and Drug Administration for the treatment of SUD; of these, only the opioid 
antagonist naltrexone for alcohol dependence, the atypical antidepressant bupropion 
or the nicotinic acetylcholine receptor partial agonist varenicline for nicotine 
dependence, and methadone or buprenorphine maintenance therapy for opioid 
dependence have gained widespread acceptance among clinicians (Corelli & 
Hudmon, 2002; Rastegar, Kunins, Tetrault, Walley, & Gordon, 2013).  Because of 
the high failure rate of clinical trials and costs associated with central nervous 
system drug development, many pharmaceutical companies have begun to rely on 
investigators in academic settings to identify and validate promising treatment 
targets for neuropsychiatric conditions, including addiction, through preclinical 
translational research (Bartlett & Heilig, 2013; Hurko & Ryan, 2005). 
 In 2003, the U.S. National Institutes of Health Annual Report, released by then 
director Elias Zerhouni, prioritized ‘translational research’ that would translate basic 
science discoveries into new therapeutic treatments and improved patient care by 
emphasizing multidisciplinary efforts between basic scientists and clinical 
researchers and creating centers of excellence in translational research (Check, 
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2003).  Recent technological advances that make ‘-omic’ information (e.g. genomic, 
proteomic, transcriptomic, epigenomic, etc.) readily available to basic scientists has 
greatly expanded the number of druggable targets beyond the approximately five 
hundred that comprise the current pharmacopeia (Hurko & Ryan, 2005; Schadt, 
Monks, & Friend, 2003).  As such, interest in developing pharmacotherapies for SUD 
has increased, and ongoing investigations using rodent, primate, and other 
mammalian and non-mammalian models of disease should yield tangible benefits to 
patient populations in the upcoming decades.  Pre-clinical drug development is 
aided by the fact that several aspects of addictive behavior can be modeled in 
laboratory animals, including escalation of drug intake, the emergence of 
neurocognitive deficits with prolonged use, drug seeking that is resistant to 
extinction, increased motivation to consume drugs, drug preference over non-drug 
rewards, and continued drug consumption despite negative consequences or 
punishment (Vanderschuren & Ahmed, 2013).  When these behavioral models are 
used in conjunction with molecular biological, neurochemical, and/or cellular 
physiological techniques, one can elucidate pathophysiological mechanisms 
underlying substance abuse, validate drug targets in the context of perturbed neural 
signaling, and predict the utility of experimental therapeutics.  
Drugs of abuse are potent positive reinforcers (i.e. they increase the 
probability that an action associated with a stimulus will be repeated) that are readily 
consumed by laboratory animals, presumably due to their rewarding effects (i.e. they 
are stimuli that the brain perceives as inherently positive).  These rewarding effects 
have been described as the ability to produce euphoria, elevated mood, or feelings 
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of well-being (Balster & Bigelow, 2003; de Wit & Phillips, 2012) and appear to be 
due to actions on neural circuits that evolved to promote behaviors necessary to 
survival (e.g. obtaining food or water) (Nestler, Hyman, & Malenka, 2001).  Given 
that human subjects who report feelings of euphoria or liking are more likely to self-
administer drugs or alcohol in a laboratory setting (Chutuape & de Wit, 1994; de Wit, 
1998), there has been great interest in developing pharmacotherapies that decrease 
intake by attenuating drug or alcohol reward (Heilig et al., 2010), such as opioid 
receptor antagonists for the treatment of alcohol dependence (Anton et al., 2006). 
Like natural reinforcers, drugs of abuse promote positive reinforcement 
through coordinated activity of limbic motor and brain reward circuits (Figure 1).  
These regions include the mesencephalic ventral tegmental area (VTA) and 
substantia pars compacta 
(SNc), which send 
dopaminergic projections 
to the forebrain nucleus 
accumbens (NAc) and 
dorsal striatum (STR); the 
limbic neocortex, which 
includes the medial prefrontal (PFC), orbitofrontal, and anterior cingulate cortex; the 
hippocampus (HIPP); and the amygdala (AMYG) (Wise, 2005).  Midbrain 
dopaminergic projections are particularly important in appetitive behavior, reward 
expectancy, and motivated or goal-oriented behaviors (Di Chiara & Imperato, 1988; 
Salamone, Kurth, McCullough, Sokolowski, & Cousins, 1993; Schultz, Dayan, & 
Figure 1. Mesocorticolimbic circuits involved in the rewarding 
and motivational effects of positive reinforcers. 
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Montague, 1997; Wise, 2005).  These projections are regulated by diverse inputs, 
including local GABAergic interneurons; inhibitory afferents from the NAc and 
rostromedial tegmental nucleus (RMTg); and excitatory afferents from the PFC, 
other tegmental nuclei, lateral hypothalamus, etc. (Geisler & Wise, 2008; Wise, 
2005)  While brain reward circuits are normally activated by sensory cues associated 
with natural reinforcers, drugs of abuse act on these pathways directly to produce 
supraphysiological neurotransmission, leading to enhanced motivational states and 
conditioned reinforcement of drug taking (Di Chiara & Imperato, 1988; Salamone, et 
al., 1993; Wise, 2005).  Although drug-induced pleasurable states promote initial 
drug or alcohol consumption, these euphorigenic effects may become blunted during 
prolonged use and promote escalated intake (Koob & Le Moal, 2008; Robinson & 
Berridge, 1993).  As a result, the existence of evolutionarily conserved systems that 
promote desirable behaviors via reinforcement by natural rewards has made 
humans vulnerable to addiction (Nestler, et al., 2001).  
While the measurability of hedonic processes in rodents is debatable, several 
behavioral methods have been developed that attempt to model these subjective 
rewarding effects in laboratory animals, including conditioned place preference 
(CPP) and intracranial self-stimulation (ICSS) procedures.  CPP methods measure 
an animal’s preference for a previously drug-paired environment and infer that these 
effects are due to positive subjective drug experiences that occur during the 
conditioning procedure (Mucha, van der Kooy, O'Shaughnessy, & Bucenieks, 1982).  
The CPP method has also been used to model drug-seeking and has shown some 
utility in screening anti-craving drugs (McGeehan & Olive, 2003; Sanchis-Segura & 
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Spanagel, 2006).  While there is utility in measuring the ability of a possible 
pharmacotherapy to alter the emotional valence (e.g. reward or aversion) of a drug 
of abuse by blocking the development or expression of place preference, this 
methodology rarely produces graded or dose-dependent effects that are needed to 
characterize drug potency in vivo.  Furthermore, there is heterogeneity in the ability 
of a drug to produce CPP that depends on species, strain, route of drug 
administration, and dose that does not always reflect a drug’s ability to produce 
positive reinforcement under similar conditions (Sanchis-Segura & Spanagel, 2006).  
As a result, one must use caution when interpreting CPP data in the context of other 
drug and alcohol related behaviors.  
Since the discovery by James Olds and Peter Milner in 1954 that rats would 
respond for electrical stimulation of the septal or medial olfactory areas (Olds & 
Milner, 1954), the intracranial self-stimulation (ICSS) method has been used to study 
motivated behaviors in laboratory animals.  ICSS measures the ability of a drug to 
alter the value of reinforcing electrical stimulation of discrete brain regions (referred 
to as ‘brain stimulation reward’ or BSR).  Since drugs or alcohol are given non-
contingently in this procedure, it may quantify the subjective rewarding effects of 
abused drugs independent of drug seeking and/or the desire to consume them 
(Kornetsky, 1985).  While early experiments demonstrated that d-amphetamine 
enhanced ICSS (e.g. (Stein & Ray, 1960)), several drugs potentiate BSR, including 
morphine and other opioids, methamphetamine, methylenedioxymethamphetamine 
(MDMA), cocaine, phencyclidine, nicotine, and ethanol (reviewed by (Kornetsky & 
Bain, 1992; Wise & Bozarth, 1987)).  Similarly, drugs that have known aversive or 
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anhedonic effects in human subjects, such kappa opioid receptor agonists (Pfeiffer, 
Brantl, Herz, & Emrich, 1986), devalue BSR in rodents (Carlezon et al., 2006).  
Several pharmacological agents diminish or enhance the effects of abused drugs on 
ICSS (e.g. (Bain & Kornetsky, 1987; Tzchentke & Schmidt, 2000)), and drug-
pretreatment studies allow for the preclinical evaluation of potential 
pharmacotherapies to alter the subjective effects of drugs or alcohol.  
Several brain regions will sustain operant responding for BSR, including the 
VTA, SNC, PFC, NAc, etc.  The medial forebrain bundle (MFB) at the level of the 
lateral hypothalamus is one of the most commonly used electrode implantation sites 
because it produces reliable self-stimulation at low current intensities without motor 
side effects (Carlezon & Chartoff, 2007; Liebman, 1983).  The MFB is a complex 
fiber system that courses through the lateral hypothalamus and carries ascending 
and descending fibers from several sites, including the olfactory tubercle, central 
amygdala, lateral septal nucleus, bed nucleus of the stria terminalis, nucleus 
accumbens, frontal cortex, ventral tegmental area, lateral preoptic area, and several 
hypothalamic nuclei (Nieuwenhuys, Geeraedts, & Veening, 1982; Veening, 
Swanson, Cowan, Nieuwenhuys, & Geeraedts, 1982).  The reinforcing effects of 
MFB stimulation appear to be primarily due to large, possibly cholinergic, fibers that 
descend to the pedunculopontine or laterodorsal tegmental nuclei, which in turn 
project to the VTA and SNc to promote dopamine release in terminal fields (Gratton 
& Wise, 1985; Kuhr, Wightman, & Rebec, 1987; Wise, 2005; Yeomans, Mathur, & 
Tampakeras, 1993).  Dopamine release during ICSS has been extensively studied 
using fast-scan cyclic voltammetry, and it has been shown that MFB stimulation 
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produces robust, time-locked dopamine release in the nucleus accumbens that is 
independent from transients associated with the presentation of reward cues (Cheer 
et al., 2007).  As such, ICSS is attenuated by dopamine D1- and D2-like receptor 
antagonists (Duvauchelle, Fleming, & Kornetsky, 1998; R. U. Esposito, Faulkner, & 
Kornetsky, 1979; Nakajima & Patterson, 1997) and potentiated by both D1 and D2 
receptor agonists (Gilliss, Malanga, Pieper, & Carlezon, 2002; Hunt, Atrens, & 
Jackson, 1994; Malanga, Riday, Carlezon, & Kosofsky, 2008; Ranaldi & Beninger, 
1994).  Dopamine receptor antagonists block the effects of cocaine (Kita, Shiratani, 
Takenouchi, Fukuzako, & Takigawa, 1999; Vorel et al., 2002), opioids (Kornetsky & 
Duvauchelle, 1994; Kornetsky & Porrino, 1992), alcohol (Malanga, unpublished 
observations), nicotine (Huston-Lyons, Sarkar, & Kornetsky, 1993), and 
amphetamine (Gallistel & Karras, 1984) on ICSS, indicating the involvement of 
mesencephalic dopaminergic projections in the effects of drugs of abuse on ICSS. 
Although effects of the pharmacological agents on ICSS of the lateral 
hypothalamus are largely due to their ability to interact with midbrain dopaminergic 
projections to forebrain targets, several strategies can be used to investigate the role 
of other loci in brain reward function.  The most straightforward of these strategies 
involves the use of alternative electrode placement sites that may or may not 
promote evoked striatal dopamine release, yet produce positive reinforcement.  This 
caveat is important because ICSS could hypothetically be maintained by negatively 
reinforcing electrical stimulation e.g. stimulation that provides relief from an 
anhedonic state that may occur during withdrawal from chronic drug exposure.  
Lesioning studies or site-specific microinjection of receptor agonists or antagonists 
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are also helpful in determining the involvement of specific circuits in brain reward 
function, as these treatments often change the pattern and frequency of lateral 
hypothalamic self-stimulation.  For example, NMDA receptor antagonists lower 
reward thresholds when injected into the nucleus accumbens shell region (Carlezon 
& Wise, 1996), yet injection of these drugs into the VTA attenuates reward cue-
mediated phasic NAc dopamine release and increases the latency to respond for 
BSR (Sombers, Beyene, Carelli, & Wightman, 2009).  This example demonstrates 
that a single class of pharmacological agents can have bi-directional effects on ICSS 
depending on the injection site, and similar approaches may help identify circuits 
that are involved in different aspects of the complex behavioral response to a 
systemically administered drug.   
Experimenters using ICSS have reported several qualities that make this 
operant conditioning method appealing to behavioral pharmacologists.  Unlike 
operant self-administration of drugs or alcohol, satiety never develops to BSR, and 
animals will maintain robust responding (up to 48 hours continuously) as long as 
they are reinforced with electrical stimulation (Olds, 1958).  Implanted electrodes 
consistently support high response rates over months of testing, allowing the 
researcher to measure the effects of chronic drug or alcohol exposure on brain 
reward function (e.g.(McCarter & Kokkinidis, 1988)).  Furthermore, drugs of abuse 
often enhance ICSS in a dose-dependent manner, which permits the generation of 
relatively smooth dose-response curves to measure in vivo drug potency.  Several 
studies have examined repeated drug exposure using ICSS and have for the most 
part failed to demonstrate significant tolerance, sensitization, or cross-sensitization 
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of acute drug effects (Bauco, Wang, & Wise, 1993; Bauco & Wise, 1997; R. Esposito 
& Kornetsky, 1977; Frank, Martz, & Pommering, 1988; Frank & Zubrycki, 1989).  
This phenomenon is particularly striking when examined in the context of the 
locomotor sensitization that occurs with repeated psychostimulant exposure.  For 
example, mice will display progressive increases in the locomotor response to 15.0 
mg/kg cocaine when dosed repeatedly, yet the potency of that drug dose to 
potentiate BSR is consistent across several challenges in the same experimental 
animals (Riday, Kosofsky, & Malanga, 2012).  Because desensitization or 
sensitization is not typically observed with ICSS, a within subjects design can be 
used to assess drug effects on BSR, which reduces data variability and the number 
of subjects needed per experiment.  This represents a major advantage of this 
method over CPP, which requires a between subjects design to assess dose-effects.  
When discussing the utility of ICSS, one must consider differences in 
methodology that are often employed to measure the subjective effects of abused 
drugs.  In ICSS, experimental animals – usually rats or mice – are implanted with 
monopolar or bipolar electrodes in a brain region of interest and trained to respond 
for reinforcing electrical stimulation using a bar (often employed with rats), wheel 
(mice), nose poke, or other manipulandum.  Early investigations employed response 
rate (e.g. number of lever presses) as the primary dependent variable using 
continuous reinforcement or low fixed-ratio schedules.  In these experiments, 
increased or decreased responding following drug administration was interpreted as 
changes in sensitivity to the reinforcing stimulus, although this interpretation may be 
limited by confounding factors, such as drug-mediated changes in general 
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psychomotor stimulation or ability to perform the operant task (Kornetsky & Bain, 
1992).  In order to address this concern, new variations of ICSS were developed that 
are less sensitive to changes in maximum operant response rate.  In the curve-shift 
method of ICSS, rodents are trained to respond during discrete response periods in 
which the current intensity is fixed, but the frequency of stimulation declines in 0.05-
log unit steps from period to period.  This testing method produces characteristic 
rate-frequency curves that are similar to dose-response curves in pharmacology.  As 
such, positive reinforcers with rewarding effects tend to produce leftward shifts in the 
rate-frequency curve, which are indicated by decreases in EF50 (the frequency that 
produces half-maximal responding) or θ0 (or BSR threshold; the lowest frequency 
that sustains responding, defined as the x-intercept of the least squares regression 
line through the frequencies that sustain 20%, 30%, 40%, 50%, and 60% of the 
maximum response rate (Rompre & Wise, 1989)), while drugs with anhedonic 
effects produce leftward shifts.  Because a decrease in maximum operant response 
rate can alter EF50, changes in θ0 are typically used to describe drug effects 
(Carlezon & Chartoff, 2007; Miliaressis, Rompre, Laviolette, Philippe, & Coulombe, 
1986).    
Because the curve-shift method of ICSS is a rate-dependent method, 
attempts were made to determine BSR thresholds independent of their effects on 
operant response rate or ability to perform an operant task.  The psychophysical 
discrete trial method (abbreviated ‘psychophysical method’) was developed by 
Kornetsky and colleagues and requires a single operant response during discrete 
response periods in order for the subject to receive stimulation following a 
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noncontingent prime.  If the animal fails to respond within 7.5s, the trial is 
terminated.  By varying current intensity (uA) in a stepwise fashion in ascending and 
descending order, response-intensity curves can be generated to calculate BSR 
threshold (Kornetsky & Bain, 1992).  By increasing the force necessary to turn a 
wheel manipulandum, Markou and Koob showed that performance manipulations 
did not alter BSR thresholds, although they did observe changes in response 
latency, number of extra responses, and responses during intertrial timeout periods.  
Interestingly, reward manipulations – changes in the train duration of electrical 
stimulation – altered BSR threshold without altering other measures of ICSS 
(Markou & Koob, 1992).  While the psychophysical method has been widely 
employed to study brain reward mechanisms in rats, it has not been widely adopted 
for use in mice, possibly due to difficulty learning the task.  Kornetsky and 
colleagues reported that restraining experimental mice improved training efficiency, 
and they hypothesized that difficulties were due to a relatively short attention span in 
mice compared to rats (Gill, Knapp, & Kornetsky, 2004).  As such, most 
investigations that measure ICSS in mice employ curve-shift methodology.  
In these investigations, I used several behavioral, pharmacological, and 
electrophysiological techniques in conjunction with the curve-shift method of ICSS in 
mice to probe the effects of drugs of abuse on circuits involved in positive 
reinforcement.  For the most part, these pre-clinical studies fell into one or more of 
three general categories:  
1) The characterization of the cellular, cognitive, or behavioral effects of 
drugs of abuse.  
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2) The assessment of neuroactive substances that modulate drug or alcohol 
related behaviors, subjective states, or cellular effects.   
3) Assessments of the role of known human genetic variants to alter drug 
responses or treatment efficacy using transgenic or ‘humanized’ animals.  
As such, the specific aims of this dissertation were: 
 Aim 1: To characterize reward-potentiating effects of the designer 
psychostimulant mephedrone (4-methylmethcathinone; Chapter 2), which – along 
with other cathinone-derivatives – has emerged during the last five years as an 
easily obtained, recreational drug of relatively unknown abuse potential (Gunderson, 
Kirkpatrick, Willing, & Holstege, 2013).   
Aim 2: To investigate novel uses of two FDA-approved drugs to attenuate the 
acute rewarding effects of several drugs of abuse.  These studies examined the 
ability of neurokinin-1 receptor (NK1R) antagonists to alter the reward-potentiating 
effects of morphine (Chapter 3).  I also examined the effects of the synaptic vesicle 
2A inhibitor levetiracetam on alcohol- or cocaine-related behaviors using several 
behavioral assays, including ICSS (Chapter 4). 
Aim 3: To use ICSS to probe the rewarding potency of alcohol and abused 
opioids in a  humanized mouse model of the clinically significant A118G mu opioid 
receptor gene (OPRM1) polymorphism (Chapter 5).  ICSS was used in conjunction 
with pharmacological and electrophysiological assays to gain mechanistic insight 
into human phenotypes associated with this variant.  
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Taken together, these investigations reflect the neuropharmacological utility 
of ICSS as a translational tool to help address unmet needs in the treatment of 
substance use disorders and investigate pathophysiological mechanisms of disease.   
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CHAPTER 2: MEPHEDRONE (4-METHYLMETHCATHINONE) AND 
INTRACRANIAL SELF-STIMULATION IN C57BL/6J MICE: COMPARISON TO 
COCAINE1 
 
INTRODUCTION 
Recreational use of cathinone-derived synthetic stimulants, more commonly 
known as “bath salts”, has increased in prevalence during the last five years.  Of 
these, mephedrone (4-methylmethcathinone or “meow-meow”) is popular among 
recreational users, most likely due to its availability and ability to elevate mood and 
produce euphoria (Freeman et al., 2012).  Mephedrone use is associated with 
several stimulant-like drug effects, including increased concentration, talkativeness, 
psychomotor stimulation, reduced appetite, and insomnia (Freeman, et al., 2012).  
Recent studies have described compulsive drug taking (Winstock et al., 2011), and 
several deaths have been attributed to mephedrone use (Maskell, De Paoli, 
Seneviratne, & Pounder).  Not surprisingly, several countries, including the United 
States, have recently banned the production, possession, and sale of mephedrone 
and other cathinone derivatives (Fass, Fass, & Garcia, 2012).  
Activation of mesocorticolimbic dopamine circuits is a common effect of drugs 
of abuse, and these circuits play a critical role in motivated behaviors, drug 
                                                 
1
 This chapter previously appeared as an article in Behavioural Brain Research; doi: 
10.1016/j.bbr.2012.06.012 (http://www.sciencedirect.com/science/article/pii/S0166432812004251). 
The original citation is as follows: J. E. Robinson, A.E. Agoglia, E.W. Fish, M.C. Krouse, C.J. 
Malanga (2012). Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J 
mice: Comparison to cocaine. Behavioural Brain Research, 21;234(1):76-81. 
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reinforcement, and drug seeking (Wise, 2005).   The effects of drugs of abuse on 
these circuits can be modeled in laboratory animals using several behavioral 
conditioning techniques, including intracranial self-stimulation (ICSS) (Kornetsky & 
Bain, 1992; J. Olds & Milner, 1954).  ICSS measures the effects of drugs on operant 
responding for electrical stimulation of several brain regions, particularly the medial 
forebrain bundle (MFB).  The MFB  carries ascending dopaminergic projections from 
the ventral tegmental area (VTA) to targets in the nucleus accumbens (NAc) and 
prefrontal cortex (PFC), as well as descending glutamatergic and GABAergic fibers 
to the midbrain (Wise, 2005).  Stimulation of the MFB is potently reinforcing 
(Valenstein & Campbell, 1966) and enhances dopamine release in terminal fields 
(Kuhr, Wightman, & Rebec, 1987).  Drugs of abuse, especially psychomotor 
stimulants, reduce the amount of stimulation required to sustain responding, as 
measured by the stimulation frequency that supports half-maximal responding 
(EF50) or the brain stimulation reward (BSR) threshold, θ0 (Carlezon & Chartoff, 
2007; Gallistel & Freyd, 1987; Kornetsky & Bain, 1992).   
In these studies, we investigated the behavioral effects of mephedrone in 
C57BL/6J mice using ICSS.  While previous studies have examined mephedrone 
pharmacology and patterns of misuse in human populations (reviewed in (Schifano 
et al., 2011)), the behavioral effects of mephedrone have been largely unexplored in 
rodents.  BSR threshold, EF50, and maximum response rates were determined in 
C57BL/6J mice before and after treatment with mephedrone, cocaine, or saline 
vehicle to test the hypothesis that mephedrone would potentiate brain stimulation 
reward similarly to the psychostimulant cocaine.  
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METHODS 
Mice 
Male C57BL/6J mice (n = 6; Jackson Laboratories, Bar Harbor, ME) weighing 
at least 25 g were housed individually in polycarbonate cages (28 × 17 × 14 cm) with 
food and water freely available through wire lids.  Cob-bedding was changed weekly, 
and the vivarium was 21°C with a 12 hour light cycle (lights on at 8:00 PM).  
Procedures, approved by the University of North Carolina Institutional Animal Care 
and Use Committee (IACUC), were conducted according to the Guide for the Care 
and Use of Laboratory Animals (NIH publication No. 85-23, revised 2011) between 
8:30 AM and 12:30 PM.   
 
Surgery 
Under ketamine (120 mg/kg) and xylazine (18 mg/kg) (Sigma, St Louis, MO) 
anesthesia, mice were stereotaxically implanted with insulated monopolar stainless 
steel electrodes (0.28 mm diameter, Plastics One, Roanoke, VA) aimed at the right 
medial forebrain bundle at the level of the lateral hypothalamus (coordinates relative 
to bregma: AP -1.2 mm, ML -1.0 mm, DV -5.0 mm) (Franklin & Paxinos, 2008), 
grounded to a stainless steel skull screw and secured to the skull with dental 
cement.   
 
Intracranial Self-Stimulation 
ICSS experiments were performed as previously described (Fish et al., 2010; 
J. E. Robinson et al., 2012) in sound-attenuating chambers (16 × 14 × 13 in, 
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MedAssociates, St Albans, VT) containing operant conditioning boxes with a grid 
floor (ENV-005A; MedAssociates), wheel manipulandum (ENV-113AM; 
MedAssociates) and house light (ENV-315W; MedAssociates).  MED-PC software 
for Windows (v4.1; MedAssociates) controlled electrical stimulation (500 ms train of 
unipolar cathodal square-wave current 100 μs pulses and a trial-dependent 
frequency)  through a stimulator (PHM-150B/2; MedAssociates) connected to a 
swivel commutator and insulated wire (Plastics One, Roanoke, VA) attached to the 
stimulating electrode.  Each response (1 response = ¼ turn of the wheel 
manipulandum) activated the house light and produced a stimulation.  During the 
500 ms stimulation period, wheel responses were recorded but did not earn 
additional stimulation.  
Mice were initially conditioned to respond for brain stimulation reward (BSR) 
at a single stimulus intensity and frequency, after which stimulus intensity remained 
constant for each mouse.  Mice were subsequently trained to respond for 15 
decreasing stimulation frequencies (0.05 log10 steps) presented in three series.  
Each frequency was available for 50 seconds and separated by a 10-second timeout 
in which 5 non-contingent priming stimulations were delivered.  For each response 
series, the maximum response rate was measured, and the frequency that maintains 
half-maximal responding (EF50) and sustains responding (BSR threshold or θ0) 
were estimated through least squares regression.  Daily baseline values were 
calculated from responses during the second and third series.  When ICSS 
responding was stabilized, the mice were tested for the effects of mephedrone (1.0, 
3.0, 10.0 mg/kg or saline i.p.) or cocaine (1.0, 3.0, 10.0 mg/kg or saline i.p.).  After 
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baseline responding, the mice were removed from the conditioning chambers, 
injected with drug, and returned immediately for four 15-minute response series (i.e. 
60 minutes of testing).  Post-injection ICSS measures were expressed as a 
percentage of the pre-injection baseline on that day. 
 
Histology  
At the end of the experiment, 50 μm coronal brain sections were collected from 
each mouse following anesthesia with sodium pentobarbital (120 mg/kg i.p.) and 
intracardiac perfusion with 0.9% saline followed by 4% paraformaldehyde in 0.1 M 
phosphate buffered saline. Sections were stained with cresyl violet for Nissl, and 
electrode locations were confirmed by direct microscopic visualization.  One mouse 
died before the end of the study, and electrode placements were unavailable for this 
subject.   
 
Drugs 
Mephedrone (4-methylmethcathinone; generously provided by Dr. Michael 
Taffe, Scripps Research Institute, La Jolla, CA) and cocaine (Sigma) were dissolved 
in 0.9% saline and injected intraperitoneally through a 27-gauge needle in a volume 
of 1ml/100g body weight.  Drug doses were given in a random order that alternated 
every other day with saline injections.  Each drug dose was given twice and its 
effects on ICSS measures were averaged for each mouse.  Only behavioral data 
from mice that received all drug doses were included in analyses of each drug effect.  
All experiments involving mephedrone were performed prior to scheduling by the 
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United States Drug Enforcement Agency on October 21, 2011.  
 
Data Analysis 
One-way repeated measures analysis of variance (ANOVA) determined the 
effects of mephedrone and cocaine on measures of ICSS.  Bonferroni-corrected 
post hocs were performed when p < 0.05.   
 
RESULTS 
The electrode placements are shown in Figure 1A-B.  All 6 mice that were 
implanted responded for electrical stimulation of the medial forebrain bundle within 2 
sessions.  Although electrodes were implanted at the AP (skull, relative to bregma) 
coordinate of -1.3 mm, tip locations varied from -1.06 to -1.58 mm.  The average 
baseline EF50 and response threshold (θ0) in these mice prior to all drug 
experiments expressed as charge delivery was -0.31 ±0.028 μC and -0.36 ±0.036 
μC, respectively.  The average baseline maximum response rate prior to all drug 
experiments was 162 ±20.6 responses/50s.  The mice responded in a frequency-
dependent manner, and mephedrone and cocaine produced parallel leftward shifts 
the rate-frequency curves, despite having different effects on maximum response 
rate (Figure 1C).  No significant differences were detected between drug replicates 
for each drug, dose, and response series. 
 Mephedrone dose-dependently lowered EF50 (Figure 2) and BSR threshold 
(θ0; Figure 3) during the second (F3,15 = 19.0, p < 0.001; F3,15 = 7.4, p = 0.003, 
respectively), third (F3,15 = 5.4, p = 0.01; F3,15 = 3.7, p = 0.04, respectively), and 
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fourth (F3,15 = 12.6, p < 0.001; F3,15 = 3.7, p = 0.03, respectively) 15-minute post-
injection response series when compared to saline vehicle.  There was no significant 
effect on responding during the first 15-minutes of testing.  Post hoc analysis 
revealed that the 3.0 mg/kg (i.p.) mephedrone dose significantly lowered EF50 
during the second 15-minute post-injection response series, while the 10.0 mg/kg 
dose (i.p.) significantly lowered EF50 during the second, third, and fourth response 
series.  The 3.0 and 10.0 mg/kg (i.p.) mephedrone dose significantly lowered θ0 
during the second 15-minute post-injection response series. 
Cocaine dose-dependently lowered EF50 (Figure 2) and BSR threshold (θ0; 
Figure 3) during the first 15-minute post-injection response series when compared to 
saline (F3,12 = 7.1, p = 0.005; F3,12 = 6.3, p = 0.008, respectively).  Cocaine lowered 
the EF50, but not BSR threshold, during the second (F3,12 = 9.0, p = 0.002) and third 
(F3,12 = 7.4, p = 0.006) 15-minute post-injection response series when compared to 
saline.  These doses did not significantly affect responding during the final 15 
minutes of testing.  Post hoc analysis revealed that the 3.0 mg/kg (i.p.) cocaine dose 
significantly lowered EF50 during the first and second 15-minute post injection series 
when compared to saline vehicle.  The 10.0 mg/kg (i.p.) cocaine dose significantly 
lowered EF50 during the first, second, and third response series and lowered the 
BSR threshold in the first series only.  
 Mephedrone dose-dependently lowered maximum response rate (Figure 4) 
during the second 15-minute post-injection response series (F3,15 = 6.8, p = 0.004); 
only the 10.0 mg/kg dose was significantly different from  the saline vehicle.  
Cocaine tended to increase maximum response rate in the first 15-minute response 
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period, but this effect was not significant (Figure 4). 
 
DISCUSSION 
The intracranial self-stimulation (ICSS) method has been used since the 1950’s 
to characterize brain reward system function in rodents (Wise, 2005).  Drugs with 
abuse potential, regardless of their pharmacological class, potentiate brain 
stimulation reward (BSR) (Kornetsky & Bain, 1992).  Using ICSS, we examined the 
behavioral effects of the synthetic stimulant mephedrone in C57BL/6J mice and 
compared them to cocaine.  We found that across the dose range tested (1.0, 3.0, 
and 10.0 mg/kg i.p.), cocaine and mephedrone both lowered EF50 and θ0 with 
similar potency.  Mephedrone also decreased maximum response rate during the 
second 15-minute response series, while cocaine produced a non-significant trend 
toward increased maximum response rate during the first 15 minutes of testing.  
Although the behavioral effects of mephedrone were detected 15 minutes after the 
effects of cocaine, the duration of action of each drug on measures of ICSS was 
similar.   
In these studies, we used the “curve-shift” method of ICSS to test the 
behavioral effects of mephedrone and cocaine on brain reward circuitry.  During 
each testing session, mice responded for descending frequencies of brain 
stimulation, generating characteristic rate-frequency curves.  Drugs that potentiate 
BSR produce a leftward shift in the rate-frequency curve (e.g. cocaine (Fish, et al., 
2010)), as evidenced by decreases in the EF50 and θ0.  Drugs that devalue BSR 
(e.g. neuroleptics (Nakajima & O'Regan, 1991)), produce a rightward shift in the 
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rate-frequency curve and increase the EF50 and θ0.  Since drugs are given non-
contingently in ICSS, one can use this method to quantify the behavioral effects of a 
substance on mesocorticolimbic reward circuitry independent of drug consumption.  
In these experiments, both cocaine and mephedrone produced robust parallel 
leftward shifts in the rate frequency curve (e.g. Figure 1C), and the magnitude of 
these effects on EF50 and θ0 was similar for both drugs.  The maximum effect of the 
10.0 mg/kg cocaine dose on EF50 and θ0 was (66.4 ± 9.4%; 60.1 ± 12.7% of pre-
injection baseline, respectively), while the maximum effect of 10.0 mg/kg 
mephedrone dose on EF50 and θ0 was (72.3 ± 5.8%; 59.6 ± 10.9% of pre-injection 
baseline, respectively).  These results suggest that mephedrone potentiates 
responding for BSR in C57BL/6J mice similarly to cocaine, which may be indicative 
of its abuse potential. 
Mesocorticolimbic dopamine pathways are a common substrate of drugs of 
abuse, and involve neurotransmitter release in cortical and subcortical areas, such 
as the NAc and PFC, by A10 projection neurons in the midbrain VTA.  Activation of 
these pathways is thought to motivate and reinforce drug taking (Wise & Rompre, 
1989).  Mephedrone administration robustly increases activity in the NAc, PFC, and 
VTA, as measured by c-Fos expression (Motbey, Hunt, Bowen, Artiss, & McGregor, 
2012), and increases extracellular levels of dopamine (DA; 498%) and serotonin (5-
HT; 941%) in the NAc of awake rats (Kehr et al., 2011).  These effects are most 
likely due to transporter-mediated efflux of monoamines (Baumann et al., 2012), 
rather than by re-uptake inhibition, which is the mechanism of action of cocaine 
(Ritz, Lamb, Goldberg, & Kuhar, 1987).  Mephedrone displays nanomolar potency 
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for the dopamine transporter (DAT), serotonin transporter (SERT), and 
norepinephrine transporter (NET) and is similar to 3,4-
methylenedioxymethamphetamine (MDMA or “ecstasy”) in selectivity and potency 
(Baumann, et al., 2012).  In ICSS, drugs that enhance dopaminergic 
neurotransmission lower response thresholds (Nakajima & O'Regan, 1991), while 
serotoninergic agents have diverse effects on ICSS responding depending on the 
receptor subclass they target (Hayes & Greenshaw, 2011).  For example, 5-HT1A 
receptor agonists lower thresholds (A. A. Harrison & Markou, 2001), while 5-HT1B 
agonists (Hayes, Graham, & Greenshaw, 2009), 5-HT2C agonists (Hayes, Clements, 
& Greenshaw, 2009), and the selective serotonin re-uptake inhibitor fluoxetine (A. A. 
Harrison & Markou, 2001) increase thresholds.  MDMA, which produces similar 
elevations of extracellular DA and 5-HT as mephedrone (Baumann, et al., 2012; 
Kehr, et al., 2011), robustly lowers ICSS thresholds in rats (Hubner, Bird, Rassnick, 
& Kornetsky, 1988).  Although mechanisms underlying the observed effects of 
mephedrone in these studies are unknown, the enhancement of dopaminergic, as 
well as serotonergic, neurotransmission in loci associated with positive 
reinforcement (e.g. NAc) may contribute to the potentiation of BSR by the drug.  
Future studies using electrophysiological or voltammetric techniques would be 
required to support this hypothesis.    
To date, there have been only a few studies examining the effects of 
mephedrone on substance abuse-related behaviors in animal models.  These 
methods include drug self-administration, in which a drug reinforces operant 
responding, and the conditioned place preference method (CPP), a variant of 
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Pavlovian conditioning in which laboratory animals display preference for previously 
drug-paired environments.  For example, the psychostimulant cocaine, as well as 
methamphetamine (Carney, Landrum, Cheng, & Seale, 1991) and amphetamine 
(Elmer, Pieper, Hamilton, & Wise, 2010), is readily self-administered by C57BL/6J 
mice (Carney, et al., 1991) and produces robust conditioned place preference 
(Miner, 1997).  Although the behavioral effects of mephedrone have not been 
investigated in mice using these methods, the drug is intravenously self-
administered by Sprague-Dawley rats using a fixed-ratio reinforcement schedule 
(Hadlock et al., 2011).  In planaria, mephedrone induces place preference and 
causes abstinence-induced withdrawal-like behavior (Ramoz et al., 2012).  The 
current findings, when examined in the context of other behavioral effects of the 
drug, suggest that mephedrone is a potent reinforcer that requires further behavioral 
characterization in animal models of drug abuse.  
We also observed that mephedrone dose-dependently decreased maximum 
response rate during the second 15 minutes of testing, while cocaine produced a 
non-significant trend toward increased maximum response rate during the first 15-
minute response period, which has been previously reported in C57BL/6J mice 
(Fish, et al., 2010).  The curve-shift ICSS method is rate-dependent, and therefore 
maximum response rate provides some information about the psychomotor effects 
of the drug tested (Carlezon & Chartoff, 2007; Miliaressis, et al., 1986).  It is unlikely 
that the effects of mephedrone on maximum response rate were due to sedation, 
however, given that it produces locomotor stimulation in rats (Baumann, et al., 2012; 
Motbey, et al., 2012) and mice (Angoa-Perez et al., 2012).  Alternatively, 
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mephedrone may have induced behaviors that interfered with operant responding, 
such as stereotypies, which are observed following MDMA exposure (Baumann, 
Clark, & Rothman, 2008).   Most likely, divergent effects of cocaine and mephedrone 
on maximum operant response rate reflect differences in their mechanism of action.  
Unlike the monoamine re-uptake inhibitor cocaine, mephedrone produces a robust 
transporter-mediated increase in striatal 5-HT levels (Baumann, et al., 2012; Kehr, et 
al., 2011), which is associated with reduced ICSS response rate (e.g. following 
fenfluramine administration (M. E. Olds & Yuwiler, 1992)).  Given that selective DAT 
blockade by GBR-12909 enhances responding for BSR (Phillips, Blaha, & Fibiger, 
1989), the effects of cocaine on maximum response rate are probably due to its 
effects on extracellular dopamine levels.  Future studies that further characterize the 
psychomotor effects of mephedrone in the context of dopaminergic and serotonergic 
neurotransmission may help explain the observed effect of mephedrone on 
maximum response rate.   
 
CONCLUSION 
Recreational use of “bath salts” has increased in recent years, and stimulant 
abuse represents a significant public health problem.  These substances are 
associated with compulsive drug taking and have dangerous side effects (e.g. 
neurotoxicity, hyperthermia, seizures, etc.).  As of October 21, 2011, mephedrone 
was temporarily assigned Schedule I status for one year by the United States Drug 
Enforcement Agency while the United States Department of Health and Human 
Services investigates whether it should be permanently controlled under the 
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Controlled Substances Act.  Schedule I status denotes substances that have a high 
potential for abuse without having a legitimate therapeutic use (Fass, et al., 2012).  
This study examined the ability of acutely administered cocaine and mephedrone to 
alter responding for electrical stimulation of the medial forebrain bundle using the 
curve-shift method of ICSS in C57BL/6J mice.  We demonstrate that mephedrone, 
like cocaine and amphetamines, potentiates brain stimulation reward, which may 
indicate that it has a high potential for abuse.  Future studies will be necessary to 
fully characterize the cellular and behavioral effects of acute and chronic 
mephedrone exposure and compare them to more extensively characterized 
psychostimulants.   
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FIGURES
 
Figure 1.  Placement of intracranial self-stimulation monopolar electrodes (Panels 
A-B) and representative rate-frequency curves (Panel C) in C57BL/6J mice. 
Electrodes were aimed at the right medial forebrain bundle at the level of the lateral 
hypothalamus.  Black circles represent the most ventral position of the electrode tip 
(Panel A) as detected by visual inspection of Nissl stained brain sections using light 
microscopy (Panel B).  Panel C depicts responding for different frequencies of brain 
stimulation reward by an individual C57BL/6J mouse.  These rate-frequency curves 
depict the effects of saline vehicle (i.p.; white circles), 10.0 mg/kg cocaine (i.p.; black  
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circles), and 10.0 mg/kg mephedrone (i.p.; gray triangles) during the first (0 – 15 
min) and second (16 – 30) post-injection response period following a baseline 
determination (white diamonds).  
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Figure 2.  Dose-response relationship for the effects of mephedrone and cocaine on 
the frequency that supported half-maximal responding (EF50) in C57BL/6J mice.  
EF50 was measured before and after intraperitoneal injection with saline vehicle 
(white symbols), mephedrone (1.0, 3.0, and 10.0 mg/kg, i.p.; gray triangles; n = 6), 
or cocaine (1.0, 3.0, and 10.0 mg/kg, i.p.; black circles; n = 5).  Results are 
presented as mean percentage of pre-injection baseline during four 15-minute post-
injection response series (0-15, 16-33, 31-45, and 46-60 minutes post-injection) ± 
S.E.M. Asterisks indicate significance (p < 0.05) vs. saline vehicle. 
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Figure 3.  Dose-response relationship for the effects of mephedrone and cocaine on 
the brain stimulation reward threshold (θ0) in C57BL/6J mice.  θ0 was measured 
before and after intraperitoneal injection with saline vehicle (white symbols), 
mephedrone (1.0, 3.0, and 10.0 mg/kg, i.p.; gray triangles; n = 6), or cocaine (1.0, 
3.0, and 10.0 mg/kg, i.p.; black circles; n = 5).  Results are presented as mean 
percentage of pre-injection baseline during four 15-minute post-injection response 
series (0-15, 16-33, 31-45, and 46-60 minutes post-injection) ± S.E.M. Asterisks 
indicate significance (p < 0.05) vs. saline vehicle.   
39 
 
 
Figure 4.  Dose-response relationship for the effects of mephedrone and cocaine on 
the maximum response rate (MAX) in C57BL/6J mice.  Maximum response rate was 
measured before and after intraperitoneal injection with saline vehicle (white 
symbols), mephedrone (1.0, 3.0, and 10.0 mg/kg, i.p.; gray triangles; n = 6), or 
cocaine (1.0, 3.0, and 10.0 mg/kg, i.p.; black circles; n = 5).  Results are presented 
as mean percentage of pre-injection baseline during four 15-minute post-injection 
response series (0-15, 16-33, 31-45, and 46-60 minutes post-injection) ± S.E.M. 
Asterisks indicate significance (p < 0.05) vs. saline vehicle.   
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CHAPTER 3: POTENTIATION OF BRAIN STIMULATION REWARD BY 
MORPHINE: EFFECTS OF NEUROKININ-1 RECEPTOR ANTAGONISM2 
 
INTRODUCTION 
Morphine, an alkaloid isolated from the Papaver somniferum plant, has been 
widely used since the early 19th century as an analgesic.  In addition to its 
antinociceptive effects, morphine and other opioid narcotics, such as heroin, 
fentanyl, and oxycodone, result in euphoria and alleviate psychological distress 
(Goodman, Brunton, Chabner, & Knollmann, 2011).  It is therefore not surprising that 
abuse of these drugs is a significant public health concern.  According to the 
National Center for Health Statistics, the number of deaths from the misuse of 
prescription opioid analgesics has tripled from 1999 to 2006 (Warner, Chen, & 
Makuc, 2009), and approximately 1.7 million Americans meet the DSM-IV criteria for 
abuse or dependence of these drugs (Substance Abuse and Mental Health Services 
Administration 2010).  As part of a solution to this problem, new pharmacological 
strategies are needed to diminish the reinforcing effects of opioids and prevent their 
abuse.  
Morphine is a potent agonist of the mu opioid receptor (MOR), which is 
                                                 
2
 This chapter previously appeared as an article in Psychopharmacology; doi: 10.1007/s00213-011-
2469-z (http://link.springer.com/article/10.1007%2Fs00213-011-2469-z). The final publication is 
available at link.springer.com. The original citation is as follows: J.E. Robinson, E.W. Fish, M.C. 
Krouse, A. Thorsell, M. Heilig, C.J. Malanga (2012). Potentiation of Brain Stimulation Reward by 
Morphine: Effects of Neurokinin-1 Receptor Antagonism. Psychopharmacology, 220(1):215-24.  
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expressed in many areas of the mammalian central nervous system, including the 
ventral tegmental area (VTA), nucleus accumbens (NAc), periaquaductal  grey, 
inferior colliculus, interpeduncular nucleus, and the molecular layer of the cerebellum 
(Maurer, Cortes, Probst, & Palacios, 1983).  Opioid signaling in the VTA and NAc 
alters activity of the mesolimbic dopamine system, which is hypothesized to mediate 
the rewarding effects of drugs of abuse (Bozarth & Wise, 1986; Kornetsky, 1995).  In 
the VTA, MOR activation causes hyperpolarization of inhibitory interneurons 
(Johnson & North, 1992) and increases dopamine release in the NAc (Di Chiara & 
Imperato, 1988; Spanagel, Herz, & Shippenberg, 1990).  This mechanism plays a 
critical role in reward perception and behavioral reinforcement by opioids (Phillips & 
LePiane, 1980, 1982; Spyraki, Fibiger, & Phillips, 1983).  
The rewarding and reinforcing effects of morphine can be modeled in 
laboratory animals using several behavioral conditioning techniques, including drug 
self-administration (Ross, Laska, & Fennessy, 1978; Wilson, Hitomi, & Schuster, 
1971), conditioned place preference (CPP) (Mucha, et al., 1982), and intracranial 
self-stimulation (ICSS) (Kornetsky & Bain, 1992; J. Olds & Milner, 1954).  
Intracranial self-stimulation is an operant behavioral method that measures the value 
of electrical stimulation (brain stimulation reward or BSR) applied to the fibers of the 
medial forebrain bundle (MFB) at the level of the lateral hypothalamus, and can be 
used to assess the reward-potentiating or reward-devaluing effects of a drug (J. Olds 
& Milner, 1954; Wise, 1998).  The MFB carries ascending dopaminergic fibers from 
the VTA to the NAc, as well as descending glutamatergic fibers from the cortex to 
the pedunculopontine and dorsolateral tegmental nuclei, which in turn send 
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excitatory cholinergic projections to the VTA (Wise, 2005).  Direct electrical 
stimulation of this pathway is potently reinforcing (Valenstein & Campbell, 1966), 
and results in release of dopamine in forebrain targets (Cheer et al. 2007). Drugs of 
abuse enhance the activity of these fibers and reduce BSR threshold, which is the 
minimum amount of electrical stimulation necessary to sustain responding (Carlezon 
& Chartoff, 2007; Kornetsky & Bain, 1992).  
The effects of opioid drugs on ICSS have been measured in rats (R. Esposito 
& Kornetsky, 1977; R. U. Esposito, McLean, & Kornetsky, 1979; Holtzman, 1976; 
Koob, Spector, & Meyerhoff, 1975; M. E. Olds, 1979; Schaefer & Holtzman, 1977) 
and mice (Bendani & Cazala, 1988; Criswell, 1982; Elmer, Pieper, Goldberg, & 
George, 1995; Elmer, et al., 2010).  Early studies using a discrete trial-based 
procedure in rats demonstrated that morphine lowers the threshold for ICSS 
responding at low doses but becomes aversive at higher doses (Marcus & 
Kornetsky, 1974).  Interestingly, the acute reward-potentiating effect of morphine 
does not sensitize with repeated administration (R. Esposito & Kornetsky, 1977), 
although more recent studies have demonstrated that cycles of withdrawal from 
heroin progressively raises baseline ICSS threshold (Kenny, Chen, Kitamura, 
Markou, & Koob, 2006).  Activation of the delta opioid receptor and kappa opioid 
receptor also alters ICSS responding.  DOR agonists lower BSR threshold 
(Duvauchelle, Fleming, & Kornetsky, 1996), whereas KOR agonists raise the 
threshold (Todtenkopf, Marcus, Portoghese, & Carlezon, 2004). 
Studies investigating the effects of morphine in C57BL/6J and DBA/2J mice 
have revealed distinct strain differences.  Using a rate-dependent method of ICSS, 
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Elmer at al. (2010) found that C57BL/6J mice are sensitive to the reward-
potentiating effects of morphine, whereas DBA/2J mice display elevations of BSR 
threshold suggestive of an aversion to the drug.  DBA/2J mice also fail to self-
administer morphine intravenously, which C57BL/6J mice do readily (Elmer, et al., 
2010). These results are consistent with previous results that show that C57BL/6J 
mice are more sensitive to the drug’s locomotor stimulating effects (Cunningham, 
Niehus, Malott, & Prather, 1992; Oliverio & Castellano, 1974), although both strains 
readily acquire a place preference to morphine paired environments (Cunningham, 
et al., 1992).  
Recent evidence has suggested that substance P, a peptide neurotransmitter 
of the tachykinin family, and its target, the neurokinin-1 receptor (NK1R), are 
involved in modulating the rewarding effects of opioids (reviewed by (Commons, 
2010)).  NK1R-null mice on a C57BL/6J background (De Felipe et al., 1998) display 
morphine reward deficits in the conditioned place preference model (CPP) (Gadd, 
Murtra, De Felipe, & Hunt, 2003; Murtra, Sheasby, Hunt, & De Felipe, 2000) and 
self-administer less morphine than wild type littermates (Ripley, Gadd, De Felipe, 
Hunt, & Stephens, 2002).  However, animals lacking NK1R display no difference in 
CPP or the self-administration of cocaine (Gadd, et al., 2003; Murtra, et al., 2000) or 
food reinforcers (Murtra, et al., 2000), suggesting that the observed reward deficits 
are specific to opioids.  In addition, these mice are less sensitive to the locomotor-
stimulating effects of morphine and fail to display behavioral sensitization to 
morphine, but not cocaine (Ripley, et al., 2002).  Blockade of NK1 receptors could 
be one approach to limiting the rewarding and reinforcing effects of morphine. In this 
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study, we investigated the ability of neurokinin-1 receptor antagonists to alter the 
rewarding effects of morphine using ICSS.  BSR thresholds were determined in 
C57BL/6J mice before and after treatment with the opioid antagonist naltrexone, or 
after one of two NK1R antagonists, L-733,060 and L-703,606. We also tested the 
ability of naltrexone, L-733,060, and L-703,606 to alter the effects of morphine on 
BSR threshold. C57BL/6J mice were chosen for this study because they exhibit 
robust responses to morphine with ICSS (Elmer, et al., 2010) and were used as the 
genetic background for NK1R deletion mutants (De Felipe, et al., 1998).  
 
METHODS 
Mice 
Male C57BL/6J mice (n = 15) were purchased from Jackson Laboratories (Bar 
Harbor, ME), individually housed in polycarbonate cages (28 × 17 × 14 cm) with wire 
lids, and allowed to acclimate to the vivarium for one week.  Mice had free access to 
food and water throughout all stages of the experiment and were housed in a 
vivarium kept at 21°C with a 12 hour inverse light cycle (lights on at 8PM, off at 
8AM).  Cages were changed once a week, during which time fresh bedding was 
provided.  Animals were weighed at least once a week during training and before 
every experimental session in which drug or vehicle was administered.  Three 
animals died before testing with L-703,606 (n = 10), and their brains were 
unavailable for collection.  
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Surgery 
The Institutional Animal Care and Use Committee (IACUC) of the University of 
North Carolina approved all procedures, and they were conducted according to the 
Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, 
revised 2011).  Mice were anesthetized with ketamine (120 mg/kg) and xylazine (18 
mg/kg) (Sigma, St Louis, MO), and insulated monopolar stainless steel electrodes 
(0.28 mm diameter, Plastics One, Roanoke, VA) were stereotaxically-implanted in 
the right medial forebrain bundle at the level of the lateral hypothalamus 
(coordinates: AP -1.2, ML -1.0, DV -5.0).  The electrode was grounded with a 
stainless steel skull screw and secured to the skull using dental cement.  A heating 
pad was used to maintain body temperature during the surgery and the first 30 
minutes of recovery.  Following surgery, animals were returned to their cages for 
one week of recovery.   
 
Apparatus 
A sound-attenuating chamber (16 × 14 × 13 in, Med Associates, St Albans, VT) 
contained an operant conditioning chamber with a grid floor (ENV-005A; Med 
Associates), wheel manipulandum (ENV-113AM; Med Associates), and house light 
(ENV-315W; Med Associates).  Delivery of stimulation was controlled by MED-PC 
software for Windows (version 4.1; Med Associates) and delivered via a stimulator 
(PHM-150B/2; Med Associates) connected to a swivel commutator and insulated 
wire (Plastics One) that attached to the stimulating electrode.  A computer interface 
was connected to each box that could record responses (1 response = ¼ turn of the 
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wheel manipulandum), activate the house light, and issue electrical current (BSR). 
Each stimulation was a 500 ms unipolar cathodal square-wave current delivered at a 
trial-dependent frequency with 100 μs pulse width.  During the 500 ms stimulation 
period, wheel responses were recorded but did not earn additional stimulation.  Each 
response was accompanied by the illumination of the house light as a secondary 
reinforcer.  
 
Procedure 
Following recovery from surgery, mice were conditioned to respond for BSR as 
previously described (Malanga et al., 2008; Fish et al., 2010).  During each day of 
drug testing, mice responded during three consecutive 15-frequency series. 
Because responding during the first series of each test day is variable, daily BSR 
thresholds (θ0) were calculated using responses made during the 2
nd and 3rd series. 
After baselines were recorded, mice were removed from the conditioning chambers, 
injected with drug or saline, and placed in their home cages for 15 minutes, at the 
end of which mice were returned to the conditioning chambers and allowed to 
respond during six series of frequencies (90 minutes total).  Before any drugs were 
administered, animals were habituated to saline injection in this manner on five 
consecutive days.  In all antagonist pre-treatment studies, a second injection of drug 
(morphine) or saline was given 15 minutes after the first.  The mice were then 
returned to the conditioning chambers 15 minutes after the second injection and 
responses were measured. In the first experiment, morphine sulfate (MS; 1.0 – 17.0 
mg/kg, calculated as the sulfate salt, i.p.) and the NK1R antagonists L-703,606 (1.0 
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– 17.0 mg/kg, i.p.) and L-733,060 (1.0 – 17.0 mg/kg, i.p.) were administered alone. 
The largest doses of L-703,606 and L-733,060 that were not reward-devaluing alone 
(i.e. did not increase BSR threshold) were chosen for NK1R antagonist pre-
treatment studies (10.0 mg/kg for both compounds).  In the second experiment, the 
daily baseline was determined; naltrexone (NTX, 0.1 – 1.0 mg/kg, i.p.) or saline 
vehicle was given 15 minutes before morphine sulfate (1.0 – 10.0 mg/kg i.p.); and 
the animals were allowed to respond during six  subsequent 15-minute series.  In 
the third experiment, L-703,606, L-733,060, or saline was given 15 minutes prior to 
injection with 10.0 mg/kg morphine or saline (i.p.).  MAX and θ0 were calculated for 
each post-injection pass.  For each experiment, a within-subjects design was used, 
and all mice received all drug doses in random order unless otherwise noted. 
Because current intensity for ICSS training and frequency range for ICSS testing is 
adjusted for each animal such that only the top 5-6 frequencies sustain responding, 
the mean baseline θ0 is reported as total charge delivered, which is a function of 
both stimulus train frequency (Hz) and current (μA). 
 
Drugs 
Morphine sulfate, naltrexone, L-703,606, and L-733,060 were purchased from 
Sigma (St. Louis, MO), dissolved in 0.9% saline, and injected intraperitoneally 
through a 27 gauge needle at a volume of 1 ml/100 g body weight.  All doses were 
calculated as their respective salt.  Within each experiment, all drugs and doses 
were administered in a counterbalanced manner.  Experiments were completed in 
the following order: single-drug testing (vehicle, morphine sulfate, L-703,606, and L-
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733,060), acute naltrexone pre-treatment prior to morphine, and acute NK1R 
antagonist pre-treatment prior to morphine.  No effect of experiment order on post-
injection θ0 or MAX following administration of morphine sulfate or vehicle was found 
in these studies.  Drug doses were chosen on the basis of previous studies 
(Castellano & Puglisi-Allegra, 1982; Elmer, et al., 2010; Rupniak et al., 2000; 
Thorsell, Schank, Singley, Hunt, & Heilig, 2010). 
 
Histology 
At the end of the experiment, light microscopy was used to confirm the 
placement of the most ventral tip of the stimulating electrode.  50 μm coronal brain 
sections were collected from each animal after anesthesia with sodium pentobarbital 
(120 mg/kg i.p.) and intracardial perfusion with 0.9% saline followed by 4% 
paraformaldehyde in 0.1 M phosphate buffered saline.  Sections were stained with 
cresyl violet for Nissl and the electrode location was confirmed by direct 
visualization.  
 
Statistical Analysis 
All θ0 and MAX values were expressed as percent of pre-injection baseline for 
each animal.  For initial dose-response curves, one-way analysis of variance 
(ANOVA) tests were used to detect significant effects of dose or time within groups. 
Post hoc Dunnett’s tests were used to compare the effects of individual doses 
against vehicle (saline) values.  For antagonist studies, repeated measures ANOVAs 
were used to compare the effects of drug and dose, and post hoc 2-sided Dunnett’s 
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tests were used to compare individual doses.  As there were no interaction between 
time and drug or dose in each single-drug and pre-treatment experiment, percent of 
pre-injection baseline was averaged across six frequency series for each 
experiment.  
 
RESULTS 
The electrode placements are shown in Figure 1.  Of the 15 mice that were 
implanted, 13 were trained to spin the wheel within 2 sessions, and responding was 
robust following the initial acquisition of the behavior.  Although electrodes were 
implanted at the AP (skull, relative to bregma) coordinate of -1.3, most tip locations 
were slightly caudal to this location and sustained responding.  The average 
baseline threshold (θ0) that sustained responding in these mice prior to all drug 
experiments expressed as charge delivery was 0.51 μC (SEM = 0.062 μC). Two 
mice did not respond for electrical stimulation and were excluded from testing. 
Throughout all experiments, mice responded in a frequency-dependent manner 
(Figure 2). 
  
Morphine Dose-Effects and Naltrexone Antagonism  
When given alone, morphine dose-dependently lowered θ0 (Figure 3A) across 
90 minutes of testing (F(4, 66) = 25.0, p < 0.001).  Post hoc analyses revealed that 
the 3.0, 10.0, and 17.0 mg/kg doses lowered θ0 when compared to saline vehicle, 
and the 1.0 mg/kg dose approached significance (p = 0.052).  Morphine also 
biphasically altered maximum response rate (MAX; F(4, 66) = 4.4, p = 0.01; Figure 
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3B), although no doses were significantly different from vehicle. The 1.0, 3.0, and 
10.0 mg/kg doses trended toward an increased MAX, whereas the 17.0 mg/kg dose 
produced a trend toward a decreased MAX. 
When 10.0 mg/kg morphine was administered following pre-treatment with 
saline or various doses of naltrexone, the effect of morphine on θ0  depended on the 
naltrexone dose (F(3, 30) = 7.9, p = 0.01; Figure 4A).  Post-hoc analyses revealed 
that morphine lowered θ0 after saline or the 0.10 mg/kg naltrexone dose but not after 
the 0.3 and 1.0 mg/kg doses.  The 10.0 mg/kg morphine dose had no significant 
effect on MAX and did not interact with naltrexone dose (F(3,30) = 0.74, p = 0.0.536; 
Figure 4B), although there was a significant main effect of naltrexone pre-treatment 
on morphine-induced changes in MAX (F(3, 30) = 6.7, p = 0.027).  No dose of 
naltrexone alone affected θ0 or MAX.  
 
L-733,060 and L-703,606 Dose-Effects 
When given alone, L-733,060 (F(4,57) = 4.2, p = 0.009) and L-703,606 (F(4,45) 
= 3.4, p = 0.016) altered θ0 when compared to saline vehicle (Figure 5A).  Post hoc 
analysis revealed that 17.0 mg/kg L-733,060 produced a significant increase in θ0. L-
733,060 (F(4, 57) = 5.8, p = 0.001), but not L-703,606, affected MAX when given 
alone (Figure 5B).  Post hoc analysis revealed that the 3.0 and 17.0 mg/kg doses 
decreased MAX.  The 10.0 mg/kg dose of these drugs had no significant effect on θ0 
and MAX; this dose was used for pre-treatment studies with morphine. 
Pre-treatment with either 10.0 mg/kg L-733,060 (F(3,36) = 3.79, p = 0.018) or 
L-703,606  (F(3,27) = 5.22, p = 0.006) reduced morphine potentiation of BSR (Figure 
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6A) compared to pre-treatment with saline.  As compared to pre-treatment with 
saline, the effects of 3.0 and 10.0 mg/kg morphine were reduced by pre-treatment 
with 10.0 mg/kg L-733,060 or L703,606.  There was no difference in MAX between 
groups pre-treated with saline, L-733,060, or L-703,606.  
 
DISCUSSION 
The reward-potentiating effects of morphine have been previously studied 
using the ICSS technique (e.g. (R. Esposito & Kornetsky, 1977; R. U. Esposito, et 
al., 1979; Kornetsky, 1995; M. E. Olds, 1979; Schaefer & Holtzman, 1977)).  We 
examined the potentiation of brain stimulation reward by morphine and investigated 
the ability of naltrexone and NK1R antagonists to alter these effects.  First, we 
observed that morphine lowers θ0 in C57BL/6J mice in a dose-dependent manner 
using the curve shift method of ICSS (Carlezon & Chartoff, 2007; Miliaressis, et al., 
1986), confirming previous observations (Elmer, et al., 2010).  Second, we found 
that the non-selective opioid antagonist naltrexone attenuated the θ0-lowering effects 
of morphine, confirming that this effect of morphine is reversible.  This finding 
extends previous observations in rats (Jenck, Gratton, & Wise, 1987) to C57BL/6J  
mice.  Third, we observed that the NK1R antagonists, L-733,060 and L-703,606, 
also attenuated the potentiation of BSR by morphine.  This finding supports those 
from other behavioral models of drug reward using NK1R-null mutant mice (Murtra, 
et al., 2000).   
Morphine causes rapid and long-lasting changes in behavioral measures of 
reward (Wise, 1989) and brain dopamine concentration (Murphy, Lam, & Maidment, 
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2001).  Depending on the dose, acute administration of morphine stimulates 
locomotor behaviors, an effect that is large in the C57BL/6J  strain (Shuster, 
Webster, Yu, & Eleftheriou, 1975), and can induce both behavioral sensitization 
(Shuster, Webster, & Yu, 1975) and conditioned place-preference (Cunningham, et 
al., 1992) when given repeatedly.  Acute morphine can also reduce the threshold for 
BSR (e.g. (Adams, Lorens, & Mitchell, 1972; Izenwasser & Kornetsky, 1987; Lorens 
& Mitchell, 1973)).  In the current study, doses between 1.0 and 17.0 mg/kg lowered 
θ0 across a 90 minute testing interval.  This long duration of action has been 
previously demonstrated (Izenwasser & Kornetsky, 1987) and contrasts to the short-
acting effects of alcohol and cocaine (Fish, et al., 2010) on θ0 in C57BL/6J mice.  
Elevations in brain dopamine follow a similar time course (Murphy, et al., 2001) and 
it is likely that they contribute to changes in BSR threshold (Cooper & Breese, 1975; 
Koob, Fray, & Iversen, 1978; Phillips & Fibiger, 1978).  
Morphine also appeared to have biphasic effects on maximum operant 
response rate.  The curve-shift method of ICSS is a rate-dependent measure of 
reward, and MAX provides indirect information about locomotor activity (Schaefer & 
Holtzman, 1977) and a direct measure of the effect of a given drug on operant 
responding (Carlezon & Chartoff, 2007).  It is possible that the increase in MAX that 
was observed over 1.0, 3.0, and 10.0 mg/kg doses was indicative of psychomotor 
stimulation by morphine.  However, elevations in maximum response rate typically 
only occur during the highest frequencies and are not sustained across each 15 
minute series (see Figure 2), so it is unlikely that motor stimulation alone could 
explain the changes in θ0.  Additionally, 17.0 mg/kg morphine decreased MAX and 
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may have impaired responding, although much larger doses of morphine (40 mg/kg) 
enhance locomotion in C57BL/6J mice (Shuster, Webster, Yu, et al., 1975).  Further 
studies using both lower and higher morphine doses would be needed to determine 
the mechanism of its biphasic effects on maximum operant response rate.   
The potent, long-acting opioid receptor antagonist naltrexone has been 
studied in several animal models of reward and addiction-related behaviors.  For 
example, it has been shown to be reward-devaluing in ICSS (West & Wise, 1988) 
and in the conditioned place-aversion model (Parker & Rennie, 1992), although 
ICSS results are mixed (reviewed by (Trujillo, Belluzzi, & Stein, 1989)).  Naltrexone 
also suppresses locomotion in C57BL/6J mice at doses of 1.0 mg/kg or greater 
(Castellano & Puglisi-Allegra, 1982).  In the current study, there was no evidence of 
elevated reward threshold or psychomotor depression when naltrexone was given 
alone, suggesting that opioid receptor blockade is not reward-devaluing in the 0.1 – 
1.0 dose range.  In contrast, naltrexone dose-dependently attenuated the reward-
potentiating effects of morphine.  These results mirror findings that opioid receptor 
blockade diminishes behavioral responses to morphine, such as ICSS responding 
(Schaefer & Michael, 1981), locomotor stimulation (Castellano & Puglisi-Allegra, 
1982; Frischknecht, Siegfried, Riggio, & Waser, 1983), reward conditioning 
(Olmstead & Burns, 2005; Olmstead & Franklin, 1997; Piepponen, Kivastik, 
Katajamaki, Zharkovsky, & Ahtee, 1997; Shippenberg, Heidbreder, & Lefevour, 
1996), and operant drug self-administration (Harrigan & Downs, 1978).  
The most significant result of the current study was that antagonism of the 
neurokinin-1 receptor attenuated the reward-potentiating effects of morphine without 
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altering maximum response rate, suggesting that distinct neural mechanisms 
mediate these rewarding effects without affecting operant responding.  Multiple 
findings suggest that substance P and opioid signals interact in limbic reward 
pathways.  Similar to opioids, substance P or NK1R agonists increase VTA 
dopaminergic neuron activity (Korotkova, Brown, Sergeeva, Ponomarenko, & Haas, 
2006), enhance dopamine release in the prefrontal cortex and NAc (Boix, Sandor, 
Nogueira, Huston, & Schwarting, 1995; Elliott, Alpert, Bannon, & Iversen, 1986; 
Elliott, Mason, Stephens-Smith, & Hagan, 1991), and produce locomotor stimulation 
(Elliott, et al., 1991; Kelley, Stinus, & Iversen, 1979).  In the NAc, both substance P 
(Galarraga, Hernandez-Lopez, Tapia, Reyes, & Bargas, 1999) and opioid peptides 
(Britt & McGehee, 2008) alter medium spiny neuron (MSN) output via actions on 
cholinergic interneurons, which may affect reward states (Carlezon & Thomas, 
2009).  Morphine also activates immediate early genes (e.g., Fos-B) in the NAc shell 
region, and this effect is absent in NK1R knockout mice (Murtra, et al., 2000).  The 
amygdala, where MOR trafficking following morphine exposure is regulated by 
NK1Rs in vitro (Yu, Arttamangkul, Evans, Williams, & von Zastrow, 2009), also 
appears to be critical for opioid reward and reinforcement, as ablation of NK1R-
expressing neurons abolishes CPP to morphine (Gadd, et al., 2003).  Most likely, 
NK1R blockade alters limbic reward circuit activation by morphine and diminishes its 
rewarding effects.  Alternatively, L-703,606 and L-733,060 could increase the 
aversive effects of morphine, although this is unlikely, given the known anxiolytic-like 
effects of these drugs (reviewed by (Heilig, et al., 2010)).   
Human NK1R antagonists differ in their affinity and selectivity for the rodent 
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NK1R, which was an important consideration in this study.  Geometry of the NK1R 
binding pocket differs across species (Fong, Yu, & Strader, 1992), and off-target 
antagonist binding sites include neurokinin-2 and neurokinin-3 receptors, as well as 
L-type calcium channels (Seabrook et al., 1996).  L-733,060 has been shown to be 
effective in mice (Rupniak, et al., 2000), although its affinity for the rodent receptor 
(Kd = 550 nM) is lower than that of the human receptor (Kd = 0.8 nM) (Seabrook, et 
al., 1996).  This drug binds NK1R in the striatum and amygdala (Duffy, Varty, 
Morgan, & Lachowicz, 2002), and modulates cocaine-evoked overflow of dopamine 
in the rat caudate putamen (Kraft, Noailles, & Angulo, 2001).  L-703,606 also binds 
with higher affinity to the human NK1 receptor (Kd = 0.3 nM) than to the rat receptor 
(Kd = 300 nM) (Cascieri et al., 1992).  It has been used to block the rewarding effects 
of alcohol in C57BL/6J mice in a manner similar to genetic deletion (Thorsell, et al., 
2010).  Although non-specific effects of other NK1R antagonists have been reported 
(Rupniak et al., 2001; Rupniak & Jackson, 1994), L-733,060 and L-703,606 had 
similar reward-devaluing effects when given before morphine, making it unlikely that 
off-target effects were responsible for behavioral observations reported here.  
Although opioids are potent and widely-used analgesics used in the clinical 
management of pain, they are also widely abused due to their rewarding effects. 
These effects, as measured by changes in brain stimulation reward threshold, were 
attenuated by two different NK1R antagonists.  The cellular mechanisms by which L-
733,060 and L-703,606 antagonize morphine reward are not entirely clear, however, 
and await further investigation.  New techniques, such as optogenetic control of 
specific cell populations, may shed light on these findings.  Clinically, NK1R 
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antagonists, which do not affect the antinociceptive effects of morphine in animal 
models (Jasmin et al., 2002), could represent a viable strategy for limiting the abuse 
potential of opioid analgesics.  NK1R antagonists are well-tolerated by human 
subjects (Quartara, Altamura, Evangelista, & Maggi, 2009) and warrant further 
investigation into their potential effectiveness in the treatment of substance abuse 
disorders.  
61 
 
FIGURES  
 
 
Figure 1. Placement of intracranial self-stimulation monopolar electrodes in 
C57BL/6J mice.  Electrodes were aimed at the right medial forebrain bundle at the 
level of the lateral hypothalamus (panel A).  Black circles represent the most ventral 
position of the electrode tip as detected by visual inspection of Nissl-stained brain 
sections using light microscopy (panel B).  
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Figure 2.  Responding for different frequencies of brain stimulation reward for an 
individual C57BL/6J mouse.  Each response curve depict the effects of the following 
drug treatment combinations on responding: saline/saline (open circles), saline/10.0 
mg/kg morphine sulfate (gray circles),1.0 mg/kg naltrexone/10.0 mg/kg morphine 
sulfate (black square), 10.0 mg/kg L-733,060/10.0 mg/kg morphine sulfate (black 
triangle), or 10.0 mg/kg L-703,606/10.0 mg/kg morphine sulfate (black diamond).  
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Figure 3.  Dose-response relationship for morphine on BSR threshold and maximum 
operant response rate in C57BL/6J mice.  BSR threshold (θ0, panel A) and maximum 
response rate (MAX, panel B) are presented as mean (±1 SEM, vertical lines) 
percent of pre-injection baseline after treatment with saline vehicle (white circle, n = 
13) or morphine sulfate (grey circles; 1.0, 3.0, 10.0, and 17.0 mg/kg; n = 13). 
Asterisks indicate significance (p < 0.05) vs. saline vehicle.   
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Figure 4.  Effect of naltrexone pre-treatment on morphine-induced changes in BSR 
threshold and maximum response rate in C57BL/6J mice.  BSR threshold (θ0, panel 
A) and maximum response rate (MAX, panel B) are presented as mean (±1 SEM, 
vertical lines) percent of pre-injection baseline after treatment with naltrexone 
followed by saline vehicle (white squares, n = 13) or morphine sulfate (10.0 mg/kg, 
grey squares, n = 13).  Asterisks indicate significance (p < 0.05) vs. naltrexone 
alone.   
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Figure 5.  Dose-response relationship for the neurokinin-1 receptor (NK1R) 
antagonists L-733,060 and L-703,606 on BSR threshold and maximum response 
rate in C57BL/6J mice.  BSR threshold (θ0, panel A) and maximum response rate 
(MAX, panel B) are presented as mean (±1 SEM, vertical lines) percent of pre-
injection baseline after treatment with saline (white circles, n = 13), L-733,060 (black 
triangles, n = 13), or L-703,606 (black diamonds, n = 10).  Asterisks indicate 
significance (p < 0.05) of L-733,060 dose vs. saline vehicle.   
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Figure 6.  Effect of L-733,060, L-703,606, or saline vehicle pre-treatment on 
morphine-induced changes in BSR threshold and maximum response rate in 
C57BL/6J mice.  BSR threshold (θ0, panel A) and maximum response rate (MAX, 
panel B) are presented as mean (±1 SEM, vertical lines) percent of pre-injection 
baseline after treatment with L-733,060 (10.0 mg/kg, black triangles, n = 13), L-
703,606 (10.0 mg/kg, black diamonds, n = 10), or saline vehicle (grey circles, n = 13) 
followed by morphine sulfate.  Asterisks indicate significance (p < 0.05) of morphine 
dose vs. vehicle.  
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CHAPTER 4: LEVETIRACETAM HAS OPPOSITE EFFECTS ON ALCOHOL AND 
COCAINE RELATED BEHAVIORS3 
 
INTRODUCTION 
The mood-elevating effects of drugs and alcohol are important contributors to 
substance abuse, and reducing their acute rewarding effects represents a viable 
strategy for limiting consumption.  One example of this clinical approach is the use of 
the opioid receptor antagonist naltrexone, which blunts the alcohol “high” reported by 
users and can reduce alcohol intake (Anton, et al., 2006).  As new 
pharmacotherapeutic candidates are identified, it is important to determine how they 
alter the acute rewarding effects of drugs and alcohol.  Preclinical studies in 
laboratory animals provide the advantages of precise control over drug 
administration and the individual subject’s history of drug exposure.  
In laboratory animals, drugs such as psychostimulants that increase 
locomotor activity commonly also enhance intracranial self-stimulation (ICSS) 
through activation of the mesocorticolimbic dopamine system (Wise, 1996).  ICSS is 
an operant behavioral method that measures the effects of a drug on responding for 
rewarding electrical brain stimulation by detecting changes in the minimum amount 
                                                 
3
 This chapter previously appeared as an article in Neuropsychopharmacology; 
doi:10.1038/npp.2013.30 (http://www.nature.com/npp/journal/v38/n7/full/npp201330a.html). The 
original citation is as follows: J.E. Robinson, M. Chen, A. Stamatakis, E.C. Howard, M.C. Krouse, 
E.W. Fish, C.W. Hodge, and C.J. Malanga (2013). Levetiracetam Has Opposite Effects on Alcohol- 
and Cocaine-Related Behaviors in C57BL/6J Mice. Neuropsychopharmacology, 38(7):1322-3. 
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of stimulation required to sustain responding, the brain stimulation reward (BSR) 
threshold (θ0, (Miliaressis, et al., 1986).  Acutely administered alcohol or cocaine 
lowers BSR threshold in mice, as well as stimulates locomotor activity (Fish, et al., 
2010).  Identifying candidate drugs that block alcohol- or cocaine-mediated changes 
in ICSS or locomotor activity may be useful in the development of new treatments for 
substance abuse.  
While studies examining acute drug effects are useful in determining 
mechanisms of action, they are unable to assess long term neural adaptations to 
repeated drug exposure.  Behavioral sensitization is the progressive enhancement 
of locomotor responses elicited by repeated drug administration and is associated 
with persistent hypersensitivity of mesocorticolimbic reward circuits to acute drug 
challenge (reviewed in (Vanderschuren & Kalivas, 2000).  The induction of 
behavioral sensitization has consistently been shown to be separable from effects 
on ICSS, as the potentiation of BSR does not change with repeated administration of 
alcohol and other drugs of abuse (Bauco & Wise, 1997; R. Esposito & Kornetsky, 
1977; Riday, et al., 2012).  This phenomenon allows researchers to measure the 
acute rewarding effects of a drug independent from the neural adaptations that occur 
following prolonged exposure. 
Drug effects on acute locomotor stimulation, sensitized locomotor activity, and 
ICSS share a common neural substrate, the mesencephalic dopaminergic 
projections to the nucleus accumbens (NAc), dorsal striatum (STR), prefrontal cortex 
(PFC), and amygdala (Wise, 2005).  The NAc also receives convergent 
glutamatergic input from PFC, hippocampus, and basolateral amygdala (Britt et al., 
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2012), which interacts with dopaminergic signaling to generate adaptive responses 
to behaviorally relevant stimuli (Vanderschuren & Kalivas, 2000).  Electrical 
stimulation of this circuitry is potently reinforcing (J. Olds & Milner, 1954), and 
animals will perform operant tasks for stimulation of the medial forebrain bundle, 
which carries ascending dopaminergic projections and descending glutamatergic 
and GABAergic fibers to and from the midbrain (Wise, 2005).  Glutamatergic 
neurotransmission is particularly relevant to drug-mediated behaviors, as both 
ionotropic and metabotropic glutamate receptor antagonists alter drug and alcohol 
seeking and prevent the induction of behavioral sensitization (reviewed in (Gass & 
Olive, 2008). 
One approach to blocking the acute and adaptive effects of drug exposure, 
therefore, is to interfere with glutamatergic neurotransmission.  Levetiracetam (S-α-
ethyl-2-oxo-pyrrolidine acetamide) is an antiepileptic drug that decreases excitatory 
transmission preferentially at more active synapses in vitro (Meehan, Yang, 
McAdams, Yuan, & Rothman, 2011; Yang & Rothman, 2009; Yang, Weisenfeld, & 
Rothman, 2007).  Levetiracetam selectively binds to synaptic vesicle glycoprotein 2A 
(SV2A) in presynaptic terminals throughout the brain (Bragina et al., 2011; Lynch et 
al., 2004).  SV2A interacts with the calcium-sensor synaptotagmin through its N-
terminal (cytosolic) domain (Schivell, Mochida, Kensel-Hammes, Custer, & Bajjalieh, 
2005) and appears to play a modulatory rather than a necessary role in vesicular 
neurotransmitter release, as SV2A knockout mice show reduction but not elimination 
of excitatory neurotransmission (Custer, Austin, Sullivan, & Bajjalieh, 2006). 
Despite clinical interest in levetiracetam, there have been few studies 
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examining its effects on alcohol- or drug-influenced behaviors in laboratory animals.  
We investigated the effects of levetiracetam on locomotor activation by alcohol or 
cocaine in C57BL/6J mice to determine if it affects acute or sensitized responses.  
We also assessed the effects of levetiracetam on alcohol- or cocaine-potentiated 
reward using ICSS and the effects of levetiracetam on excitatory neurotransmission 
in both ventral tegmental area (VTA) dopaminergic neurons and NAc medium spiny 
neurons (MSNs) in vitro.  Given its ability to alter glutamatergic neurotransmission, 
we hypothesized that levetiracetam would attenuate the acute rewarding and 
locomotor-stimulating effects of alcohol and cocaine, as well as interfere with 
behavioral sensitization following repeated administration.    
 
METHODS 
Mice 
Adult male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were 
group-housed, four mice per cage for locomotor activity (n = 85) and in vitro 
electrophysiology experiments (n = 18), or housed individually for ICSS experiments 
(n = 11), and had free access to food and water.  The vivarium was at 21°C with a 
12-hour light cycle (lights on at 20:00).  All procedures were conducted between 
08:30 and 12:30, approved by The Institutional Animal Care and Use Committee 
(IACUC) of the University of North Carolina at Chapel Hill, and conducted according 
to the Guide for the Care and Use of Laboratory Animals (NIH publication 85-23, 
revised 2011). 
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Locomotor Activity 
Locomotion was measured in 28 x 28 cm plexiglass chambers containing two 
sets of 16 infrared photobeams (MedAssociates, St. Albans, VT).  Data were 
collected with software (MED-PC v4.1; MedAssociates) that calculated the total 
distance traveled (cm) by measuring the position of the mouse every 100 ms.  
During test sessions mice were placed into the center of the chamber and 
locomotion was measured for 15 minutes.  Mice were removed from the chambers, 
injected intraperitoneally (i.p.) with saline or levetiracetam (LEV; 100 mg/kg), and 
returned to the chamber for 30 minutes.  Mice were removed again and injected i.p. 
with saline, alcohol (2.0 g/kg), or cocaine (15.0 mg/kg) and returned to the chamber 
for 15 minutes. 
 
Locomotor Sensitization  
Mice were habituated to i.p. saline injections on Days 1 and 2 for alcohol and 
cocaine sensitization experiments.  Alcohol sensitization experiments were adapted 
from Lessov et al. (2001) and Melón and Boehm (2011).  On Day 3, mice were 
randomly assigned and tested for acute effects of the following treatments on 
locomotor activity:  saline/saline (SAL/SAL; n = 10), LEV/saline (LEV/SAL; n = 12), 
saline/alcohol (SAL/ALC; n = 12), or LEV/alcohol (LEV/ALC; n = 15).  On Days 4 – 
13, mice received treatments in their home cages with SAL/SAL, LEV/SAL, 
SAL/alcohol (3.0 g/kg), or LEV/alcohol (3.0 g/kg).  On Day 14, all mice received 
saline followed by alcohol 2.0 g/kg i.p.  On Day 15, all mice received LEV 100 mg/kg 
i.p. followed by alcohol 2.0 g/kg i.p. 
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Cocaine locomotor sensitization experiments were adapted from Thomas et 
al. (2001).  On Day 3, mice were randomly assigned to the following treatment 
groups: saline/saline (SAL/SAL; n = 9), LEV/saline (LEV/SAL; n = 9), saline/cocaine 
(SAL/COC; n = 9), or LEV/cocaine (LEV/COC; n = 9), and locomotion before and 
after injection with each drug was measured on Days 3-7 as described above.  Ten 
days after the fifth cocaine injection, all mice were retested after injection of saline 
followed by saline on Day 18, saline followed by 15 mg/kg i.p. cocaine on Day 19, 
and LEV 100 mg/kg i.p. followed by cocaine 15 mg/kg i.p. on Day 20. 
 
Electrode Implantation  
Intracranial self-stimulation experiments were conducted in a separate group of 
mice (n = 11) that were anesthetized (120 mg/kg ketamine and 18 mg/kg xylazine; 
Sigma, St Louis, MO) and stereotaxically implanted in the right medial forebrain 
bundle at the level of the lateral hypothalamus (A/P -1.3, M/L -1.0, D/V -5.0; 
(Paxinos & Franklin, 1996) with insulated monopolar stainless steel electrodes (0.28 
mm diameter; Plastics One, Roanoke, VA).  The electrode was grounded to the skull 
with a stainless steel screw and secured to the skull using dental cement.  Following 
surgery, mice were returned to their cages for one week of recovery. 
 
Intracranial Self-Stimulation 
Intracranial self-stimulation experiments were performed as previously 
described (Fish, et al., 2010) in operant conditioning chambers with a grid floor, 
wheel manipulandum, and house light (MedAssociates).  Delivery of electrical 
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stimulation was controlled by MED-PC software (v4.1; MedAssociates) and a 
stimulator (PHM-150B/2; MedAssociates) connected to a swivel commutator and 
insulated wire (Plastics One) attached to the stimulating electrode.  A computer 
interface recorded responses (1 response = ¼ turn of the wheel), activated the 
house light, and issued electrical current (brain stimulation reward, or BSR).  Each 
stimulation was a 500 ms train of unipolar cathodal square-wave current pulses (100 
μs) delivered at a trial-dependent frequency.  During the 500 ms stimulation period, 
responses were recorded but did not earn additional stimulation.  Each response 
was accompanied by illumination of the house light for 500 ms.  
During each testing session, mice responded during three consecutive series 
of 15 descending stimulus frequencies.  The first series served as a warm-up and 
was discarded; daily baseline BSR thresholds (θ0) were calculated from the second 
and third series.  In initial LEV experiments, mice were removed from the chambers 
after baseline determinations, injected (i.p.) with saline or LEV (10.0 - 100.0 mg/kg), 
and returned to the chambers for 30 minutes (i.e. two 15-minute response series).  
In drug pretreatment studies, mice were removed from the chambers after baseline 
determinations, injected with saline or LEV (100.0 mg/kg i.p.), and placed in their 
home cages for thirty minutes.  Mice were then either injected (i.p.) with saline or 
cocaine (1.0, 5.0, or 15.0 mg/kg) or gavaged (p.o.) with water or alcohol (0.6, 1.7, or 
2.4 g/kg) and immediately returned to the chambers for one 15-minute response 
series.  Maximum response rate (MAX) and θ0 were calculated with custom-
designed software. 
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Brain Slice Preparations 
Adult male C57BL/6J mice (n = 18) were anesthetized (100 mg/kg ketamine 
and 10 mg/kg xylazine, i.p.), transcardially perfused with ice-cold (4ºC) sucrose 
cutting solution (75 mM sucrose, 87 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 7 
mM MgCl2, 0.5 mM CaCl2, 10 mM glucose, 26 mM NaHCO3, and 1 mM ascorbic 
acid) and decapitated. The brain was removed and sectioned in the same sucrose 
cutting solution at 4ºC with a vibratome.  Coronal slices (250 µm) were used for NAc 
(n = 6) and horizontal slices (200 µm) were used for VTA recordings (n = 12).  Slices 
were recovered in a submerged holding chamber with oxygenated (95% O2/5% CO2) 
artificial cerebrospinal fluid (aCSF: 126 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 
2.5 mM CaCl2, 1.2 mM MgCl2, 26 mM NaHCO3, and 11 mM glucose) at 32ºC for at 
least 30 minutes prior to recording. 
 
In Vitro Electrophysiology 
After recovery, slices were placed in the recording chamber and continuously 
perfused with oxygenated aCSF (2 ml/min).  All recordings were performed at 32ºC 
in the presence of picrotoxin (50 µM) to block inhibitory currents.  Whole cell 
recordings were made under voltage clamp at a holding potential of -70 mV using a 
MultiClamp 700B amplifier and DigiData 1322A interface (Molecular Devices, 
Sunnyvale, CA).  Excitatory synaptic currents (EPSCs) were evoked with a bipolar 
stainless-steel electrode through an isolated stimulator (Digitimer Ltd., Letchworth 
Garden City, England).  Signals were sampled at 10 KHz and filtered at 2 KHz.  
Recordings were performed on NAc MSNs with the stimulation electrode at the NAc 
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core/anterior commissure border.  Recording pipettes had a resistance of 3-5 MΩ 
and were filled with a cesium methanesulfonate-based internal solution (120 mM 
CsMeSO4, 3.7 mM NaCl, 10 mM TEA-Cl, 20 mM HEPES, 0.3 mM EGTA, 4 mM 
MgATP, 0.3 mM Na3GTP).   The VTA region was identified by the interpeduncular 
nucleus and medial terminal nucleus of accessory optic tract, and recordings were 
obtained from neurons identified by the presence of a hyperpolarization-activated 
cation current (Ih) with hyperpolarizing steps from -60 mV to -120 mV in -10 mV 
increments.  Stimulation electrodes were placed rostral to the recording site.  
Recording pipettes had a resistance of 2-4 MΩ and were filled with a potassium 
gluconate-based internal solution (135 mM K-Gluconate, 4 mM KCl, 10 mM NaCl, 10 
mM HEPES, 0.3 mM EGTA, 2.5 mg/ml MgATP, and 0.25 mg/ml Na3GTP). 
 
Drugs 
Cocaine HCl (doses calculated as salt) and levetiracetam were purchased from 
Sigma, dissolved in 0.9% saline, and injected intraperitoneally in a volume of 
1ml/100g body weight.  For locomotion experiments, alcohol was diluted in 0.9% 
saline to a 15% v:v solution and injected intraperitoneally to deliver either 2.0 or 3.0 
g/kg.  For ICSS experiments, alcohol solutions were prepared in tap water and 
administered via oral gavage in a volume of 1ml/100g body weight.  For ICSS 
experiments, drug doses and vehicle injections were given in a random order using 
a Latin square design, each dose was given twice and the results averaged; and no 
drug was given two days in a row.  For in vitro electrophysiology experiments, all 
drugs were bath-applied. 
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Data Analysis 
All statistical analyses were performed with SPSS (IBM, Armonk, NY).  
Comparisons of acute effects of LEV were performed using a t-test for locomotor 
activity and one-way analysis of variance (ANOVA) for ICSS responses.  
Comparisons of pretreatment effects on locomotor activity or ICSS responses were 
made using one- or two-way ANOVAs.  Bonferroni-corrected post hocs were 
performed when p < 0.05.  Electrophysiological data were analyzed using Clampfit 
9.2 software (Molecular Devices).  Three sweeps were averaged, and the baseline 
was adjusted manually by subtracting a line from the first stimulus to 100 ms after 
the last stimulus.  EPSC amplitudes were adjusted by subtracting the baseline 
amplitude and normalized to the amplitude of the first EPSC in each train.  
Comparison of acute effects of LEV were made using ANOVA for repeated 
measures.  For all comparisons, p < 0.05 was considered significant. 
 
RESULTS 
For ICSS experiments, electrode tip locations ranged between -1.34 and -
1.82 mm relative to bregma (Figure 1A and B) and the average baseline BSR 
threshold (θ0) expressed as charge delivery when mice met training criteria (≤±10% 
variation of θ0 x 3 consecutive days) was 5.49 ± 0.39 μC (n = 11).  Throughout all 
experiments, mice responded in a frequency-dependent manner (Figure 1C and D).  
In ICSS experiments, after initial dose-response determinations to LEV alone, 
alcohol and cocaine doses were administered in a random order following LEV 
pretreatment. 
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Behavioral Effects of Levetiracetam on Locomotor Activity and ICSS 
In initial experiments, the effects of LEV on both locomotor activity and ICSS 
were determined before pretreatment studies.  When given alone, 100 mg/kg LEV 
had no significant effect on locomotion during the 30-minute period following 
injection when compared to saline (1757.1 ± 202.2 cm vs. 1543.6 ± 164.9 cm; t80 = 
1.1, p = 0.30).  LEV alone (10.0, 30.0 or 100.0 mg/kg) had no effect on BSR 
threshold (θ0) or MAX during the first or second 15-minute post-injection response 
series (Table 1), suggesting that these doses of LEV do not possess rewarding 
potency.  While LEV appeared to elevate MAX during the first response series, this 
effect was not statistically significant (F3,30 = 0.66, p = 0.59). 
 
Behavioral Effects of Levetiracetam and Alcohol 
Locomotor Activity 
There was no significant effect of acute drug treatment combination on the 
total distance traveled during the first 15-minute testing period (Figure 2B - Day 3; 
F3,45 = 1.2, p = 0.33); however, there was a significant interaction between drug 
combination and time after alcohol administration (Figure 2A; F3,90 = 5.2, p < 0.001).  
Post hoc analyses revealed that alcohol (2.0 g/kg i.p.) administered after saline 
pretreatment significantly enhanced locomotor activity during the first 5 minutes of 
testing, but not in mice pre-treated with LEV.  During the last 5 minutes of testing, 
locomotor activity after alcohol was significantly lower in the LEV pre-treatment 
group (Figure 2A).   
On Day 14, following repeated treatments, the effect of 2.0 g/kg alcohol (i.p.) 
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depended on repeated drug treatment (Figure 2B - Day 14; F3,45 = 6.1, p = 0.001).  
Post hoc analyses revealed that locomotion was significantly higher in mice that 
received daily alcohol injections after saline but not LEV pretreatment on Days 4 – 
13.  On Day 15, when all mice received 100 mg/kg LEV before 2.0 g/kg alcohol (i.p.), 
there was no significant effect of repeated drug treatments, and alcohol did not affect 
locomotor activity in any of the treatment groups (Figure 2B - Day 15).  When 
locomotor activity on Day 14 was compared to Day 15, the behavioral effects of 2.0 
g/kg alcohol were dependent on 100.0 mg/kg LEV (F3,45 = 4.6, p = 0.007; Figure 2C).  
Post hoc analyses revealed that the effects of alcohol on locomotor activity were 
decreased following LEV 100.0 mg/kg (Day 15) when compared to saline 
pretreatment (Day 14) in mice that received saline pretreatment on Days 3-7. 
 
Intracranial Self-Stimulation 
As we have previously shown (Fish, et al., 2010), alcohol (0.6, 1.7, and 2.4 
g/kg, p.o.) had biphasic, dose-dependent effects on BSR threshold (θ0) in C57BL/6J 
mice (Figure 2D).  These effects depended on LEV or saline pretreatment (F3,27 = 
3.2, p < 0.05).  Post hoc analyses revealed that 0.6 g/kg alcohol (p.o.) significantly 
lowered θ0 when mice were pretreated with saline, but not with LEV 100.0 mg/kg 
(i.p.).  The 1.7 g/kg  alcohol dose (p.o.) significantly elevated θ0 when mice were 
pretreated with LEV, but not with saline.  The 2.4 g/kg alcohol dose significantly 
elevated θ0 when mice were pretreated with either saline or LEV 100.0 mg/kg.  
Pretreatment with LEV appeared to increase maximum response rate, but there was 
no interaction between LEV and alcohol dose (F3,27 = 0.18, p = 0.91; Figure 2D).   
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Behavioral Effects of Levetiracetam and Cocaine 
Locomotor Activity 
To determine if the effects of LEV on locomotor sensitization were specific to 
alcohol, similar experiments were conducted with cocaine.  There was no significant 
effect of drug treatment combination on the total distance traveled during the first 15-
minute testing period (Figure 3B - Day 3), however there was a significant interaction 
between drug combination and time after cocaine administration (Figure 3A; F3,64 = 
6.2, p < 0.001).  Post hoc analyses revealed that cocaine (15.0 mg/kg i.p.) increased 
total distance traveled during the final 10 minutes of testing when compared to 
saline, and this effect was greater in mice that received LEV pretreatment.   
 On Days 3-7, there was a significant interaction between repeated drug 
treatments and day (F3,128 = 18.2, p < 0.001).  Post hoc analyses revealed that 
locomotor activity was higher in the mice receiving cocaine than in saline controls.  
Within the mice receiving cocaine, locomotor activity was greater on Days 4-7 than 
on Day 3.  LEV pretreatment was associated with a greater increase in locomotor 
activity on Days 6 and 7 than saline pretreatment (Figure 3B).     
Following 10 days of withdrawal, there was no significant difference between 
treatment groups when all mice were treated with saline injections (Figure 3B - Day 
18).  On Day 19, when all mice received saline followed by 15.0 mg/kg cocaine, 
locomotor activity depended on prior repeated drug treatment (Figure 3B - Day 19; 
F3, 32 = 30.0, p < 0.001).  Post hoc analyses revealed that locomotion during the 15-
minute post-injection testing period was significantly greater in groups with previous 
exposure to cocaine.  On Day 20, when all groups received 100.0 mg/kg LEV 
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followed by 15.0 mg/kg cocaine, there was no effect of prior repeated drug treatment 
on total distance traveled (Figure 3B - Day 20).  When total distance traveled on Day 
19 was compared to Day 20, the locomotor effects of cocaine depended on LEV 
administration (F3,32 = 12.3, p < 0.001; Figure 3C).  Post hoc analyses revealed that 
the effects of 15.0 mg/kg cocaine on locomotor activity were increased following 
100.0 mg/kg LEV on Day 20 when compared to saline pretreatment on Day 19 in 
mice that received saline on Days 3-7.  
 
Intracranial Self-Stimulation 
To determine if the effects of LEV on potentiation of BSR were specific to 
alcohol, similar experiments were performed using cocaine.  Cocaine (1.0, 5.0, 15.0 
mg/kg, i.p.) dose-dependently lowered θ0, and the magnitude of this effect depended 
on pretreatment with 100.0 mg/kg LEV (Figure 3D; F3,27 = 6.2, p < 0.01).  Post hoc 
analyses revealed that all cocaine doses lowered θ0, and 1.0 and 5.0 mg/kg cocaine 
produced a greater reduction in BSR threshold following LEV pre-treatment.  
Pretreatment with levetiracetam appeared to increase maximum response rate, but 
there was no interaction between levetiracetam and cocaine dose (F3,27 = 0.41, p = 
0.75; Figure 3D). 
 
Effects of Levetiracetam on Excitatory Neurotransmission in VTA and NAc 
Neurons 
To further explore the possible mechanisms underlying the behavioral effects 
of LEV, we examined the effect of LEV on excitatory synaptic transmission in NAc 
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MSNs and VTA dopaminergic neurons.  Acute brain slices for LEV experiments 
were exposed to LEV (100 μM) for at least 1.5 hours prior to and continuously 
throughout all recordings.  Stimulus intensity was adjusted with single pulses 20 
seconds apart to elicit stable evoked excitatory postsynaptic currents (EPSCs) of 
200 - 500 pA.  and stimulus intensity was adjusted to match the amplitude of the first 
EPSC in control and LEV-exposed cells (-281.7 ± 26.8 pA vs. -272.2 ± 23.5 pA , p = 
0.80 in VTA; -318.6 ± 38.1 pA vs. -394.9 ± 46.0 pA, p = 0.22 in NAc).  Trains of 20 
stimuli at 20 and 40 Hz were used for LEV experiments (Meehan, et al., 2011; Yang 
& Rothman, 2009).  The amplitude of EPSCs decreased significantly across stimulus 
trains in both control and LEV-exposed cells; however, in both NAc and VTA, LEV-
exposed cells showed more reduction in EPSC amplitude than controls (Figure 4).  
Repeated measures ANOVA of the 2nd to 20th EPSC normalized to the first EPSC in 
each train revealed significant reduction of EPSC amplitude at 20 Hz (F1, 28 = 4.70, p 
= 0.04) but not at 40 Hz (F1, 23 = 0.71, p = 0.41) in NAc MSNs (Figure 4A).  In 
recordings of VTA dopaminergic neurons, a significant effect of LEV on EPSC 
amplitude was observed at 40 Hz (F1, 26 = 6.6, p = 0.02), while depression of EPSCs 
by LEV at 20 Hz was observed but did not reach significance (F1, 27 = 4.01, p = 
0.055; Figure 4B). 
 
DISCUSSION 
Although the antiepileptic drug levetiracetam (LEV) is a possible novel 
therapeutic agent in the treatment of alcohol and other substance abuse disorders, 
surprisingly little is known about its behavioral effects in preclinical animal models.  
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In these studies, we found that LEV differentially affected responses to alcohol and 
cocaine in two behaviors relevant to drug and alcohol abuse, locomotor stimulation 
and intracranial self-stimulation (ICSS).  LEV pretreatment reduced alcohol-
stimulated motor activity after both acute and repeated administration and caused a 
vertical shift in the alcohol dose-response curve on brain stimulation reward (BSR) 
threshold, biasing alcohol toward more aversive than rewarding effects.  Conversely, 
LEV pretreatment increased the locomotor stimulant effects of acute and repeated 
cocaine and produced a leftward shift in the dose-response curve of cocaine on BSR 
threshold.  We also found that LEV reduced excitatory neurotransmission in the VTA 
and NAc, neural substrates that are critical to the behavioral effects of alcohol and 
other drugs of abuse. 
The exact cellular mechanism of action of LEV is not completely understood, 
although it is known that that LEV binds selectively to synaptic vesicle glycoprotein 
2A (SV2A, (Gillard, Chatelain, & Fuks, 2006; Lynch, et al., 2004).  SV2A is 
expressed throughout the brain and localizes to both glutamatergic and GABAergic 
presynaptic terminals.  The other two members of the SV2 protein family, SV2B and 
SV2C, which have no apparent affinity for LEV, are enriched in glutamatergic and 
GABAergic vesicles, respectively (Bragina, et al., 2011).  SV2A has been shown to 
reduce excitatory (Yang & Rothman, 2009) and possibly inhibitory (Meehan, Yang, 
Yuan, & Rothman, 2012) but see also (Margineanu & Klitgaard, 2003) 
neurotransmission by affecting vesicular release mechanisms in response to 
intracellular calcium (Chang & Sudhof, 2009; Schivell, et al., 2005; Wan et al., 2010).  
The molecular mechanisms by which SV2 proteins function in the synaptic vesicle 
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cycle remain unknown, but may relate to a role in vesicle priming (Chang & Sudhof, 
2009; Nowack, Yao, Custer, & Bajjalieh, 2010).  However, it is evident that binding of 
LEV to SV2A inhibits excitatory neurotransmission, and that this effect occurs 
preferentially at more active synapses (Yang & Rothman, 2009; Yang, et al., 2007).  
Therefore, we hypothesized that LEV administration would affect behaviors that are 
strongly regulated by glutamatergic neurotransmission. 
Levetiracetam (Keppra®) is approved by the U.S. Food and Drug 
Administration for the treatment of epilepsy, and is virtually unaffected by hepatic 
metabolism, making it extremely unlikely that changes in alcohol or cocaine 
pharmacokinetics can account for our behavioral findings in mice.  We chose the 
100 mg/kg LEV dose because it approximates the weight-based dose used for 
seizure prevention in patients with epilepsy, typically 40-100 mg/kg/day, and had no 
independent effects on mouse behavior.  LEV crosses the blood-brain barrier freely, 
with peak serum concentrations achieved within 30 minutes after intraperitoneal 
administration and a serum half-life between 1 and 3 hours in rats and mice.  In the 
rat, cerebrospinal fluid concentrations of levetiracetam reached concentrations of 
300 μM by 30 minutes after a dose of 80 mg/kg i.p. (Doheny, Ratnaraj, Whittington, 
Jefferys, & Patsalos, 1999). 
When given alone, LEV (100 mg/kg i.p.) did not significantly affect 
locomotion, although there was a trend towards motor activation.  Across a range of 
doses (10 – 100 mg/kg i.p.), LEV did not affect brain stimulation reward (BSR) 
threshold or the maximum operant response rate, although there was a trend 
towards increased operant responding.  The absence of effects on motor activity and 
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ICSS was unexpected, as electrical stimulation of the medial forebrain bundle in the 
lateral hypothalamus affects both descending glutamatergic fibers (Herberg & Rose, 
1990; You, Chen, & Wise, 2001) and firing of GABAergic MSNs in the NAc (Cheer, 
Heien, Garris, Carelli, & Wightman, 2005).  However, in vitro studies in the 
hippocampus have demonstrated that entry of LEV into presynaptic vesicles is 
highly activity dependent (Meehan, et al., 2011; Yang & Rothman, 2009; Yang, et 
al., 2007), and our electrophysiological data suggest that LEV may have a similar 
effect in NAc and VTA neurons; that is, the amplitude of stimulated EPSCs with 
repetitive firing is progressively decreased by LEV.  These in vitro data are 
consistent with, but do not conclusively prove, that LEV may have a presynaptic 
effect on excitatory neurotransmission in the VTA and NAc, and in the absence of a 
stimulus that induces sustained cell firing (e.g. following exposure to drugs of abuse) 
LEV may not fully enter the necessary cells to affect neurotransmission and thereby 
alter behavior.  Nevertheless, when LEV was administered prior to alcohol or 
cocaine injection, pronounced effects on alcohol or cocaine-induced behaviors were 
observed. 
Acutely administered alcohol exerts dose and time dependent effects on 
motor activity (Crabbe, Johnson, Gray, Kosobud, & Young, 1982).  In C57BL/6J 
mice, alcohol (2.0 g/kg i.p.) produced an initial stimulant response in the first 5 
minutes of testing followed by a return to baseline activity.  Although it did not affect 
activity on its own, LEV pretreatment prevented this initial stimulation and appeared 
to depress activity during the final 5 minutes of testing, suggesting that LEV either 
directly antagonized motor stimulation by alcohol or enhanced its sedative or ataxic 
93 
 
effects.  Acute alcohol administration stimulates glutamate release in the NAc 
(Lominac et al., 2006; Moghaddam & Bolinao, 1994) and excites dopaminergic VTA 
neurons (Gessa, Muntoni, Collu, Vargiu, & Mereu, 1985; Verbanck et al., 1990), both 
directly (Brodie & Appel, 1998; Brodie, Shefner, & Dunwiddie, 1990) and through 
glutamate-dependent mechanisms (Deng, Li, Zhou, & Ye, 2009; Xiao et al., 2009).  
Overall, the effects of LEV on motor activity following acute alcohol exposure are 
consistent with attenuation of excitatory neurotransmission, as both AMPA and 
NMDA antagonists also reduce the locomotor stimulant effects of alcohol 
(Broadbent, Kampmueller, & Koonse, 2003).  Our electrophysiological data support 
this interpretation and demonstrate for the first time that LEV attenuates excitatory 
neurotransmission in both NAc and VTA neurons in vitro. 
Repeated administration of alcohol can induce behavioral sensitization in 
mice.  Consistent with previous results using this procedure in C57BL/6J mice 
(Lessov, et al., 2001; Melon & Boehm, 2011), we observed that 10 days of repeated 
alcohol treatments (3.0 g/kg) increased motor activity upon exposure to the 2.0 g/kg 
test dose of alcohol.  This sensitized response did not occur in mice that received 
LEV before each repeated alcohol treatment, suggesting that LEV is capable of 
preventing the development of alcohol sensitization.  Moreover, acute LEV 
administration can attenuate the expression of behavioral sensitization, as seen in 
the reduction of the locomotor response to alcohol on Day 15 in sensitized mice.  
NMDA receptor antagonists prevent the induction of behavioral sensitization to 
alcohol in mice (Broadbent & Weitemier, 1999; Camarini, Frussa-Filho, Monteiro, & 
Calil, 2000), while both NMDA and AMPA receptor antagonists block expression of 
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alcohol sensitization (Broadbent, et al., 2003).  These previous findings support the 
hypothesis that LEV may decrease the development of alcohol sensitization by 
decreasing glutamatergic neurotransmission in vivo.  Dopamine receptor antagonists 
also attenuate both acute and sensitized responses to alcohol (Camarini, 
Marcourakis, Teodorov, Yonamine, & Calil, 2011; S. J. Harrison & Nobrega, 2009).  
It is therefore possible that LEV affects these behaviors by decreasing excitatory 
neurotransmission to VTA dopaminergic neurons, which we have now demonstrated 
LEV can do in vitro, thereby decreasing dopamine release in forebrain targets, 
including the NAc.  The reduction in acute alcohol-stimulated activity in the LEV/SAL 
mice on Day 14 replicates our finding that LEV can attenuate acute stimulation by 
alcohol.  Interestingly, repeated LEV exposure appeared to reduce its efficacy to 
attenuate acute alcohol-mediated locomotor stimulation, as the reduction in the 
acute effects of a first alcohol exposure by LEV was greater in the chronically saline 
pretreated (SAL/SAL) than LEV pretreated (LEV/SAL) mice (i.e., Day 14 vs. Day 15 
in Figure 2C).  Further study with repeated LEV administration is necessary to 
determine if tolerance to these effects of LEV develops over time.  
Previous studies in our laboratory have shown that alcohol administered by 
oral gavage has biphasic dose effects on BSR threshold in C57BL/6J mice (Fish, et 
al., 2010).  We found that LEV pretreatment resulted in a vertical shift in the alcohol 
dose-response curve, antagonizing the rewarding effects of 0.6 g/kg and enhancing 
the aversive-like effects of 1.7 g/kg alcohol compared to the saline-pretreated group.  
Alcohol-stimulated excitation of dopaminergic VTA neurons may contribute to the 
potentiation of BSR by the 0.6 g/kg alcohol dose.  It is therefore possible that the 
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effects of LEV on changes in ICSS by alcohol were due to inhibition of glutamatergic 
neurotransmission in the VTA, consistent with our in vitro results.  This hypothesis is 
supported by the finding that NMDA receptor antagonists microinjected into the VTA 
suppress NAc dopamine transients evoked by MFB stimulation (Sombers, Beyene, 
Carelli, & Wightman, 2009).  In addition, one in vivo microdialysis study (Fukuyama 
et al., 2012) has shown that local infusion of LEV decreases stimulated but not basal 
neurotransmitter release in a concentration-dependent manner in the medial 
prefrontal cortex.  Further studies measuring the effects of systemic LEV on 
neurotransmitter release using microdialysis or microvoltammetry in the NAc and 
other reward-relevant targets will be informative in this regard. 
Similar to alcohol, cocaine produces a dose-dependent increase in acute 
locomotor stimulation in mice that sensitizes with repeated treatment (Riday, et al., 
2012).  In contrast to its effects on alcohol-mediated behaviors, LEV pretreatment 
enhanced locomotor stimulation by cocaine (15.0 mg/kg i.p.) during the last ten 
minutes of testing when compared to saline-pretreated mice.  Repeated cocaine 
dosing (Days 3-7) produced behavioral sensitization in both the LEV and saline 
pretreatment groups, and the magnitude of sensitization was greater following LEV 
pretreatment.  After 10 days without drug exposure, mice demonstrated a persistent 
sensitized response to cocaine challenge that did not depend on repeated 
pretreatment (Days 19 and 20), indicating that LEV did not affect the expression of 
behavioral sensitization.  Since both cocaine-treated groups showed behavioral 
sensitization, it is unclear whether LEV altered cellular adaptations to repeated 
cocaine administration on Days 3-7, and it is possible that LEV only has an acute 
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effect on the locomotor response to cocaine that becomes more apparent as 
behavioral sensitization develops.  However, the absence of an acute LEV effect 
when comparing cocaine challenge days (Days 19 and 20) in mice from repeated 
treatment groups suggests that LEV may have altered the neuroadaptive response 
to cocaine.  Since glutamate release in the NAc sensitizes with repeated cocaine 
administration (Bell, Duffy, & Kalivas, 2000; Pierce, Bell, Duffy, & Kalivas, 1996), 
further investigation using neurochemical and electrophysiological methods will be 
necessary to test this hypothesis. 
Binding of SV2A by LEV enhances the effects of acute cocaine on locomotor 
activity and the development of behavioral sensitization, possibly due to events up- 
or downstream from glutamatergic signaling.  While acute cocaine and alcohol 
administration both stimulate glutamate release in the NAc (Smith, Mo, Guo, Kunko, 
& Robinson, 1995), cocaine only appears to stimulate significant glutamate release 
in the VTA after cocaine sensitization (Kalivas & Duffy, 1998) or a history of cocaine 
self-administration (You, Wang, Zitzman, Azari, & Wise, 2007).  Although LEV 
decreases excitatory neurotransmission both in vitro and in vivo, its behavioral 
effects are opposite those of systemically administered glutamate receptor 
antagonists on the locomotor response to acute or repeated cocaine.  Both AMPA 
(Jackson, Mead, Rocha, & Stephens, 1998; Li, Vartanian, White, Xue, & Wolf, 1997) 
and NMDA (Karler & Calder, 1992; Kim, Park, Jang, & Oh, 1996) receptor 
antagonists attenuate acute locomotor stimulation and the development of 
behavioral sensitization to cocaine.  Interestingly, relatively fewer drugs are found 
that increase cocaine-induced locomotor stimulation, including mGluR2 antagonists 
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(O'Neill, Heron-Maxwell, Conway, Monn, & Ornstein, 2003) and low dose 
benzodiazepines, although GABAA receptor antagonists do not affect this behavior 
(Thiebot et al., 1981).  Future studies will be necessary to identify the specific neural 
substrates of cocaine that are altered by presynaptic SV2A antagonism.  
The mechanism underlying the ability of LEV to enhance the acute and 
sensitized locomotor response to cocaine and inhibit the response to alcohol is 
unknown, but may involve changes in glutamatergic neurotransmission in 
mesocorticolimbic circuitry during drug exposure.  Although both alcohol and 
cocaine exert effects throughout brain reward circuitry, in general the rewarding 
effects of alcohol are thought mainly to involve its actions in the VTA while those of 
cocaine are thought mainly to involve its actions in the NAc (McBride, Murphy, & 
Ikemoto, 1999).  Acute cocaine administration does not stimulate significant 
glutamate release in VTA (reviewed in (Wise, 2009) and depresses spontaneous 
VTA firing but not excitatory synaptic responses from descending cortical projections 
onto dopaminergic neurons (Almodovar-Fabregas et al., 2002).  In contrast, acute 
alcohol increases the firing rate of dopaminergic VTA neurons in vivo both directly 
and through synaptic mechanisms (Morikawa & Morrisett, 2010).  These differences 
in responses of VTA neurons to acute drug administration may explain in part why 
levetiracetam blocks the development of locomotor sensitization to alcohol but not to 
cocaine, despite observations that increased glutamatergic sensitivity of 
dopaminergic VTA neurons is an early triggering event in sensitization to both 
cocaine and alcohol (Stuber, Hopf, Tye, Chen, & Bonci, 2010). 
Several investigations have demonstrated that cocaine dose-dependently 
98 
 
decreases BSR threshold in mice (Riday, et al., 2012), and we found that LEV 
produces a leftward shift in the cocaine dose-response curve in C57BL/6J mice.  
These results may reflect an effect of LEV on glutamatergic neurotransmission, as 
the NMDA receptor antagonists MK-801 (Ranaldi, Bauco, & Wise, 1997) and 
memantine (Tzchentke & Schmidt, 2000) also increase the potentiation of BSR by 
cocaine.   Cocaine, which blocks monoamine reuptake, elevates dopamine levels 
and decreases excitatory neurotransmission in the NAc.  Since decreased NAc MSN 
firing and output are thought to be one common pathway by which drugs of abuse 
may be perceived as rewarding (Beurrier & Malenka, 2002; Cheer, et al., 2005; Taha 
& Fields, 2006; Thomas, et al., 2001), LEV may have enhanced the effects of 
cocaine on BSR by attenuating activity-dependent glutamate release in the NAc.  In 
this context, it is also important to reiterate that, unlike their effects on locomotor 
behavior, the ability of cocaine (Bauco & Wise, 1997; Riday, et al., 2012) and alcohol 
(our laboratory, unpublished observations) to potentiate BSR does not sensitize with 
repeated exposure. 
In these studies, we observed that LEV oppositely affected the psychomotor 
and rewarding effects of alcohol and cocaine.  While LEV diminished the effects of 
alcohol on locomotor activity, behavioral sensitization, and BSR, it augmented the 
effects of cocaine on these same behaviors.  LEV reduced excitatory 
neurotransmission in vitro in both the VTA, where alcohol is thought to exert much of 
its rewarding effect, and the NAc, where cocaine may exert its primary rewarding 
effect.  Our results suggest that LEV may have clinical utility in the treatment of 
alcohol use disorders by decreasing alcohol reward, by interfering with the 
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development of neuroadaptations to chronic alcohol, or both.  While results from 
open-label trials of LEV for maintenance of sobriety in alcohol-abusing patients were 
initially positive (Mariani & Levin, 2008; Muller et al., 2010; Sarid-Segal et al., 2008), 
recent double-blind placebo-controlled clinical trials have been less convincing 
(Fertig et al., 2012; Richter et al., 2012).  However, the use of LEV as an add-on 
agent to other pharmacotherapy regimens has not been extensively explored (Muller 
et al., 2011), but may provide benefit for patients with alcohol abuse disorders.  In 
contrast, LEV enhanced both the acute and sensitized effects of cocaine, suggesting 
that it may increase the abuse potential of psychostimulants.  Taken together, these 
findings suggest that further studies in preclinical models relevant to drug and 
alcohol abuse in addition to carefully designed clinical trials are necessary to 
determine how LEV alters the behavioral effects of abused drugs.  
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FIGURES AND TABLES 
Table 1.  Effects of Levetiracetam on Measures of ICSS 
 
Dose 
(mg/kg) 
 BSR Threshold (Hz)  Maximum Response Rate 
(responses/min) 
 0-15 min 16-30 min  0-15 min 16-30 min 
V  95.5 ± 5.5 107.6 ± 5.8  109.3 ± 5.4 95.6 ± 4.1 
10.0  94.4 ± 5.1 98.2 ± 5.1  121.9 ± 12.1 108.9 ± 5.3 
30.0  97.8 ± 7.5 106.1 ± 4.0  118.2 ± 9.9 111.1 ± 7.9 
100.0  98.1 ± 2.8 102.2 ± 2.9  125.4 ± 4.8 112.0 ± 5.8 
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Figure 1.  Intracranial self-stimulation (ICSS) electrode tip locations and 
representative rate frequency curves.  (A)  Photomicrograph (4x) displaying the 
electrode tip location in a Nissl-stained coronal section from a representative mouse.  
(B)  Ventral electrode tip placements (mm posterior to bregma) for each mouse 
(black circles, n = 11).  (C) Representative rate-frequency curves from one 
C57BL/6J mouse displaying the effects of treatment with saline i.p./water p.o. 
(VEH/H2O; white circles), 100.0 mg/kg levetiracetam i.p./water p.o. (LEV/H2O; grey 
circles), saline i.p./0.6 g/kg alcohol p.o. (SAL/ALC0.6; grey triangles), or 100.0 mg/kg 
levetiracetam i.p./0.6 g/kg alcohol p.o. (LEV/ALC0.6; black triangles).  (D) 
Representative rate-frequency curves from one C57BL/6J mouse displaying the 
effects of intraperitoneal injection with saline/saline (SAL/SAL; white circles), 100.0 
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mg/kg levetiracetam/saline (LEV/SAL; grey circles), saline/5.0 mg/kg cocaine 
(SAL/COC5.0; grey diamonds), or 100.0 mg/kg levetiracetam/5.0 mg/kg cocaine 
(LEV/COC5.0; black diamonds).   
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Figure 2.  Effects of levetiracetam (LEV) pretreatment on alcohol-affected behaviors 
in C57BL/6J mice.  (A)  Locomotor activity (total distance traveled, in cm) during 
each 5-minute interval of the 15-minute testing period on Day 3 (± SEM, vertical 
lines).  Mice were randomized to receive intraperitoneal injections of the following 
treatments: saline/saline (SAL/SAL, white circles, n = 10), 100.0 mg/kg 
levetiracetam/saline (LEV/SAL, light grey circles, n = 12), saline/2.0 g/kg alcohol 
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(SAL/ALC, dark grey circles, n = 12), or 100.0 mg/kg levetiracetam/2.0 g/kg alcohol 
(LEV/ALC, black circles, n = 12).  (B) Locomotor activity during the 15-minute post-
injection test on each experimental day (± SEM, vertical lines).  On Days 1-2, all 
mice received saline/saline.  On Day 3, mice received the following treatments, as in 
(A):  SAL/SAL (white bars), LEV/SAL (light grey bars), SAL/ALC (dark grey bars), or 
LEV/ALC (black bars).  On Day 14, all mice received saline/2.0 g/kg alcohol.  On 
Day 15, all mice received 100.0 mg/kg levetiracetam/2.0 g/kg alcohol.  (C)  
Comparison of locomotor activity during the 15-minute post-injection test on Days 14 
(white bars) and 15 (grey bars; ± SEM, vertical lines).  Chronic daily treatment 
groups are abbreviated on the x-axis (S/S = SAL/SAL, L/S = LEV/SAL, S/A = 
SAL/ALC, L/A = LEV/ALC).  Number signs (#) indicate significant differences (p < 
0.05) between days.  (D)  Effect of levetiracetam pretreatment on ICSS after alcohol 
in C57BL/6J mice.  Changes in BSR threshold (θ0) and maximum response rate 
(MAX) are shown as mean percentages (± SEM, vertical lines) of pre-injection 
baseline after intraperitoneal injection with saline (+SAL, white circles) or 100.0 
mg/kg levetiracetam (+LEV, grey circles) followed by oral gavage with water (H2O) 
or alcohol (n = 11).  Asterisks (*) indicate significance (p < 0.05) vs. SAL/SAL 
(SAL/H2O in D).  Daggers (†) indicate significance (p < 0.05) vs. SAL/ALC. 
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Figure 3.  Effects of levetiracetam (LEV) pretreatment on cocaine-affected 
behaviors in C57BL/6J mice.  (A)  Locomotor activity (total distance traveled, in cm) 
during each 5-minute interval of the 15-minute testing period on Day 3 (± SEM, 
vertical lines).  Mice were randomized to receive intraperitoneal injections of the 
following treatments: saline/saline (SAL/SAL, white circles, n = 10), 100.0 mg/kg  
levetiracetam/saline (LEV/SAL, grey circles, n = 12), saline/15.0 mg/kg cocaine 
(SAL/COC, grey diamonds, n = 9), 100.0 mg/kg levetiracetam/15.0 mg/kg cocaine 
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(LEV/COC, black diamonds, n = 9).  (B)  Locomotor activity during the 15-minute 
post-injection test on each experimental day (± SEM, vertical lines).  On Days 1-2, 
all mice received saline/saline.  On Days 3-7, mice received the following 
treatments, as in (A):  SAL/SAL (white circles), LEV/SAL (grey circles), SAL/COC 
(grey diamonds), or LEV/COC (black diamonds).  On Day 18, all mice received 
saline/saline.  On Day 19, all mice received saline/15.0 mg/kg cocaine.  On Day 20, 
all mice received 100 mg/kg levetiracetam/15.0 mg/kg cocaine.  (C) Comparison of 
locomotor activity during the 15-minute post-injection test on Days 14 (white bars) 
and 15 (grey bars; ± SEM, vertical lines).  Chronic daily treatment groups are 
abbreviated on the x-axis (S/S = SAL/SAL, L/S = LEV/SAL, S/C = SAL/COC, L/A = 
LEV/COC).  Number signs (#) indicate significant differences (p < 0.05) between 
days.  (D)  Effect of levetiracetam pretreatment on ICSS after cocaine in C57BL/6J 
mice.  Changes in BSR threshold (θ0) and maximum response rate (MAX) are 
shown as mean percentages (± SEM, vertical lines) of pre-injection baseline after 
intraperitoneal injection with saline (+SAL, white circles) or 100.0 mg/kg 
levetiracetam (+LEV, grey circles) followed by injection with saline (V) or cocaine (n 
= 11).  Asterisks (*) indicate significance (p < 0.05) vs. SAL/SAL (SAL/V in D).  
Daggers (†) indicate significance (p < 0.05) vs. SAL/COC. 
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Figure 4.  Effect of bath-applied levetiracetam (LEV) on excitatory 
neurotransmission in nucleus accumbens medium spiny neurons (NAc) and ventral 
tegmental area dopaminergic neurons (VTA) in vitro.  In both cell types, stimulus 
trains at 20 and 40 Hz were repeated three times each at a 1.5 minute interval, 2.5 
minutes apart.  LEV (+LEV 100 µM, red traces) progressively reduced mean 
excitatory postsynaptic current (EPSC) amplitudes in averaged raw current traces 
(right panels) of recordings from both (A) NAc (n = 15 control, 17 LEV cells) and (B) 
VTA (n = 19 control, 16 LEV cells).  Amplitudes of each successive EPSC 
normalized to the first EPSC in each stimulus train (EPSCn/EPSC1 ± SEM, left 
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panels) show a greater progressive reduction in EPSC amplitude in LEV-exposed 
(red circles) than control neurons (black circles) in both NAc and VTA.  At the end of 
each stimulus train (EPSC16-20/EPSC1 ± SEM) this inhibitory effect of LEV (insets, 
red bars) was significant at 20 Hz stimulation in NAc and at 40 Hz in VTA.  Asterisks 
(*) indicate significance (p < 0.05) of LEV-exposed vs. controls. 
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CHAPTER 5: ALTERED RESPONSES TO ALCOHOL AND MORPHINE IN A 
HUMANIZED MOUSE MODEL OF THE OPRM1 A118G POLYMORPHISM 
 
INTRODUCTION 
Alcohol use disorders (AUDs) represent an enormous public health burden in 
the United States, yet few therapies have been approved to treat this disease 
(Bartlett & Heilig, 2011).  Of these, opioid receptor antagonists, such as naltrexone, 
are among the most effective (L. A. Ray, Chin, & Miotto, 2010).  These drugs 
attenuate the subjective pleasurable effects of alcohol by blocking the activation of 
cortical and subcortical brain reward systems by endogenous opioids (Gianoulakis, 
2009; Oswald & Wand, 2004).  These circuits perceive, process, and translate 
relevant stimuli into motivated behaviors and represent a principal substrate for all 
drugs of abuse (Wise, 2002).  By studying the ways in which mu opioid receptor 
gene (OPRM1) variation alters the effects of alcohol on brain reward circuitry, we 
can better understand the mechanisms through which these genetic differences 
moderate risk for developing AUDs. 
The psychological and neurophysiological effects of endogenous opioids (e.g. 
β-endorphin), opioid analgesics (e.g. morphine), and abused opioids (e.g. the 
acetylated morphine derivative heroin) are caused by their intrinsic activity at mu 
opioid receptors (MORs), which are seven-transmembrane G protein-coupled 
receptors (GPCRs) of the rhodopsin family.  These receptors are expressed at both 
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pre- and postsynaptic sites throughout the mammalian central nervous system 
(Maurer, Cortes, Probst, & Palacios, 1983).  The MOR interacts with the Gi/o class of 
heterotrimeric G proteins, which are composed of Giα and GiβƔ subunits that 
dissociate from the agonist-bound receptor following guanine nucleotide exchange.  
The Giα subunit decreases adenylyl cyclase activity and cyclic AMP production, while 
the GiβƔ subunit inhibits voltage-gated calcium channels (P/Q- and N-type) and 
activates G protein-coupled inwardly-rectifying potassium channels (GIRK channels 
of the Kir3 family) (Wettschureck & Offermanns, 2005).  The MOR also signals via 
interactions with β-arrestin 1 or 2 and may produce downstream cellular effects 
independent of the ability to couple Gi (Macey, Lowe, & Chavkin, 2006; Miyatake, 
Rubinstein, McLennan, Belcheva, & Coscia, 2009).  Thus, MORs can alter neural 
excitability and synaptic transmission to produce diverse behavioral effects 
depending on the cell signaling pathways they engage, which vary across circuits.  
When alcohol is consumed, endogenous opioids are released in several 
reward-relevant regions, including the mesencephalic ventral tegmental area (VTA) 
(Jarjour, Bai, & Gianoulakis, 2009; Rasmussen et al., 1998) and the forebrain 
nucleus accumbens (NAc) (Mitchell et al., 2012; Olive, Koenig, Nannini, & Hodge, 
2001).  In the VTA, activated MORs inhibit GABAergic interneurons and facilitate 
burst firing of A10/VTA dopaminergic projection neurons through disinhibition 
(Johnson & North, 1992a; Suaud-Chagny, Chergui, Chouvet, & Gonon, 1992).  By 
attenuating these tonic inhibitory inputs, opioids produce dopamine release in 
multiple forebrain regions, including the NAc (Spanagel, Herz, & Shippenberg, 
1990), prefrontal cortex (Noel & Gratton, 1995), and extended amygdala (Carboni, 
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Silvagni, Rolando, & Di Chiara, 2000; Young & Rees, 1998).  This dopaminergic 
activity plays a critical role in motivated behaviors, including those related to drug 
and alcohol reward, and drug seeking (Wise, 2005).  By changing the sensitivity of 
VTA circuits to opioids, genetic variants of the MOR may alter the abuse potential of 
alcohol and predict response to naltrexone. 
One of the most widely studied variants of the MOR results from a non-
synonymous single nucleotide polymorphism (SNP) in exon 1 of OPRM1 
(rs1799971), in which an A-to-G substitution occurs at position 118 (A118G or 
118A→G) corresponding to the loss of a putative glycosylation site in the N-terminal 
extracellular domain (Bergen et al., 1997; Bond et al., 1998).  Carrying the minor 
allele (118G) has been associated with a higher risk of alcohol dependence (Bart et 
al., 2005; Kim et al., 2004; Miranda et al., 2010; Nishizawa et al., 2006; 
Rommelspacher, Smolka, Schmidt, Samochowiec, & Hoehe, 2001), heroin or opioid 
dependence (Bart et al., 2004; Drakenberg et al., 2006; H. Zhang et al., 2006), and 
an improved clinical outcome with naltrexone treatment (Anton et al., 2008; Kim et 
al., 2009; Oroszi et al., 2009; Oslin et al., 2003).  However, only the association 
between OPRM1 A118G and naltrexone efficacy has been confirmed by meta-
analysis (Chamorro et al., 2012).  Human carriers of the 118G allele are more 
sensitive than 118A homozygotes to the subjective positive subjective effects of 
alcohol (L. A. Ray & Hutchison, 2004), but less sensitive to opioid analgesics 
(reviewed by (Diatchenko, Robinson, & Maixner, 2011)).  Because of these 
inconsistencies, there is great interest in determining how this polymorphism alters 
receptor function.  
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The mechanisms by which the A118G polymorphism may influence opioid 
and alcohol responses have been investigated but have not yet been fully 
elucidated.  Early studies reported that the potency of β-endorphin (β-END), but not 
other endogenous opioids, is increased in cells expressing the 118G receptor, which 
was due to increased binding affinity (Bond, et al., 1998).  These findings have not 
been replicated, however, and other groups have failed to detect significant 
differences between the A and G variants using a number of functional assays 
(Befort et al., 2001; Beyer, Koch, Schroder, Schulz, & Hollt, 2004; Kroslak et al., 
2007).  To address the discordance between clinical and human laboratory studies 
and in vitro receptor assays, a humanized mouse model of the OPRM1 A118G 
polymorphism has been generated on a C57BL/6J background (h/mOprm1 A118G 
mice).  In this model, mouse Oprm1 exon 1 was excised and replaced with human 
OPRM1 exon 1 containing either A or G at position 118 (Ramchandani et al., 2010).  
H/mOprm1 118GG mice are developmentally normal, yet consume greater 
quantities of alcohol when compared to 118AA littermates (Thorsell and Heilig, 
unpublished observations).   
Because human OPRM1 118G carriers report greater self-reported 
intoxication, stimulation, and positive mood after alcohol (L. A. Ray & Hutchison, 
2004), there is great interest in quantifying the rewarding effects of alcohol and 
opioids in h/mOprm1 118AA and 118GG mice.  The curve-shift method of 
intracranial self-stimulation (ICSS) is an operant behavioral method that is used to 
investigate the effects of drugs of abuse on brain reward circuitry.  In ICSS, 
experimental animals respond for electrical stimulation of the fibers of the medial 
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forebrain bundle (MFB) at the level of the lateral hypothalamus (brain stimulation 
reward or BSR) (Olds & Milner, 1954; Wise, 1998).  MFB stimulation is potently 
reinforcing (Valenstein & Campbell, 1966) and evokes dopamine release in forebrain 
targets (Kuhr, Wightman, & Rebec, 1987).  Drugs of abuse, including alcohol (Fish 
et al., 2010; Robinson et al., 2013), enhance the potency of BSR and decrease the 
minimum stimulus intensity that maintains responding (BSR threshold or 
θ0)(Carlezon & Chartoff, 2007; Miliaressis, Rompre, Laviolette, Philippe, & 
Coulombe, 1986).  In these studies, I used ICSS in conjunction with 
electrophysiological and pharmacological techniques to determine the effects of 
alcohol and opioids on brain reward function in h/mOprm1 118AA and 118GG mice 
and better understand the etiology of OPRM1 A118G phenotypes.  
  
METHODS 
Mice 
Adult (at least post-natal day 50 and older) male h/mOprm1 118AA and 
h/mOprm1 118GG mice were individually housed in a temperature- and humidity-
controlled vivarium under a 12-hr light/dark cycle and had free access to food and 
water.  All procedures were approved by The Institutional Animal Care and Use 
Committee (IACUC) of the University of North Carolina at Chapel Hill, and were 
conducted according to the Guide for the Care and Use of Laboratory Animals (NIH 
publication No. 85-23, revised 2011). 
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Intracranial Self-Stimulation 
Mice (h/mOprm1 118AA: n = 37; 118GG: n = 40) were anesthetized with 
ketamine (100 mg/kg i.p.) and xylazine (10 mg/kg i.p.) and implanted with insulated 
monopolar stainless steel electrodes (0.28 mm diameter, Plastics One, Roanoke, 
VA) in the medial forebrain bundle at the level of the lateral hypothalamus 
(coordinates from Bregma: AP -1.3, ML -1.0, DV -5.0 mm; (Paxinos & Franklin, 
1996)).  After seven days of recovery, they were conditioned to perform intracranial 
self-stimulation as previously described (Robinson et al., 2012) in operant 
conditioning chambers with a grid floor, wheel manipulandum, and house light 
(MedAssociates).  A computer interface for each chamber recorded responses (1 
response = ¼ turn of the wheel), activated the house light, and issued electrical 
current (brain stimulation reward or BSR).  Delivery of electrical stimulation was 
controlled by MED-PC software (v4.1; MedAssociates); current was generated by a 
stimulator (PHM-150B/2; MedAssociates) connected to a swivel commutator and 
insulated wire (Plastics One) that was attached to the stimulating electrode.  Each 
stimulation was a 500 ms train of unipolar cathodal square-wave current pulses (100 
μs pulse width) delivered at a trial-dependent frequency.  During the 500-ms 
stimulation period, responses were recorded but did not earn additional stimulation.  
Each response was accompanied by illumination of the house light for 500 ms.  
During each testing session, mice responded during three consecutive series 
of 15 descending frequencies.  The first series served as a warm-up and was 
discarded.  Daily baseline BSR thresholds (θ0) were calculated from the average of 
the second and third series.  Mice were removed from the chambers after baseline 
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determinations; treated with water (p.o.), vehicle (i.p. or s.c.), naltrexone HCl (0.1 - 
1.0 mg/kg i.p.), alcohol (0.6 – 2.4 g/kg p.o.), fentanyl citrate (0.1 – 0.3 mg/kg s.c.), 
oxycodone HCl (0.1 – 10.0 mg/kg i.p.), buprenorphine HCl (0.1 – 10.0 mg/kg i.p.), 
morphine sulfate (1.0 – 10.0 mg/kg i.p.), cocaine HCl 1.0 – 10.0 mg/kg i.p.), or 
U69,593 (0.01 – 0.1 mg/kg i.p.); and returned to the chambers for 15 minutes of 
testing.  In drug pretreatment studies, mice were removed from the chambers after 
baseline determinations, injected with saline (i.p.) or naltrexone (1.0 mg/kg i.p.) and 
placed in their home cages for fifteen minutes.  Mice were then gavaged with water 
(p.o.) or alcohol (0.6 g/kg) and immediately returned to the chambers for one 15-
minute response series.  Maximum response rate (MAX) and θ0 were calculated with 
custom-designed software.   
During the alcohol experiments, a three-dose alcohol dose-response curve 
was generated for all mice (118AA: n = 19; 118GG: n = 21); after a 2-week washout 
period, mice received either naltrexone (118AA: n = 11; 118GG: n = 10) alone or 
naltrexone ± alcohol (118AA: n = 8; 118GG: n = 11).  Both morphine sulfate (118AA: 
n = 10; 118GG: n = 11) and oxycodone (118AA: n = 7; 118GG: n = 8) were tested in 
drug naïve mice.  U69,593 (118AA: n = 12; 118GG: n = 11) and fentanyl (118AA: n = 
10; 118GG: n = 7) were tested in mice that previously received naltrexone following 
a two-week washout period.  Buprenorphine (118AA: n = 8; 118GG: n = 10) was 
tested in mice that previously received or naltrexone ± alcohol.  Cocaine was tested 
in mice that previously received morphine (118AA: n = 10; 118GG: n = 11).  Drug 
doses were given in ascending order beginning on different days.  No drugs were 
given two days in a row, and all drugs doses were separated by vehicle injections, 
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which were averaged for each mouse.   
During behavioral experiments, fentanyl citrate, oxycodone HCl, morphine 
sulfate, and cocaine HCl were dissolved in 0.9% saline; U69,593 and buprenorphine 
were HCl dissolved in 0.1N acetic acid diluted with saline; and alcohol was prepared 
in tap water.  Drugs were injected intraperitoneally or subcutaneously through a 27 
gauge needle in a volume of 1 mL/100 g body weight.  Alcohol was administered via 
oral gavage in a volume of 1 mL/100 g body weight.   
At the end of the experiment, light microscopy was used to confirm the 
placement of the most ventral tip of the stimulating electrode in 50 μm thick sections 
of brain tissue collected from each animal after anesthesia with sodium pentobarbital 
(120 mg/kg i.p.) and intracardial perfusion with 0.9% saline followed by 4% 
paraformaldehyde in 0.1 M phosphate buffered saline (PBS).  The brains were 
stained with cresyl violet Nissl stain to visualize the electrode location.  
 
Electrophysiological Recordings 
Adult male mice were anesthetized with ketamine (100 mg/kg i.p.) and xylazine 
(10 mg/kg i.p.), transcardially perfused with ice-cold (4ºC) sucrose cutting solution 
(containing the following, in mM: 75 sucrose, 87 NaCl, 2.5 KCl, 1.25 NaH2PO4, 7 
MgCl2, 0.5 CaCl2, 10 glucose, 26 NaHCO3, 1 ascorbic acid, and 1 kynurenic acid), 
and decapitated.  The brain was removed, and 200 µm horizontal slices were cut in 
the same sucrose cutting solution at 4ºC using a Leica VT1000S vibratome.  Slices 
were allowed to recover in a submerged holding chamber with artificial cerebrospinal 
fluid (aCSF containing the following, in mM: 126 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2.5 
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CaCl2, 1.2 MgCl2, 26 NaHCO3, and 11 glucose) at 32ºC for at least 30 minutes prior 
to recording.  Slices were continually bubbled with 95% O2/ 5% CO2 throughout 
preparation and experiments.  
After recovery, slices were placed in the recording chamber and continuously 
perfused with oxygenated aCSF (2 mL/min) that contained tetrodotoxin (500 nM) 
and kynurenic acid (1µM) to isolate miniature inhibitory post-synaptic currents 
(IPSCs).  Recording pipettes with a resistance of 2.5-3.5 MΩ were filled with a 
potassium chloride-based internal solution (containing the following, in mM: 128 KCl, 
20 NaCl, 1 MgCl2, 1 EGTA, 0.3 CaCl2, 10 HEPES, 2 MgATP, 0.3 Na3GTP) that 
contained Alexa Fluor 594 (Life Technologies, Carlsbad, CA).  Following rupturing of 
the membrane, cells were allowed to rest for 10 minutes to allow diffusion of the 
internal recording solution before experiments were conducted.  Cells were voltage-
clamped at holding potential of -70 mV using a MultiClamp 700B amplifier and 
DigiData 1322A interface (Molecular Devices, Sunnyvale, CA).  Signals were 
sampled at 10 KHz and filtered at 2 KHz.  The VTA region was identified by the 
interpeduncular nucleus and medial terminal nucleus of accessory optic tract, and 
recordings were obtained from neurons identified by the presence of a 
hyperpolarization-activated cation current (Ih) with hyperpolarizing steps from -60 mV 
to -120 mV in -10 mV increments.  For all experiments, the series resistance (Rs) 
was recorded every three minutes, and data were discarded if Rs increased by more 
than 20% or rose above 30 MΩ over the course of the experiment. 
Following a stable baseline, mIPSCs were recorded for 3 minutes before and 
after 3-min exposure to morphine sulfate (100 nM; 118AA: n = 8; 118GG: n = 9) or 
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DAMGO (100 nM; 118AA: n = 8; 118GG: n = 8).  In naloxone antagonism 
experiments, naloxone (1 µM) was applied 1 minute prior to the addition of morphine 
(100 nM; 118AA: n = 5; 118GG: n = 6).  Gabazine (SR-95531) was applied at the 
end of some experiments to confirm that mIPSCs were mediated exclusively by the 
GABAA receptor.  Events were analyzed using MiniAnalysis (Synaptosoft Inc., 
Decatur, GA), and the post-drug mIPSC frequency and amplitude were normalized 
to baseline.  After each recording, slices were placed in 4% paraformaldehyde in 0.1 
M PBS for 24 hours, washed, and stained for tyrosine hydroxylase (TH).  Alexa Fluor 
594-filled cells that expressed TH were considered to be dopaminergic.   
 
Preparation of Membranes 
For binding assays, brainstem tissue from age-matched male and female 
mice that were older than postnatal day 50 and had been transcardially perfused 
with aCSF was dissected en bloc, homogenized in cold lysis buffer (50 mM Tris HCl, 
pH 7.4, containing protease inhibitor cocktail from Roche), and centrifuged at 40,000 
x g for 20 minutes at 4°C.  The resulting supernatant was decanted and replaced 
with the same lysis buffer, and two to three additional rounds of homogenization-
centrifugation was performed to ensure thorough homogenization and wash out 
endogenous ligands.  The subcellular fractionation procedure was carried out as 
described by (S. Kumar, Sieghart, & Morrow, 2002; S. Kumar et al., 2010).  In short, 
tissue was homogenized in PBS that contained 0.32 M sucrose and protease 
inhibitors; 200 μL of the homogenate was set aside to be used as the unfractionated 
control.  The remaining tissue homogenate was centrifuged at 1000 x g for 10 min to 
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generate the crude nuclear/cytosolic pellet (P1).  The resulting supernatant was then 
centrifuged at 12,000 x g for 30 min to generate the surface membrane pellet (P2).  
The resulting supernatants from h/mOprm1 118AA and 118GG mice were pooled by 
genotype and centrifuged at 500,000 x g for 30 minutes to obtain the microsomal 
pellet (P3).   
 
Receptor Binding  
The number of h/mOprm1 118A and 118G receptor binding sites in each 
fraction was performed as described by (Bryan L. Roth, 2013) using a radioligand 
binding assay (118AA: n = 14; 118GG: n = 14).  Specific and nonspecific binding 
was carried out in triplicate in 96-well plates in a final volume of 125 μL per well.  In 
brief, 25 μL [3H]-DAMGO (9 μM) was added to each well of a 96-well plate, followed 
70 μL binding buffer (for total binding) or 70 μL naloxone (10 μM; nonspecific 
binding).  Addition of 30 μL of fresh membrane protein started the reaction, and 
membranes were incubated in the dark at room temperature for 60 minutes.  The 
reaction was stopped by vacuum filtration onto cold 0.3% polyethyleneimine-soaked 
96-well filter mats using a 96-well Filtermate harvester (PerkinElmer, Waltham, MA), 
followed by three washes with cold wash buffers.  Scintillation cocktail was melted 
onto the microwave-dried filters on a hot plate and radioactivity was counted in a 
Wallac MicroBeta TriLux plate scintillation counter (PerkinElmer, Waltham, MA) 
(Bryan L. Roth, 2013).  Results were calculated as specific binding (total binding – 
nonspecific binding; counts/min) per 1 µg of total sample protein.  Because there 
was no significant effect of sex, data from male and female mice were averaged.  
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A competition binding assay (118AA: n = 18; 118GG: n = 18) was used to 
determine the binding affinity of β-END, morphine, and [D-Ala2, N-MePhe4, Gly-ol]-
enkephalin (DAMGO) for h/mOprm1 118A and 118G receptors using freshly 
prepared membranes that had been pooled from 6 animals/group.  The binding 
assays were carried out in a 96-well plate in triplicate in a final of volume of 125 μL 
per well, which included 25 μL [3H]-DAMGO (9 μM) at a concentration close to the 
Kd determined via saturation binding, 25 μL agonist (0.1, 0.3, 1, 3, 10, 30, 100, 300 
nM, 1, 3, or 10 μM), and 75 μL of fresh membrane protein.  Plates were incubated at 
room temperature in the dark for 90 minutes, and radioligand-bound membranes 
were harvested and analyzed as described above (Bryan L. Roth, 2013).   
 
cAMP Assay 
HEK293 cells were co-transfected with plasmids encoding either OPRM1 
118A, OPRM118G, h/mOprm1 118A, or h/mOprm1 118G receptor DNA and the  
cAMP biosensor GloSensor-22F (Promega), as described (Bryan L. Roth, 2013; 
Vardy et al., 2013).   After 18 hours of incubation at 37°C, cells were seeded (20,000 
cells/20 μL/well) onto poly-L-lysine-coated 384-well white clear bottom cell culture 
plates (Sigma-Aldrich, St. Louis, MO) and plated in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 1% dialyzed fetal bovine serum.  After a 24-hour 
recovery, the medium was replaced with 20 μL of drug buffer (Hanks' balanced salt 
solution, 20 mM HEPES, pH 7.4), and the cells were treated with 10 μL β-END, 
morphine, or DAMGO prepared in drug buffer (0.1, 0.3, 1, 3, 10, 30, 100, 300 nM, 1, 
3, or 10 μM).  After 20 min, cAMP production was stimulated by addition of 10 μL 
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isoproterenol (1.2 μM) in 8% GloSensor reagent.  Luminescence per well per second 
was read on a Wallac MicroBeta TriLux plate scintillation counter (PerkinElmer, 
Waltham, MA).  Luminescence data were normalized to the isoproterenol response 
(0%) and the peak agonist-induced inhibition (100%). 
 
Data Analysis 
All statistical analyses were performed with SPSS (IBM, Armonk, NY), 
SigmaPlot (Systat, Chicago, IL), or GraphPad Prism (GraphPad Software, San 
Diego, CA).  Comparisons of the effects of genotype and drug dose were made 
using paired or unpaired t-tests and one- or two-way repeated measures ANOVAs.  
Bonferroni-corrected post hocs were performed when p < 0.05.  In competition 
binding experiments, the Ki of each agonist was determined via sigmoidal curve-
fitting in SigmaPlot.  In the cAMP assay, data were regressed using the sigmoidal 
curve-fitting feature in GraphPad Prism in order to determine EC50. 
 
RESULTS 
First, I examined the acute rewarding effects of alcohol in h/mOprm1 118GG 
and 118AA mice using the curve-shift method of intracranial self-stimulation (ICSS) 
(Carlezon & Chartoff, 2007).  During each trial, the minimum amount of electrical 
stimulation required to sustain responding (BSR threshold or θ0) for an individual 
mouse was determined before and after each manipulation (drug or vehicle).  There 
were no differences in pre-drug ICSS responding between h/mOprm1 118AA and 
118GG littermates, as evidenced by average baseline rate-frequency curves (Fig 
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1A).  There was no difference in average baseline maximum operant response rate 
(MAX 118AA = 95.9 ± 10.3 responses/50 sec; MAX 118GG = 79.5 ± 10.4 responses/50 
sec) or BSR threshold (Fig 1A inset; θ0 118AA = 0.39 ± 0.03 µC; θ0 118GG = 0.40 ± 0.03 
µC) between groups.    
Alcohol had dose-dependent effects on BSR threshold that interacted with 
genotype (Fig 2A; F5,152 = 3.85, p = 0.005).  H/mOprm1 118GG mice displayed 
biphasic dose effects of alcohol on ICSS; BSR threshold was lowered by low doses 
(0.6 g/kg p.o.) and raised by higher doses (2.4 g/kg p.o.).  This dose-response 
relationship was comparable to that observed in the founder C57BL/6J strain (Fig 
2A).  In contrast, h/mOprm1 118AA mice were relatively insensitive to alcohol when 
compared to 118AA and C57BL/6J mice; alcohol responses in118AA mice showed 
no significant difference from water across the dose range tested (Fig 2A).  Post hoc 
testing indicated that 0.6 and 2.4 g/kg alcohol significantly altered BSR thresholds 
compared to vehicle in h/mOprm1 118GG mice, yet only the response to 0.6 g/kg 
was different between genotypes.  There was a significant main effect of alcohol 
dose on MAX (Table 1; F5,152 = 3.89, p = 0.005) that did not interact with h/mOprm1 
genotype.  Although there was a trend toward increased MAX in h/mOprm1 118GG 
mice following 0.6 g/kg alcohol when compared to 118AA mice, this did not reach 
significance (p = 0.35).  
Because the potency of naltrexone to blunt the subjective effects of alcohol is 
increased in 118G carriers (L. A. Ray & Hutchison, 2007), I used this opioid 
antagonist to determine the role of endogenous opioids in the potentiation of BSR by 
alcohol.  When given alone, naltrexone (0.1 – 1.0 mg/kg i.p.) had no significant effect 
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on BSR threshold (Fig 2B) or MAX (Table 2) at any dose tested.  In a separate 
group of mice, subjects were pre-treated with either saline or naltrexone (1.0 mg/kg 
i.p.) prior to receiving water or alcohol (0.6 g/kg p.o.).  When administered after 
saline, 0.6 g/kg alcohol significantly lowered BSR threshold in h/mOprm1 118GG 
(Fig 2B; t10 = 2.42, p = 0.04), but not 118AA, mice when compared to water.  In the 
saline/alcohol trial, BSR threshold was lower in h/mOprm1 118GG mice when 
compared to 118AA mice (Fig 2B; t10 = 2.23, p = 0.04); there was no difference 
between genotypes during the saline/water trial.   
When administered after naltrexone, 0.6 g/kg alcohol significantly elevated 
BSR threshold in h/mOprm1 118GG (Fig 2B; t10 = 2.62, p = 0.01), but not 118AA, 
mice when compared to water.  In the naltrexone/alcohol trial, BSR threshold was 
significantly elevated in h/mOprm1 118GG mice when compared to 118AA mice (Fig 
2B; t10 = 2.44, p = 0.03); there was no difference between genotypes during the 
naltrexone/water trial.  In the saline/water and naltrexone/water trials, post-injection 
BSR threshold was not different from baseline, and no genotype differences were 
observed (Fig 2B).  Generally, MAX was slightly decreased from baseline across 
pre-treatment experiments (approx. 10-15%), which was most likely caused by 
stress associated with intraperitoneal injection followed by oral gavage (Table1).  No 
genotype differences in MAX were observed, although MAX was significantly lower 
in h/mOprm1 118GG mice in the naltrexone/water trial when compared to the 
saline/water trial (Table 1; t10 = 2.74, p = 0.02). 
Alcohol’s opioid-like actions are not mediated by interactions with the opioid 
receptor; rather, it acts indirectly through the release of endogenous opioids.  I 
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therefore examined whether the h/mOprm1 118G variant also affected responses to 
direct MOR agonists and compared them to the kappa opioid receptor agonist 
U69,593 and the monoamine reuptake inhibitor cocaine.  MOR agonists fentanyl 
(Fig 3; F4,60 = 15.0, p < 0.001) and oxycodone (Fig 3; F4,52 = 14.7, p < 0.001), the 
MOR partial agonist buprenorphine (Fig 3; F4,64 = 4.5, p = 0.003), U69,593 (Fig 3; 
F3,63 = 32.1, p < 0.001), and cocaine (Fig 3; F3,57 = 59.1, p < 0.001) had dose-
dependent effects on BSR threshold  that did not interact with h/mOprm1 genotype.  
A significant interaction between genotype and dose was observed for morphine 
sulfate (Fig 3; F3,57 = 8.0, p < 0.001).  h/mOprm1 118AA mice displayed biphasic 
dose effects of morphine on ICSS; BSR threshold was lowered by a low doses (3.0 
mg/kg i.p.) and raised by higher doses (10.0 mg/kg i.p.).  In contrast, h/mOprm1 
118GG mice were relatively insensitive to morphine and showed no significant 
difference from vehicle across the dose range tested (1.0 – 10.0 mg/kg i.p.).  Post 
hoc testing indicated that the effects of 3.0 and 10.0 mg/kg (i.p.) morphine on BSR 
thresholds differed between h/mOprm1 118AA and 118GG mice.   
Fentanyl (Table 2; F4,60 = 10.0, p < 0.001), oxycodone (Table 2; F4,52 = 6.6, p 
< 0.001), buprenorphine (Table 2; F4,64 = 10.7, p < 0.001), and U69,593 (Table 2; 
F3,63 = 5.09, p = 0.003) had dose-dependent effects on (MAX)  that were 
independent of h/mOprm1 genotype.  A significant interaction between genotype 
and dose was observed for morphine (Table 2; F3,57 = 7.56, p < 0.001).  Mice of both 
genotypes displayed biphasic dose effects of morphine on MAX; low doses (1.0 
mg/kg i.p.) elevated MAX in h/mOprm1 118AA mice and higher doses (10.0 mg/kg 
i.p.) decreased MAX in both h/mOprm1 118AA and 118GG mice.  Post hoc testing 
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indicated that MAX was suppressed to a lesser extent in h/mOprm1 118GG mice 
following10.0 mg/kg (i.p.) morphine.  Because there were genotype-dependent 
differences in the rewarding potency of morphine, I next examined differences in 
VTA physiology in 118AA and 118GG mice using patch clamp electrophysiology 
Opioids disinhibit dopaminergic neurons in the VTA by attenuating GABAergic 
neurotransmission at presynaptic terminals (Fig 4A) (Johnson & North, 1992b).  
Using whole-cell patch clamp electrophysiology, I measured the acute effects of 
morphine (100 nM) and the MOR-selective, high efficacy agonist DAMGO (100 nM) 
on mIPSCs in dopaminergic neurons.  Putative dopaminergic neurons were patched 
with an internal solution containing Alexa fluor 594 dye and were identified by the 
presence of a hyperpolarization-activated current (Ih).  Cells were then confirmed as 
dopaminergic by post-staining for tyrosine hydroxylase (Fig 4B).  No differences 
were observed in baseline mIPSC frequency (Fig 5; 118AA: 2.9 ± 0.6 Hz; 118GG: 
2.0 ± 0.6 Hz) and amplitude (Fig 5; 118AA: 34.5 ± 2.3 pA; 118GG: 34.8 ± 2.0 pA) in 
h/mOprm1 118AA and 118GG VTA dopaminergic neurons.  mIPSCs were 
completely abolished by bath application of the GABAA receptor antagonist gabazine 
(SR-95531, data not shown).  DAMGO robustly decreased mIPSC frequency (Fig 
4D; 118AA: 74.5 ± 3.9% baseline; 118GG: 71.6 ± 5.8% baseline), but not amplitude 
(Fig 4E; 118AA: 99.5 ± 3.2% baseline; 118GG: 97.2 ± 2.6% baseline), in both 
h/mOprm1 118AA and GG mice, suggesting that MORs functioned presynaptically 
to inhibit GABAergic transmission.  Similarly, 100 nM morphine reduced mIPSC 
frequency in h/mOprm1 118AA (Fig D; 74.5 ± 2.7% baseline), but not 118GG, mice 
(Fig 4E; 100.6 ± 4.8% baseline; t15 = 4.59, p < 0.001) without affecting mIPSC 
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amplitude (Fig 4E; 118AA: 99.7 ± 3.2% baseline; GG: 99.9 ± 2.8% baseline).  These 
effects were blocked by pre-application with the opioid antagonist naloxone (1.0 uM; 
Fig 4D-E; 118AAfreq: 96.0 ± 2.49% baseline; 118GGfreq: 104.5 ± 7.4% baseline; 
118AAampl: 100.8 ± 4.5% baseline; 118GGampl: 102.6 ± 4.7% baseline).   
 It has been reported that genotypic differences in agonist potency are due to 
changes in ligand binding affinity (Bond, et al., 1998) or receptor surface expression 
(Kroslak, et al., 2007).  Therefore, I performed several pharmacological assays to 
determine how h/mOprm1 genotype affected the number of binding sites in 
subcellular fractions, the binding affinities of MOR agonists (β-END, DAMGO, and 
morphine), and the ability of these compounds to couple Giα.  In these assays, I used 
freshly prepared brainstem tissue, which included the midbrain VTA, from h/mOprm1 
118AA and 118GG mice.  VTA alone could not be used for these experiments 
because this region is small in mice and does not yield enough enriched membranes 
for ligand binding determinations.  
Because anti-MOR antibodies are generally unreliable in their ability to 
specifically label receptors in the rodent CNS, the total number of MOR binding sites 
was measured using [3H]-DAMGO binding in subcellular fractions prepared from 
brainstem tissue.  There was 1.86 ± 0.02 µg protein per µL homogenized, 
unfractionated brain tissue per h/mOprm1 118AA mouse and 1.87 ± 0.06 µg 
protein/µL per 118GG mouse, as measured by the Bradford assay.  This was used 
to estimate the total amount of protein in tissues samples that underwent subcellular 
fractionation (Table 3; 118AA: 2424.2 ± 93.0 µg; 118GG: 2491.6 ± 105.3 µg).  The 
nuclear/cytosolic fraction (P1) fraction contained 691.0 ± 13.0 µg per 118AA mouse 
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(28.5% of the total protein) and 696.5 ± 28.5 µg per 118GG mouse (28.0% of the 
total protein).  The surface (P2) fraction contained 269.3 ± 9.2 µg per 118AA mouse 
(11.1%) and 276.1 ± 11.4 µg per 118GG mouse (11.4%).  The microsomal (P3) 
fraction contained 60.7 µg per 118AA mouse (2.5%) and 40.8 µg per 118GG mouse 
(2.2%).  Approximately 40% of the total protein (42.1% per 118AA mouse; 41.5% 
118GG mouse) was unaccounted for in membrane fractions.  This most likely 
represents soluble protein that was discarded in the third supernatant.   
There was no difference in the total number of binding sites in unfractionated 
brainstem membranes between h/mOprm1 118AA and 118GG mice (Fig 6A; 118AA: 
2.65 ± 0.23 scintillation counts/min/µg protein; 118GG = 2.47 ± 0.28 counts/min/µg 
protein).  The number of binding sites in the nuclear/cytosolic membrane fraction 
(P1) was significantly decreased in 118GG mice (Fig 6A; 118AA: 8.64 ± 0.54 
scintillation counts/min/µg protein; GG = 7.02 ± 0.32 counts/min/µg protein; t12 = 
2.45, p = 0.03).  This represents an 18.8% decrease in specific binding/µg protein.  
While there was a trend (p = 0.13) toward decreased number of binding sites in the 
surface fraction (P2; Fig 6A; AA: 7.61 ± 0.68 scintillation counts/min/µg protein; GG 
= 6.39 ± 0.29 counts/min/µg protein), P2 binding was significantly decreased in 
h/mOprm1 118GG mouse membranes when the experiment was repeated using a 
different harvester and scintillation counter (Fig 7; AA: 2.54 ± 0.09 scintillation 
counts/min/µg protein; GG = 2.24 ± 0.07 counts/min/µg protein; t12 = 2.65, p = 0.02).  
The percent decrease in number of P2 binding sites in 118GG mice was 
approximately the same across experiments (84% vs. 88%), and the 95% 
confidence interval when experiments were combined was 82.4% - 90.6% (118AA: n 
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= 14; 118GG: n = 14).  Specific binding in the pooled microsomal fraction was 
increased in 118GG mice when compared to 118AA mice (AA: 1.88 counts/min/µg 
protein; GG: 3.49 counts/min/µg protein).  This represents a 186% increase in 
specific binding/µg protein.  Samples had to be pooled in order to generate enough 
tissue for binding due to the small relative size of this fraction; this precluded 
statistical analysis between genotypes.  
 A competition binding assay that employed [3H]-DAMGO as the reference 
ligand was used to determine the binding affinity of β-END, DAMGO, and morphine.  
In these experiments, there was no significant difference in the binding affinity of β-
END (Fig 6B: Ki118AA = 35.6 nM; Ki118GG = 47.1), DAMGO (Fig 6B: Ki118AA = 4.16 nM; 
Ki118GG = 4.21 nM), and morphine (Fig 6B: Ki118AA = 0.42 nM; Ki118GG = 0.42 nM) for 
the MOR in freshly homogenized brainstem tissue from h/mOprm1 118AA and 
118GG mice.  
 Finally, I employed a cAMP biosensor assay to measure Giα coupling in 
HEK293 cells that expressed either the OPRM1 118A, OPRM118G, h/mOprm1 
118A, or h/mOprm1 118G receptor.  Generally, agonists were more potent at 
h/mOprm1 receptors when compared to OPRM1 receptors (Fig 6C-D), presumably 
due to differences in the coding regions of Exons 2-4.  DAMGO was the most potent 
agonist tested in all four experiments (Fig 6C-D), but did not differ between 118A 
and 118G variants (EC50h118A = 3.5 nM, EC50h118G = 8.6 nM, EC50h/m118A = 0.96 nM, 
EC50h/m118G = 1.6 nM).  Morphine was approximately 10-fold less potent than 
DAMGO, and potency was not significantly different between 118A and 118G 
receptors (EC50h118A = 64.4 nM, EC50h118G = 103.0 nM, EC50h/m118A = 9.8 nM, 
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EC50h/m118G = 12.3 nM).  β-END was the least potent agonist tested and also failed 
to show genotype-dependent differences in Giα coupling, although there was a trend 
toward decreased potency at h/mOprm1 118G receptors when compared to 
h/mOprm1 118A receptors (EC50h118A = 359.7 nM, EC50h118G = 413.0 nM, 
EC50h/m118A = 166.0 nM, EC50h/m118G = 303.4 nM).  
  
DISCUSSION 
In these studies, I employed a humanized transgenic mouse model of the 
OPRM1 A118G polymorphism to investigate how this genetic variant alters acute 
drug responses in vivo and in vitro.  In agreement with clinical and human 
neuroimaging findings, h/mOprm1 118GG mice were more sensitive to the reward-
potentiating effects of alcohol on ICSS, which were blocked by pretreatment with the 
opioid antagonist naltrexone.  Because alcohol in part exerts its rewarding effects 
indirectly via the release of endogenous opioids, I examined whether this OPRM1 
polymorphism also moderates responses to MOR agonists.  In the same behavioral 
test, h/mOprm1 118GG mice were less sensitive than 118AA littermates to the 
effects of morphine, but not other opioids or cocaine.  Using patch clamp 
electrophysiology in acute midbrain slices, I found that the presynaptic inhibition of 
GABA caused by morphine was blunted in h/mOprm1 118GG mice.  However, this 
effect was not seen with the selective MOR agonist DAMGO.  Receptor binding and 
functional cAMP assays demonstrate that these observations do not appear to be 
due to changes in Gαi coupling or ligand binding affinity.  A tissue fractionation and 
radioligand binding assay suggest that the A118G polymorphism alters receptor 
137 
 
trafficking without changing total receptor content.   
 During ICSS testing, h/mOprm1 118GG mice were more sensitive than 118AA 
mice to the reward-potentiating effects of a low dose of alcohol (0.6 g/kg), which was 
aversive (i.e. elevated BSR threshold) following pretreatment with the opioid 
antagonist naltrexone.  Endogenous opioid release following alcohol infusion has 
been demonstrated using [11C]-carfentanil positron emission tomography (PET) in 
humans (Mitchell, et al., 2012).  Naltrexone decreases alcohol consumption by 
blocking the subjective “high” associated with intake  (Volpicelli, Watson, King, 
Sherman, & O'Brien, 1995), and its efficacy in the treatment of AUDs is supported by 
randomized, placebo-controlled clinical trials (Anton et al., 2006; Volpicelli, Alterman, 
Hayashida, & O'Brien, 1992; Volpicelli et al., 1997).  Similar to our findings in mice, 
human OPRM1 118G carriers are more sensitive to the subjective pleasurable and 
intoxicating effects of alcohol (L. A. Ray & Hutchison, 2004), as well as the ability of 
naltrexone to block them (L. A. Ray & Hutchison, 2007).  It is important to note that 
h/mOprm1 118GG and C57BL/6J mice, which both have 4 glycosylation sites in 
Oprm1 exon 1, displayed similar responses to alcohol.  In contrast, 118AA mice, 
which have 5 glycosylation sites, were relatively insensitive to the effects of alcohol 
on ICSS, suggesting that the number of glycosylation sites is inversely correlated 
with the rewarding effects of alcohol.   
 In our studies, the ability of alcohol to lower BSR thresholds in h/mOprm1 
118GG mice was most likely due to the effects of endogenous opioids in 
mesocorticolimbic reward circuits.  The subjective effects of alcohol are correlated 
with dopamine D2 receptor availability in the striatum (Yoder et al., 2005), and 
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alcohol produces dopamine release in the nucleus accumbens of human subjects, 
as measured by [11C]-raclopride PET (Boileau et al., 2003).  Dopaminergic 
antagonists reduce alcohol consumption in rats (Panocka, Ciccocioppo, Mosca, 
Polidori, & Massi, 1995; Pfeffer & Samson, 1985, 1988) and block the reward-
potentiating effects of alcohol on ICSS in mice (Malanga, unpublished observations).  
Microdialysis studies have shown that β-END is released in the VTA following 
alcohol exposure (Jarjour, et al., 2009), and opioid antagonists decrease alcohol-
mediated dopamine release in laboratory animals (Gonzales & Weiss, 1998; Valenta 
et al., 2013) and block VTA dopaminergic cell firing following alcohol treatment in 
brain slices (Xiao, Zhang, Krnjevic, & Ye, 2007).  Dopamine release in the nucleus 
accumbens is greater in both OPRM1 118G carriers and h/mOprm1 118GG mice 
after alcohol exposure (Ramchandani, et al., 2010), which may make these mice 
more sensitive to the reward-potentiating effects of alcohol on ICSS.  
 While h/mOprm1 118GG mice appear to be more sensitive to the effects of 
alcohol on ICSS and other behaviors, the physiological mechanism that mediates 
this phenotype is currently unknown.  An early report determined that the binding 
affinity of β-END, but not other endogenous opioids, for the 118G receptor is 
approximately three times higher than for the 118A receptor, which was associated 
with increased potency to stimulate GIRK currents in Xenopus oocytes (Bond, et al., 
1998).  This finding has not been supported by other in vitro studies, however, as the 
potency of β-END was not significantly altered in either COS (Befort, et al., 2001) or 
HEK293 cells (Beyer, et al., 2004).  In order to address this discrepancy, I employed 
a competition binding assay using fresh brainstem membrane preparations and 
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confirmed that the binding affinity of β-END does not vary by genotype.  
Furthermore, I replicated Beyer et al. (2004), demonstrating that there is no 
appreciable difference in the potency of β-END, morphine, or DAMGO to decrease 
cAMP production in HEK293 cells expressing either OPRM1 118A, OPRM1 118G, 
h/mOprm1 118A, or h/mOprm1 118A receptors.  These results agree with the 
findings of Ramchandani et al. (2010) that the potency of  β-END to inhibit calcium 
currents in dissociated trigeminal ganglion neurons is not significantly different 
between h/mOprm1 118AA and 118GG mice (EC50 = 447 nM vs 608 nM). 
 While differences in Gi in coupling between OPRM1 118A and 118G receptors 
are not supported by the literature, it is unknown whether the polymorphism alters 
the functional selectivity of endogenous opioids by changing their ability recruit β-
arrestin recruitment.  Arrestin recruitment is associated with both rapid 
desensitization and the ability to produce internalization (Arttamangkul, Torrecilla, 
Kobayashi, Okano, & Williams, 2006; Dang, Chieng, Azriel, & Christie, 2011; Dang & 
Christie, 2012), which are not different between 118A and 118G receptors in 
HEK293 cells exposed to β-END, morphine, or DAMGO (Beyer, et al., 2004).  
However, this doesn’t rule out the involvement of arrestin-dependent signaling, 
which is associated with a different pattern of receptor phosphorylation by G protein-
coupled receptor kinases (Nobles et al., 2011).  ERK phosphorylation (which can be 
arrestin-dependent; e.g. (Zheng, Loh, & Law, 2008)) following alcohol place 
preference conditioning is altered in h/mOprm1 118GG mice (Thorsell and Heilig, 
unpublished observations).  Also, basal pERK levels are decreased in Neuro2a cells 
stably expressing the OPRM1 118G receptor (Deb, Chakraborty, Gangopadhyay, 
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Choudhury, & Das, 2010).  These findings emphasize the need to determine the 
functional selectivity of agonists using the h/mOprm1 A118G model and arrestin-
recruitment assays.  
Receptor-receptor interactions may also play a role in h/mOprm1 A118G-
related phenotypes, as loss of N-terminal glycosylation affects homodimerization of 
other GPCRs (J. He, Xu, Castleberry, Lau, & Hall, 2002).  The MOR crystalizes as a 
homodimer (due to tight interactions between the fifth and sixth transmembrane 
helices), raising the possibility that MOR-MOR interactions are disrupted by the 
A118G polymorphism as a consequence of the conformational effects of reduced 
receptor glycosylation.  Homodimerization, in turn, may alter agonist efficacy via 
several mechanisms.  For example, the MOR receptor binding pocket is large (in 
comparison to other GPCRs), and homodimerization may allosterically alter its 
shape (Manglik et al., 2012).   The relative size of the exposed binding surface has 
permitted the discovery of hundreds of agonists (Williams et al., 2013), but may 
increase the probability that a non-synonymous polymorphism modifies receptor 
function.  While I did not detect a difference in ligand binding affinity or β-END 
potency, it is possible that the high density of surface receptors in transfected cells 
masked a homodimerization defect; however, this mechanism is highly unlikely 
given that my findings replicated measurements in trigeminal ganglion neurons, 
where the receptor density is much lower (Ramchandani, et al., 2010). 
 It has also been shown that the MOR forms heterodimers with multiple other 
receptors, including the nociceptin/orphanin FQ receptor (H. L. Wang et al., 2005), 
the delta opioid receptor (Gomes et al., 2000), and the kappa opioid receptor 
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((Chakrabarti, Liu, & Gintzler, 2010).   Disruption of these dimers can alter agonist 
potency in vivo (Gomes et al., 2004) and may affect endogenous opioid sensitivity in 
h/mOprm1 118GG mice.  According to one report, specific chaperone proteins are 
required to traffic heterodimers to the cell surface (Decaillot, Rozenfeld, Gupta, & 
Devi, 2008).  Both these proteins and receptor dimerization partners would need to 
be expressed by HEK293 cells in order to recapitulate heterodimerization in mature 
neurons.  This example illustrates the limitations of using a heterologous expression 
system to describe receptor signaling in vivo.  Expression profiling indicates that 
HEK293 cells express most, but not all, GPCR-related proteins that exist in the 
mammalian brain (Atwood, Lopez, Wager-Miller, Mackie, & Straiker, 2011).  As 
such, caution must be used when interpreting the results of in vitro functional assays 
in the context of animal behavior or neural circuitry.  
One of the most consistent findings associated with the OPRM1 A118G 
polymorphism in cell culture, animal models, and neuroimaging studies is lower total  
MOR expression and/or a decrease in the number of surface binding sites (Beyer, et 
al., 2004; Kroslak, et al., 2007; Mague et al., 2009; R. Ray et al., 2011; Y. J. Wang, 
Huang, Ung, Blendy, & Liu-Chen, 2012; Weerts et al., 2013).  This may be due to 
differences in mRNA stability (Y. Zhang, Wang, Johnson, Papp, & Sadee, 2005), 
epigenetic regulation of OPRM1 expression (Oertel et al., 2012), and/or receptor 
trafficking (J. He, et al., 2002).  In these studies, I did not observe a difference in the 
number of total [3H]-DAMGO binding sites in 118AA and 118GG mice, which agrees 
with previously published autoradiographic analysis by Ramchandani et al. (2010).  
When tissue was subjected to a subcellular fractionation protocol, specific binding 
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was detected in nuclear/cytosolic, surface, and microsomal fractions; specific 
binding was decreased in the surface and nuclear/cytoplasmic fractions, but 
increased in the microsomal fraction.  
The MOR has been detected in multiple brain membrane fractions using 
radioligand binding (e.g. (Howells, Groth, Hiller, & Simon, 1980; B. L. Roth, 
Laskowski, & Coscia, 1981)).  The P1 fraction includes the nucleus, cytosolic 
proteins, and proteins from synaptosomes (Gu, Liu, & Yan, 2009).  The P2 fraction 
represents the synaptic plasma membrane and contains synaptosomes, cytoplasmic 
matrix, and synaptic junction proteins.  The P3 fraction contains microsomes, which 
lack synaptosomal proteins, ribosomes, and synaptic junction proteins.  These 
vesicles may contain receptors being trafficked to the extracellular surface (B. L. 
Roth, et al., 1981).  Loss of N-linked glycosylation impairs trafficking of several 
receptors to the cell surface, including the GABA-A receptor (Lo et al., 2010), 
dopamine D5 receptor (Karpa, Lidow, Pickering, Levenson, & Bergson, 1999), β2-
adrenergic receptor (Rands et al., 1990), AT1a angiotensin receptor (Jayadev et al., 
1999), melanocortin 1 receptor (Herraiz, Sanchez-Laorden, Jimenez-Cervantes, & 
Garcia-Borron, 2011), etc.  Thus, it is likely that changes in subcellular MOR 
distribution that I observed are due to differences in receptor trafficking.  Enrichment 
in microsomes, but depletion in other fractions, suggests that receptors are 
expressed at normal levels h/mOprm1 118GG mice, but are less efficiently delivered 
and integrated into the synaptic membrane.  
 While it is not immediately clear how loss of surface MOR density increases 
alcohol sensitivity, it could enhance opioid peptide release if the activity of 
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opioidergic neurons is regulated by the MOR via autoinhibition.  Recent evidence 
provides some support for this hypothesis, as proopiomelanocortin (POMC) neurons 
in the hypothalamic arcuate nucleus that produce β-END and co-release GABA 
project to the ventral tegmental area (Hentges et al., 2004; King & Hentges, 2011).  
Optogenetic approaches have determined that these projections are presynaptically 
regulated by MORs (Dicken, Tooker, & Hentges, 2012).  Given that it is difficult to 
sensitively measure β-END release with temporal precision using microdialysis, 
testing this hypothesis in humans would require the use of [11C]-carfentanil PET and 
the alcohol clamp procedure (Subramanian et al., 2002).  
In addition to the finding that h/mOprm1 118GG mice are more sensitive to 
alcohol than 118AA littermates, I found that they are less sensitive to the biphasic 
effects of morphine, but not other opioids or cocaine.  h/mOprm1 118GG mice are 
less sensitive to the analgesic effects of morphine, which is associated with a 
fivefold decrease in potency and 26% decrease in efficacy in dissociated trigeminal 
ganglion neurons (Mahmoud et al., 2011).  Our observations are very similar to 
those made using an alternate model of the OPRM1 A118G polymorphism in which 
a homologous N-linked glycosylation site was removed via site-directed 
mutagenesis of adenine to guanine at Oprm1 position 112 (A112G) (Mague, et al., 
2009).  Mague et al. (2009) demonstrated that Oprm1 112GG mice are significantly 
less sensitive to morphine in several assays, which the authors attributed to a 
substantial decrease in MOR expression.  This study only examined morphine 
responses, so it is unknown if 112GG mice differ in their sensitivity to other MOR 
agonists or alcohol.  Anesthesiological research suggests that the in vivo potency of 
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morphine and other opioid analgesics is decreased in OPRM1 118G carriers 
(reviewed by (Diatchenko, et al., 2011)), although the role of this polymorphism in 
opioid abuse is less clear.    
A large number of studies report an association between carrying the 118G 
allele and opioid dependence (Bart, et al., 2004; Deb, et al., 2010; Drakenberg, et 
al., 2006; Kapur, Sharad, Singh, & Gupta, 2007; D. Kumar, Chakraborty, & Das, 
2012; Szeto, Tang, Lee, & Stadlin, 2001; Tan, Tan, Karupathivan, & Yap, 2003), but 
this finding is not supported by meta-analysis (Haerian & Haerian, 2013).  It is of 
note that the association between the A118G polymorphism and opioid dependence 
reaches significance when analysis is restricted to Asian populations, in which 118G 
allele frequency is high compared to Caucasians (approx. 0.40 - 0.50 vs. 0.15 - 0.30, 
respectively) (Haerian & Haerian, 2013).  My studies suggest that this variant 
strongly diminishes the rewarding effects of morphine and predicts that the potency 
of heroin would be decreased as well.  It is possible that, given our findings, 
decreased morphine reward is protective against opioid abuse in some individuals, 
while resistance to the negative effects of morphine promotes intake in others, which 
would make the interaction between this polymorphism and opioid dependence 
complex.  Well controlled human laboratory studies examining the subjective effects 
and self-administration of intravenous morphine in OPRM1 118A homozygotes and 
118G carriers will be necessary to parse this relationship.    
 As is the case with alcohol, morphine and other opioids most likely potentiate 
BSR by disinhibiting the A10 dopaminergic projection from the mesencephalic VTA 
to the forebrain NAc, which is involved in motivated behavior and behavioral 
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reinforcement (Nestler, 2004; Schultz, Dayan, & Montague, 1997; Wise, 1998).  
Rodents will self-administer MOR agonists directly into the VTA (Devine & Wise, 
1994), and these effects are attenuated by administration of dopamine receptor 
antagonists (David, Durkin, & Cazala, 2002).  Morphine decreases BSR threshold in 
mice (Elmer, Pieper, Hamilton, & Wise, 2010; Robinson, et al., 2012) and rats (R. 
Esposito & Kornetsky, 1977; R. U. Esposito, McLean, & Kornetsky, 1979); these 
effects are blocked by dopamine receptor antagonists (Kornetsky & Duvauchelle, 
1994; Kornetsky & Porrino, 1992).  As intravenous opioids stimulate striatal 
dopamine release in humans (Spreckelmeyer et al., 2011), future studies should 
address the involvement of OPRM1 variants in the differential mesocorticolimbic 
response to morphine or other opioids.  
In the VTA, mu opioids act via the Gi/o-coupled MOR to disinhibit 
dopaminergic neurons by attenuating inhibitory GABAergic tone, which promotes 
burst firing and enhances dopamine release in terminal fields (Bergevin, Girardot, 
Bourque, & Trudeau, 2002; Di Chiara & Imperato, 1988; Gysling & Wang, 1983; 
Johnson & North, 1992b).  In order to assess the sensitivity of VTA circuitry to mu 
opioids in h/mOprm1 118AA and 118GG mice, I used whole-cell patch clamp 
recordings to measure the effects of morphine and DAMGO on GABAergic mIPSCs 
in dopaminergic neurons in midbrain slices.  I found that 100 nM DAMGO decreased 
mIPSC frequency, but not amplitude, to a similar extent in both 118AA and 118GG 
neurons, which is consistent with a presynaptic site of action (Bergevin, et al., 2002).  
While 100 nM morphine decreased mIPSC frequency in 118AA slices, this effect 
was absent in 118GG neurons.  The morphine concentration used was greater than 
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the EC50 shown to decrease calcium currents in h/mOprm1 118AA trigeminal 
ganglion neurons (47 nM) and below the EC50 in 118GG neurons (260 nM) 
(Mahmoud, et al., 2011).  Given that presynaptic MOR-mediated control of GABA 
release at synapses with dopaminergic neurons in the VTA is a critical mechanism 
regulating opioid reward in mice (Madhavan, Bonci, & Whistler, 2010), it is highly 
likely that decreased potency of morphine at this site contributed to the relative 
insensitivity of h/mOprm1 118GG mice to the effects of morphine on ICSS.  
It is unclear why h/mOprm1 118GG mice are less sensitive to morphine, but 
not other opioids.  Morphine had the lowest rewarding potency of the opioids tested 
in these experiments (i.e. required the largest dose to significantly reduce BSR 
threshold in h/mOprm1 118AA mice).  The global binding potential for [11C]-
carfentanil is lower in OPRM1 118G allele carriers than in 118AA homozygotes 
(Weerts, et al., 2013), and [3H]-DAMGO binding was lower in surface membrane 
fractions from h/mOprm1 118AA and GG mouse brains.  This decrease in the 
number of sites available for binding could reduce the behavioral and cellular 
response to an agonist if its receptor reserve is sufficiently low.  Thus, the behavioral 
response to any agonist with a lower in vivo potency than morphine should be 
decreased in 118GG mice.  In agreement with experimental data, highly potent 
agonists would be predicted to be efficacious in both 118AA and 118GG mice 
because their receptor reserve is large.  Potential future experiments would 
therefore include testing lower potency opioids than morphine (e.g. hydrocodone).  
Mechanisms by which receptor reserve is lower in h/mOprm1 118GG mice is 
unknown, but could involve altered trafficking of the mature MOR protein to the cell 
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surface or the inability to recycle internalized receptors.  Efforts to localize MOR 
receptors in brain tissue have been impeded by the generally poor specificity of 
antibodies; therefore, these hypotheses will need to be tested using more thoroughly 
fractionation procedures.   
The MOR agonists used in this study displayed broad differences in intrinsic 
efficacy, as well.  Morphine has a relatively low efficacy in brain slices (Osborne, 
Chieng, & Christie, 2000), so it is possible that h/mOprm1 118GG mice are generally 
less responsive to weak agonists, but retain sensitivity to full agonists, such as 
DAMGO or fentanyl.  However, I did not observe a genotype difference in response 
to buprenorphine, a highly potent partial agonist (e.g. efficacy in a GTPƔS assay = 
55% of DAMGO; Kd = 0.9 nM (McPherson et al., 2010)).  Oxycodone, which is 
structurally similar to morphine and equally efficacious in vitro (McPherson, et al., 
2010), was 30 times more potent than morphine on ICSS, presumably due to greater 
brain penetrance of oxycodone (Bostrom, Hammarlund-Udenaes, & Simonsson, 
2008) and the first-pass metabolism of i.p. morphine (Handal, Grung, Skurtveit, 
Ripel, & Morland, 2002).  These observations suggest that the ability of a MOR 
agonist to alter BSR thresholds in 118GG mice is influenced by many factors, 
including pharmacokinetics, intrinsic activity, and the size of its receptor reserve.  
Electrophysiological recordings of MOR-mediated GIRK currents in h/mOprm1 
118AA and 118GG in neurons using a broad panel of agonists would help clarify the 
relationship between genotype, agonist potency, and intrinsic efficacy.  
It is possible that pharmacogenetic responses to MOR agonists cannot be 
predicted by their pharmacological characteristics; rather, h/mOprm1 118GG mice 
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may be less sensitive to morphine alone.  In functional receptor assays, I failed to 
detect genotypic differences in the effect of morphine on cAMP accumulation, which 
suggests that its intrinsic efficacy is not affected by the A118G polymorphism.  This 
is not surprising given that the N-terminus is not particularly important for agonist 
binding and receptor activation; DAMGO and morphine retain potency at the MOR in 
the absence of the extracellular domain (Surratt et al., 1994).  Mutational analyses 
indicate that residues in the third, sixth, and seventh transmembrane domains are 
necessary for ligand binding and receptor activation (Mansour et al., 1997).  These 
measures did not differ between variants in our experiments.  The first extracellular 
loop serves an agonist selectivity filter (W. W. Wang, Shahrestanifar, Jin, & Howells, 
1995).  The third intracellular loop alters heterodimerization (O'Dowd, Ji, O'Dowd, 
Nguyen, & George, 2012), while transmembrane domains five and six may facilitate 
homodimerization (Manglik, et al., 2012).  The intracellular C-terminus, which 
undergoes heavy alternative splicing, affects signal transduction, desensitization, 
and internalization (Koch et al., 2001; Shabalina et al., 2009; Xu et al., 2013).  Given 
what is known about MOR structure and function, including the recently solved 
crystal structure (Manglik, et al., 2012), it is unlikely that intrinsic efficacy of morphine 
is altered in h/mOprm1 118GG mice.   
 There are several properties of morphine that make it unique among MOR 
agonists and could contribute to the cellular and behavioral phenotypes I observed.  
It has been well documented that morphine – unlike DAMGO, fentanyl, and several 
other opioids –  fails to produce receptor internalization (Keith et al., 1996).  This 
finding has been correlated with the propensity of morphine to cause physiological 
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tolerance (Finn & Whistler, 2001).  Mice expressing a mutant form of the MOR that is 
efficiently internalized by morphine exhibit increased morphine reward, but less 
escalation of morphine consumption, naloxone-precipitated withdrawal, and adaptive 
changes to GABAergic signaling in the VTA following prolonged exposure (Berger & 
Whistler, 2011; L. He, Kim, & Whistler, 2009; Madhavan, He, Stuber, Bonci, & 
Whistler, 2010).  It is important to note, however, that morphine can produce 
internalization when the concentration of G protein coupled receptor kinase-2 
(GRK2) is high (e.g. in striatal medium spiny neurons) (Haberstock-Debic, Kim, Yu, 
& von Zastrow, 2005).  While the inability to produce internalization makes morphine 
distinct among the opioids examined in this study, morphine-mediated internalization 
was not different between OPRM1 118A and 118G receptors in a previous study 
(Beyer, et al., 2004).  Future investigations will need to more fully examine this 
phenomenon in h/mOprm1 118AA and 118GG mice.  
Another well-characterized property of morphine is that it fails to cause robust 
desensitization when compared to other opioids (Levitt & Williams, 2012) , which 
may be due to its relative inability to recruit β-arrestin 2 (Chu, Zheng, Loh, & Law, 
2008; Dang & Williams, 2005; Whistler & von Zastrow, 1998).  Acute MOR 
desensitization following exposure to morphine, but not fentanyl or DAMGO, 
appears to be mediated by c-Jun N-terminal kinase 2 (JNK2) (Melief, Miyatake, 
Bruchas, & Chavkin, 2010).  JNK antagonists rescue several phenotypes observed 
in β-arrestin 2 knockout mice (Mittal et al., 2012) and block analgesic tolerance to 
morphine (Melief, et al., 2010).  It is possible that OPRM1 118A and G receptors 
desensitize at different rates during morphine exposure, which would shorten the 
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duration of action in vivo and reduce its rewarding potency.  Receptor 
desensitization and resensitization following prolonged morphine incubation do not 
differ between variants in vitro (Beyer, et al., 2004), and I detected a large difference 
in the effect of morphine on presynaptic receptors, which undergo minimal 
desensitization in the VTA (Lowe & Bailey, 2014) and other brain regions (Pennock, 
Dicken, & Hentges, 2012; Wetherington & Lambert, 2002).   
Overall, these studies provide evidence that the OPRM1 A118G 
polymorphism has bidirectional effects on sensitivity to alcohol and morphine, but 
not other opioids.  While these phenotypes are difficult to reconcile, they most likely 
share a common biological etiology that directly relates to the physiological role of 
the N-terminus in MOR function.  Decreased MOR surface expression and altered 
receptor trafficking most likely influenced my findings.  Given that the increased 
potency of β-END reported by Bond et al. (1998) has not been replicated in cultured 
cells or h/mOprm1 118G mouse neurons, it is possible that increased alcohol 
sensitivity is due to the amount of opioid released rather than a difference in its 
intrinsic activity at the MOR.  If opioid release is regulated by the MOR via 
autoinhibition, loss of receptor reserve in the presynaptic terminal may increase the 
sensitivity of POMC neurons (that co-release GABA) to alcohol.  Similar reductions 
in receptor reserve throughout the CNS may render some brain areas less sensitive 
to low potency agonists.  This effect appears to be most dramatic for morphine, 
which produces desensitization via a unique mechanism and does not efficiently 
stimulate receptor internalization.  At this time, the contribution of these properties to 
h/mOprm1 118GG phenotypes is unknown.  Going forward, a multidisciplinary 
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approach that employs cell type-specific manipulations and highly sensitive 
functional assays will be required to fully elucidate the mechanism by which the 
OPRM1 A118G polymorphism alters opioid and alcohol responses in vivo.   
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FIGURES AND TABLES 
 
Figure 1.  Comparison of ICSS behavior in h/mOprm1 118AA and h/mOprm1 
118GG mice.  A.  Both h/mOprm1 118AA (AA, n = 37, black circles) and h/mOprm1 
118GG mice (GG, n = 40, yellow triangles) responded for BSR in a frequency-
dependent manner.  Values are mean number of responses per 50 seconds of 
access to BSR at each stimulus frequency ± SEM.  Inset: Baseline BSR thresholds 
for h/mOprm1 118AA (black bars) and h/mOprm1 118GG mice (yellow bars) 
expressed as electrical charge delivery in μC ± SEM.  B. Ventral electrode tip 
placements (mm posterior to Bregma) for each mouse (118AA: n = 37, black circles; 
118GG: n = 40, yellow triangles).  
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Figure 2.  Effects of alcohol and naltrexone on ICSS in h/mOprm1 118AA (AA) and 
h/mOprm1 118GG (GG) mice.  A. Changes in BSR threshold following p.o. vehicle 
(water) or alcohol (0.6, 1.0, 1.7, and 2.4 g/kg) in 118AA (n = 19, black circles) and 
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118GG mice (n = 21, yellow triangles).  Data from the founder C57BL/6J strain are 
shown for comparison (blue triangles, right). B. Changes in BSR threshold following 
i.p. vehicle (saline) or naltrexone (0.1, 0.3, and 1.0 mg/kg) in 118AA (n = 11 above 
vehicle, black circles) and 118GG mice (n = 11 below vehicle, yellow triangles).  C. 
Changes in BSR threshold following p.o. vehicle (water) or alcohol (0.6 g/kg) 
following pretreatment with either i.p. vehicle (saline) or naltrexone (1.0 mg/kg) in 
118AA (n = 11, black circles) and 118GG mice (n = 11, yellow triangles).  All values 
are expressed as mean percentages of pre-injection baselines ± SEM.  Asterisk (*) 
indicates p < 0.05 vs. vehicle; pound sign (#) indicates p < 0.05 vs h/mOprm1 
118AA. 
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Table 1.  Effects of alcohol and naltrexone on 
maximum response rate (% of pre-injection baseline). 
 
Alcohol (g/kg p.o.) 
 h/mOprm1 118AA h/mOprm1 118GG 
Dose AVE SEM AVE SEM 
V 89.2 6.9 84.6 3.8 
0.6 89.1 6.4 96.7 1.9 
1.0 91.5 6.6 97.9 6.4 
1.7 99.2 8.8 101.4 4.2 
2.4 86.9 7.0 77.5 6.0 
 
Naltrexone (mg/kg i.p.) 
 h/mOprm1 118AA h/mOprm1 118GG 
Dose AVE SEM AVE SEM 
V 93.4 7.6 93.4 7.6 
0.1 93.0 7.2 93.0 7.2 
0.3 95.2 5.1 95.2 5.1 
1.0 93.5 6.1 93.5 6.1 
 
Naltrexone (1 mg/kg i.p.) + Alcohol (0.6 g/kg p.o.) 
 h/mOprm1 118AA h/mOprm1 118GG 
Treatment AVE SEM AVE SEM 
V/V 85.8 5.5 90.8 5.6 
V/ALC 87.2 8.9 95.3 5.4 
NTX/V 83.1 5.1 *75.4 3.2 
NTX/ALC 95.8 18.4 91.9 7.0 
 
Asterisk (*) indicates p < 0.05 vs. vehicle pre-treatment. 
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Figure 3.  Effects of opioid agonists and cocaine on ICSS in h/mOprm1 118AA (AA) 
and h/mOprm1 118GG (GG) mice.  Each panel displays changes in BSR threshold 
following vehicle; the MOR agonists oxycodone (0.01 – 10.0 mg/kg i.p.; 118AA: n = 
7 above vehicle, black circles; 118GG: n = 8 below vehicle, yellow triangles), 
fentanyl (0.01 – 0.3 mg/kg s.c.; 118AA: n = 7, 118GG: n = 8); and morphine (1.0 – 
10.0 mg/kg i.p.; 118AA: n = 10, 118GG: n = 11); the MOR partial agonist 
buprenorphine (0.01 – 10.0 mg/kg i.p.; 118AA: n = 8, 118GG: n = 10); the 
monoamine re-uptake inhibitor cocaine (1.0 – 10.0 mg/kg i.p.; 118AA: n = 10, 
118GG: n = 11); and the kappa opioid receptor agonist U69,593 (0.01 – 0.1 mg/kg 
i.p.; 118AA: n = 12, 118GG: n = 11).  All values are expressed as mean percentages 
of pre-injection baselines ± SEM.  Asterisk (*) indicates p < 0.05 vs. vehicle; pound 
sign (#) indicates p < 0.05 vs h/mOprm1 118AA when p(dose x genotype) < 0.05. 
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Table 2.  Effects of alcohol and naltrexone on 
maximum response rate (% of pre-injection baseline). 
 
Oxycodone (g/kg i.p.) 
 
h/mOprm1 118AA h/mOprm1 118GG 
Dose AVE SEM AVE SEM 
V 95.6 4.9 85.3 8.5 
0.01 92.4 2.4 79.7 5.0 
0.03 98.3 14.3 105.3 14.9 
0.1 120.6 16.7 124.5 24.3 
0.3 73.9 4.8 69.0 11.0 
     Fentanyl (g/kg s.c.) 
   
 
h/mOprm1 118AA h/mOprm1 118GG 
Dose AVE SEM AVE SEM 
V 100.0 6.3 86.7 4.8 
0.01 127.1 15.3 106.2 11.6 
0.1 75.4 5.8 73.2 8.2 
1 146.1 24.2 119.2 12.9 
10 75.6 13.7 59.0 11.7 
     Buprenorphine (g/kg i.p.) 
  
 
h/mOprm1 118AA h/mOprm1 118GG 
Dose AVE SEM AVE SEM 
V 91.2 4.1 97.5 3.6 
0.01 84.5 7.5 98.9 7.3 
0.1 131.0 18.7 134.8 13.9 
1 123.2 15.5 138.5 12.4 
10 78.6 9.3 90.0 9.3 
     Morphine (g/kg i.p.) 
   
 
h/mOprm1 118AA h/mOprm1 118GG 
Dose AVE SEM AVE SEM 
V 98.2 6.3 98.2 4.0 
1 117.6* 5.5 101.8 4.4 
3 114.9 5.3 102.0 5.4 
10 53.1* 6.7 78.8*# 7.9 
     Cocaine (g/kg i.p.) 
   
 
h/mOprm1 118AA h/mOprm1 118GG 
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Dose AVE SEM AVE SEM 
V 98.2 6.3 95.6 5.1 
1 102.0 4.9 102.4 7.0 
3 97.3 8.0 112.3 7.0 
10 106.5 6.9 115.6 7.1 
     U68,593 (g/kg i.p.) 
   
 
h/mOprm1 118AA h/mOprm1 118GG 
Dose AVE SEM AVE SEM 
V 85.7 7.7 85.3 6.5 
0.01 94.1 9.2 74.3 7.6 
0.03 81.6 8.7 77.1 6.8 
0.1 52.1 5.0 65.3 10.8 
     
Asterisk (*) indicates p < 0.05 vs. vehicle; pound sign 
(#) indicates p < 0.05 vs h/mOprm1 118AA when 
p(dose x genotype) < 0.05. 
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Figure 4.  Effects of MOR agonists DAMGO and morphine on mIPSCs in ventral 
tegmental area (VTA) neurons from h/mOprm1 118AA (AA) and h/mOprm1 118GG 
(GG) mice.  A. Whole-cell recordings were made from dopaminergic neurons in the 
VTA to detect the presynaptic effects of MOR agonists on GABAergic 
neurotransmission.  B. Dopaminergic neurons were identified by post-staining Alexa 
fluor 594 dye-filled cells for tyrosine hydroxylase.  C. Representative traces showing 
mIPSCs recorded in the presence of 500 nM tetrodotoxin before and after bath 
application of DAMGO (100 uM).  D. The effects of DAMGO (100 nM; 118AA: n = 8, 
black bars; 118GG: n = 9, yellow bars), morphine (100 nM; 118AA: n = 8; 118GG: n 
= 8), or morphine (100 nM) with the opioid antagonist naloxone (1 µM; 118AA: n = 5; 
160 
 
118GG: n = 6) on mIPSC frequency.  E. The effects of DAMGO (100 nM), morphine 
(100 nM), or morphine (100 nM) with the opioid antagonist naloxone (1 µM) on 
mIPSC amplitude.  All values are expressed as mean percentage baseline ± SEM.  
Pound sign (#) indicates p < 0.05 vs h/mOprm1 118AA. 
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Figure 5. Baseline mIPSC frequency and amplitude during recordings from 
dopaminergic neurons in the ventral tegmental area in midbrain slices from 
h/mOprm1 118AA and 118GG mice.  Box plots show the distribution of average 
baseline data points collected during whole cell patch clamp recordings. 
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Table 3.  Total protein in brainstem membrane fractions (µg). 
 h/mOprm1 118AA h/mOprm1 118GG 
Fraction AVE SEM % AVE SEM % 
P1 691.9 13.0 28.5 696.5 28.4 28.0 
P2 269.3 9.2 11.1 276.1 11.4 11.4 
P3 60.0 
 
2.5 52.3 
 
2.2 
Unfractionated 2424.2 93.0 
 
2491.6 105.3 
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Figure 6.  Pharmacological characterization of h/mOprm1 118A and 118G 
receptors.  A. Number of MOR binding sites in unfractionated tissue (118AA: n = 6; 
118GG: n = 8), the nuclear and cytoplasmic fraction (P1), the surface fraction (P2), 
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and the microsomal fraction (P3; total binding) expressed as specific binding of 9 µM 
[3H]-DAMGO per µg of protein ± SEM. B. The binding affinity (Ki in parentheses) of 
β-END, DAMGO, and morphine was determined with competition binding assays 
using freshly homogenized membranes from 118AA (β-END: n = 6, black circles; 
morphine/DAMGO: n = 6) and 118GG mice (β-END: n = 6, yellow triangles; 
morphine/DAMGO: n = 6). C. The potency (EC50 in parentheses) of β-END (green 
inverted triangles), DAMGO (black circles), and morphine (MS; red triangles) to 
decrease cAMP production was measured in HEK293 cells expressing OPRM1 
118A (left) or 118G (right).  D.  The potency of β-END, DAMGO, and morphine in 
HEK293 cells expressing h/mOprm1 118A (left) or 118G (right).  Pound sign (#) 
indicates p < 0.05 vs h/mOprm1 118AA. 
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Figure 7.  Replicate determination of surface fraction (P2) binding sites in 
h/mOprm1 118A and 118G membrane tissue (118AA: n = 6; 118GG: n = 8).  Data 
are expressed as specific binding of 9 µM [3H]-DAMGO per µg of protein ± SEM.  
Pound sign (#) indicates p < 0.05 vs h/mOprm1 118AA. 
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CHAPTER 6: DISCUSSION 
 
These studies employed the curve-shift method of intracranial self-stimulation 
in mice to determine the behavioral effects of rewarding substances on 
mesocorticolimbic circuitry involved in positive reinforcement.  Each chapter reflects 
the ability of this methodology to describe previously uncharacterized drugs of 
abuse, test the efficacy of candidate pharmacotherapies to blunt the positive 
subjective effects of drugs or alcohol, or determine pharmacogenetic differences in 
acute drug responses using humanized mice that model known genetic variants 
associated with substance abuse.  While Chapters 2 described the abuse potential 
of the synthetic stimulant mephedrone, Chapters 3 and 4 tested the ability of 
neurokinin-1 receptor antagonists and the synaptic vesicle 2A inhibitor levetiracetam 
to blunt the subjective rewarding effects of morphine or alcohol and cocaine, 
respectively.  In Chapter 5, pharmacological and electrophysiological techniques 
provide mechanistic insight into phenotypes associated with the OPRM1 A118G 
polymorphism using a humanized transgenic mouse line.  These studies reflect the 
utility of ICSS as a translational tool and provide insight into mechanisms by which 
drugs of abuse engage brain reward circuitry.  This chapter will examine specific 
neurobiological substrates of the rewarding substances studied, as well as discuss 
findings within the context of improving clinical practice and gaining a deeper 
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understanding of human disease.  It will also discuss how new technologies can be 
used to maximize the translational impact of ICSS. 
As discussed previously, ICSS is an operant behavioral method that probes 
brain reward function by measuring the hedonic value of electrical stimulation 
applied directly to specific brain circuits or regions, including the medial forebrain 
bundle (MFB) (Olds & Milner, 1954; Wise, 1998).  The MFB carries ascending 
dopaminergic fibers from midbrain to forebrain targets (such as the NAc) and 
descending glutamatergic fibers from the cortex to tegmental nuclei (e.g. the 
pedunculopontine and dorsolateral tegmental nuclei), which in turn send excitatory 
projections to the VTA (Wise, 2005).  Stimulation of the MFB is potently reinforcing 
(Valenstein & Campbell, 1966) and promotes dopamine release in the NAc (Cheer 
et al. 2007).  This dopaminergic neurotransmission plays a critical role in reward 
perception and behavioral reinforcement by drugs of abuse (Mirenowicz & Schultz, 
1996; Wise, 1998).  Since drugs of abuse primarily enhance the rewarding potency 
of ICSS through a dopaminergic mechanism (Wise, 1978), it is important to examine 
acute drug effects in the context of brain reward circuitry.   
In Chapter 2, I demonstrated that the cathinone-derived synthetic stimulant 4-
methylmethcathinone (mephedrone) had similar rewarding potency to cocaine as 
measured by ICSS.  These effects were most likely due to the ability of mephedrone 
to increase monoaminergic neurotransmission in mesocorticolimbic reward 
pathways.  Mephedrone induces c-Fos expression in the  NAc and PFC (Motbey, 
Hunt, Bowen, Artiss, & McGregor, 2012), presumably as a result of robust increases 
in extracellular dopamine and serotonin at these sites (Kehr et al., 2011).  Similar to 
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amphetamine or MDMA, mephedrone produces transporter-mediated efflux of 
monoamines and binds with nanomolar affinity to the dopamine transporter, 
serotonin transporter, and norepinephrine transporter (Baumann et al., 2012).  
Cocaine, on the other hand, increases monoamine levels via re-uptake inhibition 
(Ritz, Lamb, Goldberg, & Kuhar, 1987).  Relative to cocaine, mephedrone depressed 
maximum operant response rates, which has been observed following administration 
of several serotonin receptor agonists or releasing agents (reviewed by (Hayes & 
Greenshaw, 2011)).  Thus, the ability to promote dopamine release most likely 
mediated the reward-potentiating effects of mephedrone, while serotonergic 
neurotransmission may have depressed overall responding (Hayes & Greenshaw, 
2011; Nakajima & O'Regan, 1991). 
At the time of publication, the finding that mephedrone lowers reward 
thresholds contributed to the growing public health concern posed by synthetic 
stimulants.  These synthetic stimulants, which are more commonly known as “bath 
salts” and include mephedrone, were largely unregulated prior to their ban (along 
with synthetic cannabinoids and hallucinogens) by the Food and Drug Administration 
Safety and Innovation Act of 2012 (Gunderson, Kirkpatrick, Willing, & Holstege, 
2013; Schumer, 2012).  Since then, cathinone derivatives have been more 
extensively characterized using ICSS in rats, including mephedrone, methcathinone, 
3,4-methylenedioxypyrovalerone (MDPV), and 3,4-methylenedioxymethcathinone 
(methylone).  Bonano et al. demonstrated that several of these agents increase 
responding for BSR at low stimulation frequencies while decreasing responding at 
high frequencies (Bonano, Glennon, De Felice, Banks, & Negus, 2014), which is 
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analogous to the decrease in both BSR threshold and maximum operant response 
rate that I observed.  Interestingly, mephedrone was the lowest efficacy drug in their 
study, which we found to be approximately as potent and efficacious cocaine in 
C57BL/6J mice.  In another study, methylone was shown to be a potent intravenous 
reinforcer but failed to significantly lower ICSS thresholds (Watterson et al., 2012).  
These findings emphasize the need to further characterize this group of 
psychostimulants and other unregulated drugs of abuse in animal models.   
In chapter 3, I demonstrated that neurokinin 1 receptor (NK1R) antagonists 
attenuated the reward-potentiating effects of the mu opioid receptor (MOR) agonist 
morphine.  Morphine is a potent reinforcer and potentiates BSR (Wise, 1989), most 
likely due to its ability to increase dopaminergic neurotransmission in the NAc  
through disinhibition of VTA projections (S. W. Johnson & North, 1992; Murphy, 
Lam, & Maidment, 2001).  Similar to opioids, substance P or NK1R agonists 
promote VTA dopaminergic neuron firing (Korotkova, Brown, Sergeeva, 
Ponomarenko, & Haas, 2006) and enhance dopamine release in the NAc and PFC 
(Boix, Sandor, Nogueira, Huston, & Schwarting, 1995; Elliott, Alpert, Bannon, & 
Iversen, 1986; Elliott, Mason, Stephens-Smith, & Hagan, 1991).  In the NAc, NK1R 
and MOR signaling in cholinergic neurons promotes dopamine overflow at synapses 
with medium spiny neurons (Britt & McGehee, 2008; Galarraga, Hernandez-Lopez, 
Tapia, Reyes, & Bargas, 1999).  As such, NK1R knockout mice fail to show CPP to 
morphine (Murtra, Sheasby, Hunt, & De Felipe, 2000) and do not readily self-
administer the drug (Ripley, Gadd, De Felipe, Hunt, & Stephens, 2002).  These 
observations can be recapitulated via ablation of a specific population of NKR1-
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expressing cells in the amygdala (Gadd, Murtra, De Felipe, & Hunt, 2003).  Because 
NK1R antagonists were given systemically in my experiment, the mechanism by 
which they attenuate opioid reward is unknown, although they presumably involve 
several sites throughout neural circuitry mediating positive reinforcement where 
NK1Rs and MORs have synergistic effects (Commons, 2010).    
These findings add to the growing body of literature that supports the use of 
NK1R antagonists in the treatment or prevention of substance abuse.  The rat-
specific NK1R antagonist L822429 decreases intravenous operant self-
administration of heroin in short and extended access procedures, which model 
stable and escalated consumption, respectively.  L822429 also decreases the 
motivation to consume heroin using a progressive ratio drug-delivery schedule and 
reduces anxiety-like behaviors in both access groups (Barbier et al., 2013).  Thus, 
the ability of NK1R antagonists to reduce anxiety states associated with prolonged 
drug use may provide additional clinical benefit to certain patient populations.  For 
example, NK1R antagonists reverse neurocognitive deficits or negative affective 
states in recently detoxified alcoholics (George et al., 2008) and dose-dependently 
decrease stress-induced, but not cue-induced, reinstatement of alcohol (Schank et 
al., 2011) and cocaine seeking (Schank, King, et al., 2013).  Genetic variation that 
alters the pattern of expression of NK1Rs and influences downstream signaling 
events appears to strongly affect the efficacy of L822429 in rats (Schank, King, et 
al., 2013; Schank, Tapocik, et al., 2013), which supports a pharmacogenetic 
approach to assessing NK1R antagonist efficacy in humans.  To date, human 
laboratory studies examining their effects on the subjective rewarding effects of 
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oxycodone have been disappointing and will require further evaluation (Walsh, 
Heilig, Nuzzo, Henderson, & Lofwall, 2013).     
In Chapter 4, I demonstrated that inhibition of synaptic vesicle protein 2A 
(SV2A) by levetiracetam blunted the reward-potentiating effects of alcohol and 
enhanced the effects of cocaine.  Several studies have reported that levetiracetam 
preferentially inhibits excitatory neurotransmission at active synapses by interfering 
with vesicular release (Yang & Rothman, 2009; Yang, Weisenfeld, & Rothman, 
2007).  Both alcohol and cocaine decrease BSR threshold in C57BL/6J mice (Fish et 
al., 2010), although they have distinct differences in their effects on 
mesocorticolimbic reward circuitry.  Acute alcohol administration stimulates 
glutamate release in the NAc (Lominac et al., 2006; Moghaddam & Bolinao, 1994), 
excites dopaminergic VTA neurons  through a glutamate-dependent mechanism 
(Deng, Li, Zhou, & Ye, 2009; Xiao et al., 2009), and inhibits NMDA receptor 
signalling in NAc medium spiny neurons that express the dopamine D1 receptor 
(Zhang, Hendricson, & Morrisett, 2005).  Cocaine elevates NAc dopamine levels 
through re-uptake inhibition (Ritz, et al., 1987), as well as promotes glutamate 
release in this region (Smith, Mo, Guo, Kunko, & Robinson, 1995).  While the 
mechanism underlying the bidirectional effects of levetiracetam on alcohol and 
cocaine reward is unknown, my observations may be due to differences in the 
mechanisms by which these two drugs promote accumbal dopamine overflow and 
the effects of levetiracetam on the integration of dopaminergic and glutamatergic 
signaling in medium spiny neurons.   
Several FDA-approved antiepileptic drugs have been examined in a 
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preclinical setting to evaluate potential efficacy in the treatment of alcohol use 
disorders (AUDs).  These include topiramate, GABA analogues (e.g. pregabalin or 
gabapentin), lamotrigine, levetiracetam, and zonisamide (reviewed by (Padula et al., 
2013)).  Of these, only topiramate has been shown to have significant clinical 
efficacy (Arbaizar, Diersen-Sotos, Gomez-Acebo, & Llorca, 2010), but has not been 
widely implemented to treat alcohol dependence due to its cognitive side effects 
(reviewed by (Luykx & Carpay, 2010)).  My studies showed that levetiracetam, which 
has few side effects and does not undergo hepatic metabolism, attenuates the acute 
rewarding effects of alcohol.  In C57BL/6J mice, levetiracetam decreases alcohol 
intake when a chronic, 24-hour intermittent access procedure is used that produces 
relatively high levels of intake (e.g. >20.0 mg/kg/24 hrs.).  On the other hand, the 
drug enhances drinking when a binge-like, 4-hour access model is used (Fish et al., 
2014).  These results indicate that levetiracetam may be more effective in reducing 
consumption in alcohol dependent patients that is characterized by cycles of heavy 
drinking and withdrawal, while less effective in social drinkers that increase intake in 
order to overcome diminished subjective feelings of intoxication.  To date, clinical 
trials examining the efficacy of levetiracetam in alcohol dependence have been 
disappointing, and despite promising findings using rodent models of substance 
abuse, enthusiasm for large scale clinical trials may be waning (Le Strat, 2012).  The 
finding that levetiracetam enhances the behavioral effects of cocaine most likely 
precludes its use in cases of comorbid psychostimulant abuse or dependence. 
In Chapter 6, I used a humanized mouse model of the OPRM1 A118G 
polymorphism to provide mechanistic insight into the clinical phenotype caused by 
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this SNP.  Since its discovery in 1997 (Bergen et al., 1997) and subsequent 
association with increased risk of drug and alcohol dependence (Bart et al., 2005; 
Bond et al., 1998; Kranzler, Gelernter, O'Malley, Hernandez-Avila, & Kaufman, 
1998), the physiological etiology of the 118G-variant has been widely studied but not 
fully elucidated.  An influential early study suggested it increased binding affinity of 
the endogenous ligand (beta-endorphin) for the receptor (Bond, et al., 1998), yet this 
finding has not been replicated (reviewed by (Mague et al., 2009)).  My studies 
employing behavioral, pharmacological, and electrophysiological assays suggest 
that changes in the sensitivity to morphine and alcohol may be due to changes in 
receptor trafficking and surface expression, rather than differences in agonist binding 
affinity or intrinsic efficacy.  How diminished receptor reserve could increase 
sensitivity to alcohol is unknown, but may involve increased opioid release due to 
loss of auto-inhibition of opioidergic projection neurons to the ventral tegmental area. 
Loss of surface MOR surface expression most likely contributed to decreased 
morphine sensitivity associated with the OPRM1 A118G polymorphism.  Like other 
MOR agonists, morphine attenuates GABAergic neurotransmission in the VTA to 
disinhibit dopaminergic projection neurons and increase dopamine release in the 
NAc (Di Chiara & Imperato, 1988; S. W. Johnson & North, 1992).  This occurs 
through the hyperpolarization of local GABAergic neurons via somatodendritic opioid 
receptors that couple to GIRK channels (Labouebe et al., 2007), as well as inhibition 
of voltage gated calcium channels in the presynaptic terminals of local interneurons 
(Bergevin, Girardot, Bourque, & Trudeau, 2002) or GABAergic afferents from the 
rostromedial tegmental nucleus (Matsui & Williams, 2011).  Thus, it is likely that a 
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decrease in the number of binding sites in the VTA would diminish the behavioral 
and cellular response to agonists with a low receptor reserve, such as morphine, 
without affecting the response to agonists with a high receptor reserve, such as 
fentanyl.  It is unknown, however, whether this polymorphism preferentially affects 
pre- vs. postsynaptic receptors, as the potency of DAMGO is higher at the 
presynaptic terminal (Pennock & Hentges, 2011).  In this case, perturbations in MOR 
trafficking associated with the A118G polymorphism may vary in magnitude across 
subcellular domains due to local differences in protein synthesis and delivery of the 
receptor to the synaptosomal membrane.   
Morphine is also unique in that it fails to produce receptor internalization 
(Keith et al., 1996) and does not produce robust desensitization when compared to 
other opioids (Levitt & Williams, 2012).  These observations may be due to the fact 
that it does not effectively recruit β-arrestin 2 (Chu, Zheng, Loh, & Law, 2008; Dang 
& Williams, 2005; Whistler & von Zastrow, 1998).  Because arrestin-biding and 
internalization may be important in limiting cellular and physiological tolerance (Finn 
& Whistler, 2001), it is possible that lower receptor reserve is protective against 
adverse effects associated with prolonged drug use.  My behavioral and 
electrophysiological studies only examined acute drug exposures, so it is currently 
unknown if h/mOprm1 118GG mice are more or less sensitive than 118AA 
littermates to the behavioral or cellular sequelae associated with chronic opioid 
exposure.  It is likely that blunted mesocorticolimbic response to morphine would 
limit the animal’s desire and motivation to consume this drug when given restricted 
access during intravenous self-administration testing.  If given extended access to 
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intravenous morphine, it is possible that h/mOprm1 118GG mice would be less likely 
to display escalated intake as a result of diminished cellular tolerance; on the other 
hand, these mice may be resistant to the aversive effects of high morphine doses, 
which could lead to enhanced drug consumption.  Future studies examining the 
regulation of receptor reserve and mechanisms of cellular or physiological tolerance 
in the context of prolonged drug exposure would be helpful to determine the 
influence of the OPRM1 A118G polymorphism on patterns of opioid abuse and its 
involvement in the development of opioid dependence.  
Overall, these studies employing the h/mOprm1 A118G model demonstrate 
the benefits of studying disease mechanisms in humanized mice and support the 
translational value of ICSS to assess drug potency in knockout or knockin models.   
Although the use of transgenic mice that recapitulate genetic abnormalities 
associated with a number of neuropsychiatric illnesses is relatively common 
(McGonigle, 2014), this practice has not been widely adopted to study 
pharmacogenetic mechanisms of drug and alcohol abuse.  Genetic association 
studies support the involvement of SNPs affecting druggable targets in drug or 
alcohol dependence, drug-related behaviors, or clinical phenotypes.  These include 
polymorphisms in genes encoding the serotonin transporter (SLC6A4) (McHugh, 
Hofmann, Asnaani, Sawyer, & Otto, 2010), GABA-A receptor alpha-2 subunit 
(GABRA2) (Lappalainen et al., 2005), nicotinic acetylcholine receptor alpha-4 
subunit (CHRNA4) (Han et al., 2011), dopamine D2 receptor (DRD2) (Munafo, 
Matheson, & Flint, 2007), catechol-o-methyltransferase (COMT) (Ittiwut et al., 2011), 
dopamine beta-hydroxylase (DBH) (Kalayasiri et al., 2007), alcohol dehydrogenase 
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(ADH1B and ALDH2) (Edenberg, 2007), etc.  With the application of several new 
genome editing techniques, including CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeats)-Cas9 (Wang et al., 2013) and transcription activator-like 
effector nucleases (Panda et al., 2013), it will be possible to more cost effectively 
generate humanized rat and mouse models in a shorter amount of time.  Using a 
reverse translational approach where disease predictors are discovered in humans 
and modelled in animals, pre-clinical researchers should be able to fully elucidate 
the mechanisms by which many of these SNPs produce behavioral effects and 
characterize the circuit- and cell-specific perturbations that underlie them.  
Of the various techniques used in conjunction with ICSS, virus-mediated gene 
transfer may have the greatest potential to enhance the value of ICSS as a 
translational tool.  Several groups have used viral vectors to investigate the role of 
specific molecular mechanisms in positive reinforcement or in the hedonic response 
to acute and chronic drug exposure (Fowler, Lu, Johnson, Marks, & Kenny, 2011; P. 
M. Johnson & Kenny, 2010; Muschamp, Nemeth, Robison, Nestler, & Carlezon, 
2012).  Expression of molecular tools designed to give researchers temporal and 
spatial control over the activity of specific populations of neurons will be particularly 
useful going forward.  These technologies include designer receptors exclusively 
activated by designer drugs; optogenetic tools, in which microbial opsins are used to 
manipulate neuronal excitability with light (e.g. channelrhodopsin-2, halorhodopsin, 
etc.); and chimeric ligand-gated ion channels that are sensitive to designer drugs  
(Fenno, Yizhar, & Deisseroth, 2011; Magnus et al., 2011; Rogan & Roth, 2011).  
When employed in mice that express cre-recombinase under the control of cell type- 
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or tissue-specific promoters, these tools will allow researchers to manipulate the 
excitability of individual populations of neurons in order to alter the value of BSR or 
attenuate the effects of drugs of abuse on reward thresholds.  Furthermore, 
optogenetic approaches may ultimately replace electrical stimulation altogether, as 
several groups have demonstrated that ICSS can be achieved by selective 
activation of small groups of neurons using implanted fiber optic cables that can 
deliver a computer-controlled optical stimulus (Jennings, Rizzi, Stamatakis, Ung, & 
Stuber, 2013; Rossi, Sukharnikova, Hayrapetyan, Yang, & Yin, 2013).  
Although ICSS was discovered over half a century ago, it remains an 
important tool for studying brain reward function in a variety of contexts.  Several 
behavioral assays have been developed over the previous decades that aim to study 
reward and reinforcement, yet the curve-shift and psychophysical methods of ICSS 
have been resilient in their utility to researchers, likely due to the robust nature of 
operant responding for brain stimulation rewards; the clear dose-dependence of 
most drugs; and the reproducibility of drug effects across cohorts, practitioners, and 
methodologies.  These properties make ICSS particularly attractive to pre-clinical 
researchers, as behavioral pharmacological data are often difficult to replicate and 
dependent on the experimental context (Crabbe, Wahlsten, & Dudek, 1999). Going 
forward, the application of new technologies and the increasing ease of producing 
transgenic mouse lines will improve the ability of ICSS to elucidate mechanisms of 
disease and make pharmacogenetic predictions about experimental therapeutics.  
Eventually, researchers will most likely abandon electrical stimulation in ICSS, and 
optogenetics or an equivalent technology will be used to produce self-stimulation.  
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This will allow more specific inferences to be made about circuits involved in 
motivated behavior and drug reward.  Given that the best predictor of future behavior 
is past behavior, it is unlikely that scientists will abandon ICSS altogether; instead it 
will be altered and improved to reflect the state of the art and the scientific zeitgeist.  
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